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ABSTRACT
STRUCTURAL CHARACTERIZATION OF THE
PRE-AMYLOID OLIGOEMRS OF β-2-MICROGLOBULIN
USING COVALENT LABELING AND MASS SPECTROMETRY
SEPTEMBER 2010
VANESSA LEAH C. MENDOZA
B.Sc., UNIVERSITY OF THE PHILIPPINES DILIMAN
Directed by: Professor Richard W. Vachet

The initial steps involved in the assembly of normally soluble proteins into
amyloid fibrils remain unclear, yet over 20 human diseases are associated with proteins
that aggregate in this manner. Protein surface modification is a potential means of
mapping the interaction sites in early oligomers that precede amyloid formation.
This dissertation focuses on the use of covalent labeling combined with mass
spectrometry to elucidate the structural features of Cu(II)-induced β-2-microglobulin
(β2m) amyloid formation. An improved covalent modification and MS-based approach
for protein surface mapping has been developed to address the need for a reliable
approach that ensures protein structural integrity during labeling experiments and
provides readily detectable modifications. This approach involves measuring the kinetics
of the modification reactions and allows any local perturbations caused by the covalent
label to be readily identified and avoided.
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This MS-based method has been used to study human β-2-microglobulin (β2m), a
monomeric protein that has been shown to aggregate into amyloid fibrils in dialysis
patients leading to dialysis-related amyloidosis.

Under conditions that lead to β2m

amyloid formation, reactions of β2m with three complementary covalent labels have been
used to identify the Cu(II) binding site, metal-induced conformational changes, and the
oligomeric interfaces. Results confirm that Cu(II) binds to His31 and the N-terminal
amine. Binding to these residues causes several structural changes in the N-terminal
region and ABED β-sheet which likely enables formation of oligomeric intermediates.
The covalent labeling data indicate that the pre-amyloid β2m dimer has an interface that
involves the antiparallel arrangement of ABED sheets from two monomers. Moreover,
our covalent labeling data allowed us to develop a model for the tetramer in which the
interface is mediated by interactions between D strands of one dimer unit and the G
strands of another dimer unit.
Lastly, the selective covalent modification approach has been used to delineate
the structural changes in β2m after interaction with Cu(II), Ni(II), and Zn(II) and their
effect on its aggregation. Our covalent labeling data indicates that the unique effect of
Cu(II) appears to be caused by the site at which the metal binds the protein and the
conformational changes it induces.
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CHAPTER 1
PROBING PROTEIN STRUCTURE BY AMINO ACID-SPECIFIC COVALENT
LABELING AND MASS SPECTROMETRY
This chapter is part of a paper published as: Mendoza, V. L., and Vachet, R. W. (2009)
Probing protein structure by amino acid-specific covalent labeling and mass
spectrometry. Mass Spec. Rev. 28, 785-815.

1.1 Amyloid Fibril Formation
A number of proteins are known to aggregate into amyloid fibrils in vivo, leading
to a pathological disorder known as amyloidosis. Amyloidoses are protein
conformational diseases that arise from the self-assembly of normally soluble proteins
into insoluble fibrils, which accumulate in a variety of tissues and organs [1-4]. One of
the striking characteristics of these pathological states is that despite the variability in the
amino acid sequences and tertiary structures of the precursor proteins, the fibrils are very
similar in their overall appearance, morphology and properties. X-ray diffraction analyses
indicate that all amyloid fibrils share a common cross-β structure, wherein the β strands
are arranged orthogonally to the fibril axis and hydrogen bonding parallel to the fibril
axis [5,6]. Electron microscopy studies reveal that the fibrils are usually long, straight,
and unbranched and have repeating units that reflect the twisting of the component
filaments around one another [7]. Typically, amyloid fibrils are identified by their green
birefringence and ability to bind the dyes Congo Red and thioflavin T.
Another common feature exhibited by these amyloid systems is the presence of a
lag phase, which is indicative of nucleation-dependent kinetics [8]. These common
characteristics exhibited by the amyloid formation from different precursor proteins
suggest a general mechanism for amyloid formation (Figure 1.1) [8]. The process begins
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with the formation of a partially folded intermediate. The partially folded conformers
self-associate into a nucleus enriched with β sheets. β sheet extension then leads to
formation of protofibrils, which eventually give rise to mature fibrils.

Figure 1.1 General mechanism of amyloid formation.

1.2 β-2-microglobulin (β2m)
One protein that forms amyloid fibrils is β-2 microglobulin (β2m). β2m can
accumulate as amyloid fibrils in the musculoskeletal system as a complication of longterm hemodialysis, leading to a condition known as dialysis-related amyloidosis (DRA)
[9]. β2m is the non-covalently bound light chain of the class I major histocompatibility
complex (MHC-I). It has 99 residues (~12 kDa) and adopts the immunoglobulin fold with
seven β strands forming a β-sandwich in its native state (Figure 1.2) [10]. One β sheet is
formed by strands A, B, D and E and the other consists of strands C, F and G. A disulfide
bond between Cys25 and Cys80 tethers strands B and F in the folded state of the protein.
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β2m is vital for the correct folding and assembly of the major histocompatibility complex
I (MHC-I) complex that is required for antigen display [10]. As part of normal cell
turnover, β2m is released from MHC and carried to the kidney where it is degraded.
Upon renal failure, serum levels of β2m increase up to ~60 times above the normal level
of 0.1 µM, and the protein aggregates into insoluble amyloid deposits. However, elevated
β2m levels are not unique to renal failure patients and are not sufficient to trigger
fibrillogenesis [11,12]. β2m amyloid formation must therefore result from features unique
to hemodialysis.

Figure 1.2 Structure and sequence of β2m. (A) Ribbon diagram of human β2m (PDB
2D4F). (B) Amino acid sequence of β2m showing strand nomenclature [13].

Dialysis patients are exposed to both elevated levels of β2m and transition metal
cations, particularly Cu(II) [14]. The maximum level of Cu(II) allowed by the FDA in the
dialysate is 1.6 µM, which is close to the measured dissociation constant for the β2m
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complex with Cu(II) [15]. Also, some dialysis membranes typically contain ~2 mg Cu/m2
and, hence, provide high concentrations of Cu(II) [15]. Biophysical studies have shown
that in vitro interactions of stoichiometric amounts of β2m and Cu(II) under near
physiological conditions result in fibril formation [14-17]. This observation suggests that
Cu(II) interactions induce conformational changes in β2m and increase its amyloidogenic
propensity.
Cu(II)-induced β2m amyloid formation is preceded by the formation of discrete,
oligomeric intermediates (Figure 1.3) [16-19]. Characterizing reaction intermediates is
essential for understanding any biochemical reaction more deeply, and this is no less true
for amyloid fibril forming reactions. The formation of discrete oligomers as prefibrillar
intermediates has been observed for several other amyloidogenic proteins too [20-22],
and indeed acid-induced (pH = 2.5) amyloid formation of β2m has been found to be
preceded by discrete oligomers [23]. Delineating the mechanism of the early stages of
β2m fibrillogenesis and the structural properties of these oligomeric intermediates may be
critical for developing therapeutic strategies against DRA. Furthermore, recent studies of
other amyloid systems suggest that prefibrillar intermediates might be responsible for
cellular toxicity rather than the amyloid fibrils [24,25]. Consequently, any methods or
results that give insight into intermediates that precede β2m fibrils may be useful for
understanding other amyloid systems as well.
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Figure 1.3 Proposed model for Cu(II)-induced β2m fibril formation [17]. Monomeric
β2m binds Cu(II) and is destabilized. Cu(II)-bound β2m forms a dimer which
subsequently forms tetramer I. Tetramer I undergoes a conformational change, releases
Cu(II), and undergoes a rearrangement to form tetramer II. Tetramer II eventually leads
to the hexamer, presumably via an association with a dimer that releases its bound Cu(II).
An oligomer just larger than the hexamer acts as the nucleus that enables fibril or
protofibril formation.

Structural and kinetic studies of the intermediates of the Cu(II)-induced amyloid
formation reaction are challenging because these oligomers are in equilibrium, they are
transient, and they are present as a mixture. The structural properties of β2m at the onset
of fibrillogenesis have been studied using techniques such as circular dichroism (CD),
fluorescence, X-ray crystallography, and nuclear magnetic resonance (NMR) [14,26-28].
The morphologies of β2m amyloid fibrils have been elucidated by electron microscopy
(EM) and atomic force microscopy (AFM), and some information into how the protein
packs in the amyloid fibrils has been obtained by H/D exchange and NMR spectroscopy
[27,29,30].
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While these studies provide useful insight into β2m fibrillogenesis, the structure
of the oligomeric intermediates and the details of the amyloid formation mechanism
remain mostly unclear, partly because of limitations of the techniques used in previous
studies. CD, for example, gives a measure of the protein’s secondary structure but does
not provide amino-level information. Fluorescence is very sensitive to conformational
changes as well as intermolecular interactions but measurements can be interpreted in
structural terms only if the macromolecular structure is known. NMR and X-ray
crystallography are the two most important techniques for obtaining high resolution
structural information. X-ray crystallography provides detailed structural information but
only for the most stable protein state. NMR spectroscopy is restricted by the relatively
high sample concentrations required for analysis (mM range), a limited molecular weight
range (~30 kDa), difficulties with the analysis of mixtures, and interferences from
paramagnetic metals such as Cu(II). Because of the technical limitations of these
techniques, mass spectrometry (MS) is playing an ever-increasing role in protein
structure determination due to its speed, sensitivity, and specificity. This dissertation
focuses on the development and application of MS-based tools to study the structure
features of the oligomers that precede β2m fibril formation.

1.3 Protein Structural Information from Mass Spectrometry
With mass spectrometry, structural information about proteins in solution is
typically obtained by changing the mass of the protein or its proteolytic fragments in a
structure-dependent manner. This indirect way is necessary because MS measurements
occur in the gas-phase. Several approaches have been used to achieve this, including H/D
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exchange, intra- and intermolecular cross linking, and protein surface mapping via
covalent labeling. Covalent labeling entails the use of reagents that either modify specific
amino acids or react generally with many different amino acids. In contrast to H/D
exchange, the possibilities of back exchange and scrambling are essentially non-existent
with covalent labeling reagents. In addition, covalent labeling techniques provide
structural information about amino acid side chains, which can be complementary to
HDX methods. However, protein structure is more likely to be perturbed with these
labels due to the size of typical covalent reagents.
Covalent labeling is generally carried out using either non-specific labels or
amino acid-specific labels. Non-specific covalent labeling approaches almost exclusively
use protein reactions with radicals (e.g., oxidative footprinting methods). Amino acidspecific labels have been used quite extensively in conjunction with MS to study protein
structure and interactions. The sections below will describe particular amino acid-specific
covalent labeling reagents and techniques that have been used with MS that can be used
to study Cu(II)-induced β2m oligomer assembly under near physiological conditions. The
reagents that are used for amino acid-specific labeling, cautionary notes for the proper
utilization of these labels, and the protein structural problems that have been addressed
with these labels are discussed.

1.4 Basis of Covalent Labeling with Mass Spectrometry
The protein structural information obtained using covalent labeling methods
typically rely on the differential reactivity of amino acids upon exposure to a particular
labeling reagent. In these experiments the assumption is that amino acids that are exposed
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to solvent and therefore accessible to a labeling reagent will be modified, whereas buried
amino acids will be modified slowly or not at all. Protein conformational changes, ligand
binding, or oligomerization will then affect the extent to which certain amino acid(s)
react with the added labeling reagent (Figure 1.4). The amino acids that become more or
less accessible to the reagent will react to greater or lesser extents, and amino acidspecific information about a protein’s structural changes is then inferred from their
differential modification patterns. Covalent labeling has been used for at least 40 years to
map protein structure, but the more recent ability of MS to quickly, sensitively,
accurately, and precisely map protein modification sites has made covalent labeling
approaches much more powerful methods for obtaining protein structural information.
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Figure 1.4 Analytical scheme showing covalent labeling with MS detection. The label
modifies solvent accessible amino acids. ESI- or MALDI-MS can be used to calculate the
extent of modification. The modified protein can then be subjected to proteolysis
followed by either MALDI-MS or LC-MS/MS to determine the peptide fragments and/or
the specific amino acids that have been modified.
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1.4.1 Analysis and Identification of Labeled Sites
The analysis of covalent modifications by MS can be carried out in several ways.
The simplest but perhaps least informative means is to determine the number of reagent
adducts that modify the protein of interest. The maximum number of labels and/or the
average number of labels, which can provide “low resolution” information, can be
determined from the mass spectrum of the intact modified protein. This approach is most
useful when comparing two protein states and when using a highly specific amino-acid
labeling reagent. A change in the amount of modification in one state as compared to
another can indicate that a specific amino acid is involved in a structural change or is near
a ligand binding site. One example is the study by Leitner and Lindner wherein a
combination of 2,3-butanedione and phenylboronic acid was used to modify Arg residues
in myoglobin with apomyoglobin (i.e., no heme) [31]. Electrospray ionization (ESI)-MS
of the intact proteins indicated that the average number of modified Arg residues
increased in apomyoglobin, which is consistent with one or more of these residues being
partially buried next to the heme group in the holoprotein.
While monitoring the modification extent of a whole protein by MS is quick and
straightforward, it does not provide the same level of detail (or resolution) that is possible
when modified proteins are enzymatically digested and the resulting peptide fragments
analyzed by ESI-MS or matrix-assisted laser desorption/ionization (MALDI)-MS. Thus,
the most common approaches for using covalent modifications to derive protein
structural information are peptide mass mapping using MALDI-MS or ESI-MS and
peptide sequencing using tandem MS (MS/MS). With peptide mass mapping (i.e. no
MS/MS), the modified amino acids are identified by measuring the m/z ratios of the
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proteolytic fragments and finding the fragments whose m/z ratios differ, by the mass of
label, from the predicted values (Figure 1.5). If an amino-acid specific label is used, then
the specific amino acid modified in a proteolytic fragment can usually be inferred. On the
other hand, if the relative specificity of the reagent is low, then the identity of the
modified amino acid often cannot be assigned with complete confidence. Nonetheless,
localizing a modification to a particular proteolytic fragment still improves spatial
resolution so that more confident conclusions about a protein’s structure can be made.
Tandem MS is usually required to identify the specific amino acids modified in a
proteolytic fragment. In effect, MS/MS can increase the resolution of the structural
information to the single amino-acid level. Obtaining a complete peptide sequence by
MS/MS, however, is not always possible, but typically modified amino acids can be at
least narrowed down to within 2 to 3 residues.
When the extent of protein modification is low or a mixture of proteolytic peptide
fragments to be analyzed is complex, identifying specific modification sites can be
challenging. A powerful approach to address this problem is to use modification specific
product ions as markers of the modified peptides. The best example of this idea is found
in the context of lysine acetylation experiments. Dissociation of peptides with acetylated
lysine residues often results in the formation of abundant immonium ions of acetylated
lysine at m/z 143, and if extracted ion chromatograms of m/z 143 are used, peptides with
modified lysine residues can be readily identified. Another common product ion of
lysine-acetylated peptides at m/z 126 has also been used to facilitate the identification of
peptides with aceylated lysines [32]. Another means of identifying modified peptides in a
mixture of peptides is to use multiple, equally reactive labels that differ in mass.
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Recently, Gabant et al. demonstrated that three lysine specific reagents that differed in
mass by 113 Da could be used in parallel [33]. The reactivity of these reagents with the
protein of interest is virtually identical, causing modified peptides to show up as a quartet
of peaks. Finding the modified peptides was facilitated by identifying peptide fragments
that had corresponding peaks at m/z values of M+226, M+339, and M+452.

Figure 1.5 (A). Peptide mass mapping. Labeled peptides are identified from a mass
spectrum that shows unmodified and modified fragments. (B) In tandem mass spectra
unmodified and modified product ions can be used to identify the specific amino acid that
has been modified.
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An alternative to enzymatic digestion followed by peptide mass mapping or
MS/MS is top-down sequencing, which entails performing MS/MS on the whole protein.
One of the advantages of the top-down approach is that the protein sequence and any
modification site(s) can be determined potentially in a single MS/MS experiment. In
addition, the enzymatic digestion step can be avoided. This allows for faster analysis and
avoids loss of covalent labels that might not be stable during the relatively long digestion
step. However, a large number of product ions are generated by the protein dissociation
that can complicate spectral interpretation. Despite this challenge, top-down sequencing,
especially on Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometers, is
finding more widespread usage [34,35]. Using top-down sequencing to find covalent
modification sites, however, presents additional challenges. Multiple potential sites of
modification can lead to mixtures of protein isoforms. Upon dissociation, these isobaric
protein ions generate even more complicated product ion spectra. Furthermore, for labels
with relatively low specificity, narrowing down the modification site to individual amino
acids can be difficult. Nonetheless, top-down sequencing has been used effectively for
mapping labeled sites so that protein structural information can be obtained [36].

1.4.2 Extent of Modification
Aside from the identification of the modified amino acids, which helps identify
the region(s) in a protein that undergoes a structural change or forms an interface with
another molecule, the degree of modification at this amino acid is also important to
determine. The degree of modification usually reflects the solvent accessibility of the
amino acid side chain. Generally, changes in the extent of modification are used as
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indicators of the extent of a protein’s local structural change. For example, the reactivity
of an amino acid that mediates interactions in an interface with another molecule is likely
to decrease more than the reactivity of an amino acid that is at the periphery of the
interface. Given that the degree of modification can provide plenty of useful information,
several approaches have been developed and used to measure amino acid reactivities with
modification reagents. The most common approach is to simply compare the extent of
modification of the peptide fragment that contains the amino acid under two different
conditions – one condition in which the protein has its native structure and another in
which the protein undergoes the structural change of interest (Figure 1.6). The ratio of the
modified peptide fragment’s ion abundance to the peptide fragment’s total ion abundance
(i.e. unmodified + modified) allows one to easily identify the degree to which an amino
acid undergoes a reactivity change that coincides with the protein’s structural change.
While this approach is straightforward, it does have the potential to give misleading
information. Some amino acid modifications can change the ionization efficiency of the
measured peptide so that the ion abundance ratio of the modified peptide does not
accurately reflect its solution concentration. This problem is likely to be exacerbated if
LC is used because modified and unmodified peptides will usually be separated from one
another and thus be electrosprayed under different solvent conditions if solvent gradients
are used. Furthermore, modification of residues such as lysine that are proteolytic
cleavage sites could cause proteolytic enzymes such as trypsin to miss cleavage sites in
modified copies of a protein but not in the unmodified copies of the protein. Such an
occurrence could also lead to misleading ion abundance ratios if not properly accounted
for.
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Figure 1.6 Analytical scheme showing how the abundances of the unmodified and
modified peptides can identify amino acids that undergo changes in reactivity, which can
then help determine regions in a protein that undergo a structural change.

Because of these potential problems, other approaches have been developed to
measure amino acid modification extents. One method is to use isotopic labeling to
determine relative reactivities of amino acids and has been used with lysine acetylation
[37,38]. The relative reactivity of a given lysine residue can be determined by measuring
the ion abundance ratio between the unlabeled modified peptide and the isotopically
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labeled version of the modified peptide. Because an isotopically labeled version of the
reagent is used, concerns over changes in ionization efficiency upon modification are
minimized. Also, the isotopic labeling can be helpful for identifying modified peptides in
a complex mixture.
A second approach to obtain more reliable information about the extent of
modification is to use an internal standard, which is usually another peptide that does not
contain a modifiable residue [39]. This method works well when comparing the
differential reactivity of two or more residues of a given amino acid in the same protein.
Typically, the ion abundance of the unmodified version of the peptide containing the
modifiable residue of interest is compared to the ion abundances of peptides that do not
contain modifiable residues. By measuring the ion abundance of the unmodified peptide,
ionization efficiency concerns are minimized, and semi-quantitative measurements of the
modification extent can be made.
A third approach developed to more reliably measure modification extents is to
measure the modification reaction kinetics of the protein or, specifically, its peptide
fragments that contain the modified residues of interest [31,40-42]. Rate coefficients can
be determined by monitoring the extent of modification over a range of reaction times or
reagent concentrations (Figure 1.7). These kinetic measurements can be performed by
either measuring the increase in the ion abundance of the modified version of a peptide
over time or the decrease in the ion abundance of the unmodified version of a peptide
over time. Measuring modification kinetics has the additional potential advantage of
providing more detailed structural information as most studies demonstrate that a good
correlation exists between reaction rate coefficients and a residue’s solvent accessibility.
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Figure 1.7 Plot of unmodified peptide (or protein) as a function of time (or reagent
concentration) showing that a more buried residue His-B (blue) reacts more slowly and
therefore has a shallower slope in the kinetics plot compared to a more exposed residue
like His-A (orange).

1.5 Amino Acid Specific Labels and Examples of Their Applications
Amino acid specific reactions for only 8 of the 20 naturally occurring amino acids
have been used to monitor protein structure in conjunction with MS. In general, the
reactivity of the different functional groups in a protein relies on the nucleophilicity of
the amino acid and the accessibility of the residue to the reagent. In the sections that
follow, we describe amino acid specific reactions for Arg, His, and Lys with a particular
focus on (i) the reaction mechanisms; (ii) the range of reaction conditions that are
accessible with these reactions; (iii) any side reactions that need to be contended with;
and (iv) specific biochemical problems that have been addressed. These three amino
acids were chosen for the β2m structural studies described in the following chapters
because of the predicted importance of these residues in Cu(II) binding and oligomer
assembly, the suitability of the labels for studying proteins under native conditions, and
the availability of relatively small labels for these particular residues.
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1.5.1 Arginine
1.5.1.1 Reaction Mechanism
The modification of arginine residues is typically based on the reaction of vicinal
dicarbonyl compounds to form cyclic adducts. For the structural studies of β2m, 2,3butanedione (BD) was chosen because of its relatively small size. The reaction is shown
in Figure 1.8.

Figure 1.8 Modification reaction of arginine by 2,3-butandeione (BD).

1.5.1.2 Reaction Conditions
Previous studies show that arginine specific reactions are most commonly carried
out between room temperature and 37 oC over a pH range of 7-10 with 50-100 mM
buffer. The dicarbonyl labeling reagents are fairly soluble in water at concentrations up to
200 mM. Reagent concentrations typically vary from 0.1 to 3000-fold molar excess
relative to the protein of interest, and reaction time of ~ 30 min. For BD, reactions are
typically, but not universally, carried out in the dark to avoid possible photoactivation of
this molecule, which could enhance nonspecific reactions with groups other than arginine
[43,44]. Considered as a whole the accessible reactions conditions are almost ideal for
studying proteins under native conditions. It has been noticed, however, that the adducts
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that are formed with the various dicarbonyls can be somewhat unstable, especially at pHs
below 7. Borate has been shown to stabilize the adducts and prevent the regeneration of
arginine as shown in Figure 1.9 [45].

Figure 1.9 Reaction showing how borate can stabilize adducts that are formed by
arginine with the various dicarbonyl compounds.

1.5.1.3 Biochemical Problems That Have Been Addressed
Arginine specific labeling combined with MS has been actively used to probe
protein structures. Arginine has the highest pKa of all amino acid side chains and thus is
essentially always protonated under physiological conditions. As such arginines are
almost always found on protein surfaces, so their value as targets for protein surface
mapping would seem to be low because one would always expect to find them on a
protein’s surface. However, their ability to form intramolecular salt bridges with
carboxylates, which could reduce their reactivity, can occasionally make them useful
residues to probe. The use of 1,2 cyclohexanedione to modify lysozyme followed by
mass spectrometric analysis was first reported by Przybylski and coworkers [40]. Only
four of the eleven arginine residues in hen egg white lysozyme were modified, and the
reactivities that were observed correlated inversely with the solvent accessibilities of
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these arginine residues. The selective modification of only four of the arginines was
ascribed to the presence of neighboring proton acceptor groups that lead to intramolecular
catalysis, indicating that this reaction is very sensitive to the residue’s local chemical
environment.
Arginine modification and MS have also been employed to probe the active sites
of proteins. For example, modification by BD with MALDI-TOF MS detection was used
by Decottignies and co-workers to investigate the reactivities of the active site arginine
residues of sorghum NADP-malate dehydrogenase [46]. MALDI-TOF mass spectrometry
identified Arg87 and Arg134 as the sites of modification, indicating that these two
arginine residues are the most reactive and accessible arginines in the active site.
An alternative covalent labeling method that uses BD and phenylboronic acid to
cyclize the initial arginine adduct of BD was demonstrated by Leitner and Lindner [31].
Phenylboronic acid acted to stabilize the initial arginine adducts and improved the yield
and detection efficiency of the modified proteins and peptides. [47]. The reactivities of
the Arg residues in cytochrome c, lysozyme, and ubiquitin were still found to be in good
agreement with the solvent accessibilities of these residues as obtained from crystal
structures, indicating that the phenylboronic acid cap did not adversely affect the
structural information gained from the labeling reaction. In addition, reactions with
myoglobin, apomyoglobin and ribonuclease A before and after disulfide reduction were
consistent with the known structural changes undergone by these proteins.
When an electrostatic interaction is suspected to be a major contributor to a
protein-ligand binding interaction, arginine selective modification reactions can be a
valuable probe because of arginine’s ability to form salt bridges. Arginine specific
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reagents have been used to examine the surface topology of the quaternary structuredependent heparin-binding region of bovine seminal plasma PDC-109 by comparing the
reactivities of arginine residues of the free and the heparin-bound protein [48]. Peptide
mapping using N-terminal sequencing and ESI-MS revealed that Arg57, Arg64 and
Arg104 were protected from modification in the heparin-bound protein. These Arg
residues are suspected to be a part of the cationic face in the PDC-109 oligomeric state
that binds tightly to heparin.

1.5.2 Histidine
1.5.2.1 Reaction Mechanism
Diethylpyrocarbonate (DEPC) has almost exclusively been used to modify
histidine residues. A single modification predominates at low DEPC concentrations, but
higher concentrations of the reagent can lead to a second carbethoxylation of histidine.
The reactions of DEPC with histidine and other residues are shown in Figure 1.10.

1.5.2.2 Reaction Conditions
The reactions with DEPC are mostly carried out at room temperature and 37 oC in
the pH range of 5.5-7.5. DEPC is insoluble in water, but it does dissolve in watermiscible solvents such as ethanol and acetonitrile. Typically, reagent amounts between
0.5 to 1000 fold molar excess are used with reaction times ranging from 1 min to 2h.
These conditions are suitable for studying proteins under native conditions; however,
because DEPC is not water soluble, care must be taken to ensure that the amount of
organic solvent added does not disrupt the protein structure.
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Figure 1.10 Modification reactions of diethylpyrocarbonate (DEPC) with histidine,
lysine, tyrosine, serine, and threonine.

1.5.2.3 Side Reactions
Studies have shown that DEPC reacts with lysine at higher pHs. The reagent can
also modify tyrosine, cysteine, arginine, serine and threonine residues with varying
degrees of efficiencies [42,49].
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1.5.2.4 Other Details of Reactivity
DEPC hydrolysis is known to occur with a reaction half-life of 9 min at 25 °C and
pH 7, and the hydrolysis reaction is significantly faster at higher pHs [50]. Monomodification of histidine residues is reversible under both acidic and alkaline conditions
and

in

the

presence

of

nucleophiles

such

as

hydroxylamine

and

tris(hydroxymethyl)aminomethane (TRIS) [49]. The half-life of N-carbethoxyimidazole
is about 55 hours at pH 7, 2 hours at pH 2, and 18 min a pH 10 [51]. Bis-modification of
histidine residues, however, is irreversible. Modification of lysine and tyrosine residues
are irreversible and reversible, respectively [49], and it has been recently shown that
modifications to Ser and Thr residues are reversible over a 20 hr time period [42].
Finally, the extent of histidine’s reactivity with DEPC is found to increase in the presence
of acetate buffers in the pH range of 6 to 7 [52].

1.5.2.5 Biochemical Problems That Have Been Addressed
Histidine is the third least frequently occurring amino acid in proteins, yet its
aromaticity, moderate basicity, H-bonding capacity, and ability to bind divalent transition
metals causes it to be quite commonly involved in protein biochemistry. This fact and the
ease with which DEPC can be used make histidine a relatively common target for
studying protein surface structure. Most studies indicate that histidine’s reactivity is
controlled by its solvent accessibility and possibility its protonation state. Halsall and coworkers used MALDI-TOF and ESI-MS to determine the location and extent of DEPC
modification of α1-acid glycoprotein [53]. Results indicated that His97 was modified at a
faster rate than His100, which was presumed to reflect differences in either the ionization
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state of the imidazole or its accessibility to DEPC. This study also observed DEPCmodified lysine residues with the amount of lysine modification increasing over the pH
range of 6 to 8. The reactivity of insulin with DEPC has also been investigated [52]. At
DEPC:insulin ratios of 50:1, the products consisted of mixtures of the monomodified
(CEt), formyl-CEt (FCEt) modified, and urethane-CEt (UCEt) modified histidine. Peptide
mass mapping indicated that carbethoxylation occurred at His5, His10, and N-termini of
both subunits. However, only biscarbethoxylation (FCEt and UCEt) of His10 was
observed. The ε-nitrogen (NE) and the δ-nitrogen (ND) of His10 both have high solvent
accessibility in both subunits, whereas His5 was only accessible on one side of the
imidazolyl ring (Figure 1.11). These findings reveal that reactivity correlates well with
the calculated solvent accessibilities of the imidazolyl nitrogen atoms.

Figure 1.11 Crystal structure of the insulin dimer (PDB code 4INS). The ε-nitrogen (NE)
and δ-nitrogen (ND) of His-10 are both accessible. His-5 participates in the insulin core
structure and shows an accessible surface for either the ε-nitrogen (NE) or the δ-nitrogen
(ND), depending on the monomer.
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Several studies have also used DEPC modification to characterize protein-ligand
interactions. These studies have involved modifying histidine residues then assessing the
protein’s activity or monitoring the reactivity of a protein’s histidine residues with DEPC
in the presence and absence of a ligand. Glocker and co-workers studied the role of
histidine residues in the ligand-receptor interaction of rhM-CSFβ [39]. Hamasaki and coworkers investigated the possible roles of histidine residues in the conformational
changes that occur during human erythrocyte band 3-mediated anion exchange [54].
An important role of histidine residues in proteins is to bind transition metals, and
thus DEPC modification has been used to map metal-binding sites in proteins. A
particularly noteworthy example involves an assessment of the Cu(II) binding sites of the
prion protein (PrP) [55]. MALDI-MS data showed that five histidine residues within
HuPrP23-98 were protected by Cu(II) from DEPC modification. However, in HuPrP2398 solutions incubated with Zn(II) and Ni(II), only one or two histidines were partially
protected from DEPC modification. These results validate the copper-binding specificity
of the prion protein.

1.5.3 Lysine
1.5.3.1 Reaction Mechanism
Amino groups such as the ε-NH2 of lysine residues and α-NH2 of N-termini are
most commonly modified by acylation with various organic acid anhydrides such as
acetic anhydride, maleic anhydride, and succinic anhydride as well as Nhydroxysuccinimide derivatives. For the structural studies of β2m, sulfo-N-
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hydroxysuccinimide acetate (NHSA) was chosen because of its relatively small size,
solubility in water, and suitability for studying proteins under native conditions. The
reaction of NHSA with lysine is shown in Figure 1.12.

Figure 1.12 Modification reactions of lysine residues by sulfo-N-hydroxysuccinimide
acetate (NHSA).

1.5.3.2 Reaction Conditions
The reactions of N-hydroxysuccinimide derivatives are typically carried out
between 20 and 37 oC at pHs ranging from 5-8. NHSA is sparingly soluble in water.
Reagent amounts vary from 5 to 5000 fold molar excess, and reaction times range from 2
to 80 min. An interesting aspect of NHSA is its ability to efficiently modify lysine
residues at lower pH, which allows these covalent labels to be used under acid-unfolded
conditions.

1.5.3.3 Biochemical Problems That Have Been Addressed
Lysine is one of the most common amino acids found in proteins, and it is almost
always found on protein surfaces. Even so, modification of lysine residues has been the
most commonly used covalent labeling strategy to probe protein surface structure. In one
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of the earliest examples of using covalent labeling and MS, Knock et al. determined the
relative reactivities of amine groups in Aplysia egg-laying hormone using the Nhydroxysuccinimide ester of biotin [56]. Sequence analysis and FAB-MS revealed that
the α-amino group at the N-terminus was the least reactive.
Novak et al. used top-down Fourier transform ion cyclotron resonance mass
spectrometry (FTICR-MS) combined with acetylation with N-hydroxysuccinimidyl
acetate to study reactivities of the amino groups of ubiquitin under native and denaturing
conditions [36]. Under denaturing conditions ubiquitin was fully modified with 21-fold
molar excess of the label. Under native conditions, not all of the primary amino groups
were modified even with an 81-fold molar excess. FTICR-MS data revealed the order of
reactivities of the lysine residues, which are in good agreement with the solvent
accessibility of residues obtained from the crystal structure of ubiquitin.
Zou and co-workers compared the reactivities of lysine residues of full-length
native and hyperphosphorylated human replication protein A (RPA) using Nhydroxysuccinimide biotin [57]. MALDI-TOF MS and ESI-MS analysis revealed that
Lys343 was protected from modification in the hyperphosphorylated RPA, indicating a
structural rearrangement occurs upon phosphorylation. Alter and co-workers used the
solvent accessibility of lysine residues to evaluate the relevance of three dimensional
models of native RPA generated by remote-homology-based modeling procedures to the
native solution-state structure of the protein [58]. The reaction rate constants of tryptic
fragments with sulfo-N-hydroxysuccinimide were used to monitor the microenvironment
of the lysine residues. These reactivities were then compared to the anticipated
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reactivities of candidate structural models. Results showed that this approach is capable
of assessing structural models and can be a basis for selecting the most relevant model.
Lysine residues are very commonly found on the surface of proteins, but they are
not as commonly found at protein-protein interfaces, presumably due to the energetic cost
of burying its positively-charged side chain. Nonetheless, the frequency of lysine residues
on protein surfaces still make them useful probes of protein-protein interactions. Wang et
al. characterized the interactions of rhodopsin and the α-subunit of transducin (Gt) using
acetylation of lysine residues with sulfosuccinimidyl acetate [59]. Results showed that the
modification extents of the lysine residues located in the cytoplasmic C1 and C2 loops
and the C-terminal tail of rhodopsin were decreased upon light activation, indicating that
these regions undergo conformational changes. In the presence of Gtα(340-350), a
synthetic peptide corresponding to the C-terminal residues of the α-subunit of Gt,
acetylation sites on cytoplasmic loops 1, 2, and 4 of Rh* were protected, suggesting that
these sites are involved in the interaction with Gt.
Heck and co-workers used a combination of lysine acetylation with N-acetylsuccinimide and nanoLC-MALDI MS to probe the surface interactions of the DNase
domain of Colicin E9 (E9) with its immunity protein Im9 [60]. This system was used to
test if chemical modification and nanoLC-MALDI MS together with data filtering using
immonium marker ions could be used to characterize protein-protein interactions. In the
presence of Im9, Lys55, Lys63, Lys76, Lys81, Lys89 and Lys97 of E9 were protected
from modification (Figure 1.13). Based on the crystal structure of the E9:Im9 complex,
Lys89 and Lys97 are known to be directly involved in the interaction site. Lys76 and
Lys81 are located in a α-helical region near the interaction surface, and Lys55 and Lys63
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do not interact with Im9. These data suggest that Im9 binding to E9 induces
conformational changes in some amino acid residues. The results again illustrate that
chemical modification approaches can be used to probe protein-protein interactions and
provide complementary data to already available structural models from X-ray
crystallography.

Figure 1.13 Crystal structure of the E9:Im9 complex (PDB code 1EMV). Lys89 and
Lys97 are directly involved in the interaction. Lys76 and Lys81 are located in a α-helical
region near the interaction surface. Lys55 and Lys63 do not interact with Im9 (orange),
and the region of E9 (green) containing these residues possibly undergoes a
conformational change upon Im9 binding.

1.6 Summary
The use of selective covalent labeling in conjunction with MS has been
extensively used in recent years to study protein structure and interactions. As shown in
the previous section, the information obtained from this methodology is complementary
to other biophysical techniques. This dissertation presents improvements in this approach
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and its application in determining the metal binding site, binding-induced conformational
changes, and protein-protein interfaces of the oligomers that precede amyloid formation
of β2m.
Chapter 2 describes an improved protein surface mapping using DEPC with mass
spectrometric detection. It also details the use of measuring the reaction kinetics for
ensuring protein structural integrity during covalent labeling reactions.
In Chapter 3, our improved mass spectrometry-based protein surface mapping
method is used to determine the Cu(II) binding site and any Cu(II)-induced
conformational changes of β2m.
Chapter 4 shows how covalent labeling in conjunction with mass spectrometry is
used to identify the amino acid residues that mediate β2m dimer formation.
Chapter 5 describes the use of the protein surface mapping approach to gain
insight into the structure of the pre-amyloid tetramer of β2m.
In Chapter 6, the differences in oligomerization and/or fibril formation of β2m in
the presence of different divalent metal ions is investigated.
Finally, Chapter 7 contains conclusions and future research directions.
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CHAPTER 2
IMPROVED PROTEIN SURFACE MAPPING USING
DIETHYLPYROCARBONATE WITH MASS SPECTROMETRIC DETECTION
This chapter is part of a paper published as: Mendoza, V. L., and Vachet, R. W. (2008)
Protein surface mapping using diethylpyrocarbonate with mass spectrometric detection.
Anal. Chem. 80, 2895-2904.

2.1 Introduction
Determination of the molecular structure of proteins continues to be important in
molecular biology because of the relationship between protein structure and function.
Detailed structural information about a protein’s spatial arrangement is usually obtained
by X-ray crystallography and NMR; however, both of these techniques have some
limitations. As such, methods based on mass spectrometry (MS) that overcome some of
the shortcomings associated with these techniques are being developed to study higherorder protein structure.
MS does not directly provide amino-acid level information about 3D protein
structure in solution because mass spectral measurements occur in the gas phase. Hence,
some means of encoding this structural information in the mass-to-charge (m/z) ratio of
the measured ions must be applied. Two general approaches have been used, noncovalent and covalent labeling, to accomplish this. Hydrogen deuterium exchange (HDX)
coupled with MS has been extensively and successfully used as a non-covalent labeling
tool to study protein structure and dynamics in solution [1-3]. HDX provides information
about a protein’s backbone structure, but back-exchange during the various stages of
analysis (e.g. LC, MS/MS) can result in the loss of pertinent data and can complicate data
interpretation. In contrast, covalent labeling techniques reports on protein side chains,
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which can be complementary to HDX methods, while avoiding issues of back exchange.
One kind of covalent labeling approach relies on reagents that irreversibly modify either
specific amino acids [4-6] or most amino acids (e.g. hydroxyl radicals [7,8]). These
reagents provide information about protein structure by identifying solvent exposed
amino acids. The residue specific labels have the advantage of simplicity, requiring
reagents and conditions that are readily accessible and easy to use, while methods based
on hydroxyl radicals require special radiation sources to produce the reactive species.
While covalent labels usually provide information that is complementary to HDX
methods, they have some advantages that make covalent labeling methods worth further
investigation. First, the possibilities of back-exchange and scrambling are basically nonexistent. Second, confident detection and identification of modified residues and/or
regions of a protein can be readily done with most types of mass spectrometers because
of the greater mass shifts that occur upon labeling. Finally, observation of small and
locally restricted structural changes in proteins is potentially more straightforward
because the labels can typically be localized to single amino acids. The main drawback of
using covalent labels in comparison to HDX is that protein structure is more likely to be
perturbed by these relatively large labels than when D is used to probe structure.
Given its simplicity and advantages, amino acid-specific covalent labeling of
proteins with detection by MS has been used to map protein surfaces, identify ligandbinding sites, study protein-protein and protein-nucleic acid complexes, and detect
ligand-induced conformational changes [9-18]. Because protein conformational changes
affect their surface topology, amino acid residues involved in the structural changes can
be identified from differential modification patterns. Information from surface mapping
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experiments is reliable, though, only if the structural integrity of a protein is preserved
during the reaction. This is a serious concern because of the relatively large size of
typical amino acid-specific labels. Hence, appropriate checks are required to ensure that
the labeling reaction does not distort the protein’s structure and thus provide incorrect
information. Despite the importance of such checks, a survey of over 60 publications that
use MS and amino acid-specific labeling indicates that over 60% of these studies did
nothing to ensure the structural integrity of the studied protein. About 33% of these
studies either used circular dichroism (CD) spectroscopy or activity assays to check
protein structure. However, these approaches are probably not sufficient to identify
small-scale or local structural changes. CD spectroscopy provides only the populationweight average properties of a protein sample and may not be sensitive to local regions of
a protein, and activity assays will only change significantly if a protein’s structure around
its active site is sufficiently perturbed. About 5% of the reports used fluorescence
spectroscopy, which can provide information about local protein structural changes but
only around tryptophan residues. Finally, only one of the 60+ articles limited the number
of modifications to 1 per protein molecule, but this approach makes detection of the
modified residues more difficult.
In this chapter, an improved amino acid-specific modification and MS-based
approach for protein surface mapping is developed to address the need for a reliable
approach that both ensures protein structural integrity during labeling experiments and
provides readily detectable modifications. We demonstrate that measuring the kinetics of
the covalent labeling reactions ensures that the covalent probe does not disrupt a protein’s
structure during the labeling reaction. The reaction rate coefficients determined also
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provides a quantitative basis for more fully understanding the factors that influence
amino acid reactivity. In addition, we show that diethylpyrocarbonate, which is a very
convenient and easy-to-use label, may have some promise as a general covalent label
because of its ability to probe up to 25% of the residues in the average protein.

2.2 Experimental Procedure
2.2.1 Materials
Human β-2-microglobulin (β2m) was obtained from Fitzgerald Industries
International,

Inc.

(Concord,

MA).

Diethylpyrocarbonate

(DEPC),

imidazole,

dithiothreitol (DTT), equine heart cytochrome c, and equine skeletal muscle myoglobin
were obtained from Sigma-Aldrich (St. Louis, MO). Tris(hydroxymethyl)-aminomethane
(Tris) and tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) were purchased
from EM Science (Gladstone, NJ). Ammonium acetate, methanol, acetonitrile, and acetic
acid were obtained from Fisher Scientific (Fair Lawn, NJ). Trypsin was from Promega
(Madison, WI). Centricon molecular weight cutoff (MWCO) filters were obtained from
Millipore (Burlington, MA). Deionized water was prepared from a Millipore (Burlington,
MA) Simplicity 185 water purification system.

2.2.2 DEPC Modification
The covalent modification reactions were performed for 1 min at 37 oC with 100
µM protein and 50 mM ammonium acetate at pH 7 and were initiated by adding various
molar excesses of DEPC in acetonitrile. The total reaction volume was 100 µL for
cytochrome c and myoglobin, and the total amount of acetonitrile was 1 %. The DEPC
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reactions of β2m were performed for 1 min at 37 oC with 100 µM protein, 200 mM
potassium acetate and 25 mM MOPS at pH 7.4 and were initiated by adding various
molar excesses of DEPC. The total reaction volume for the experiments with β2m was 50
µL, and the total amount of acetonitrile was 1%. All the covalent modification reactions
were quenched by adding 10 mM imidazole. The DEPC-treated samples were then
purified using a 10,000 MWCO filter and reconstituted with deionized water to a final
concentration of 250 µM.

2.2.3 Proteolytic Digestion
Before the addition of trypsin, 80 µL solutions containing 1 µg/µL of unmodified
or DEPC-modified proteins in 50 mM Tris-HCl (pH = 7) and 5 mM CaCl2 were
incubated with 10 µL of acetonitrile at 40 oC for 45 minutes. Also, to reduce the disulfide
bonds in myoglobin and β2m, the proteins were reacted with 10 mM DTT at 40 oC for 45
minutes prior to addition of the acetonitrile. Trypsin (0.5 µg/µL) was then added to yield
a final enzyme:substrate ratio of 1:20. For the β2m samples, chymotrypsin (0.5 µg/µL)
was added together with the trypsin. All samples were incubated at 37 oC for 16 hours.
The enzymes were inactivated by adding 2 µL of acetic acid, and the samples were
immediately frozen at -10 oC and analyzed within 24 hours.

2.2.4 HPLC Analysis
An HP1100 (Agilent, Wilmington, DE) HPLC system with a C18 column (15 cm
x 2.1 mm, 5 µm particle size, Supelco, St. Louis, MO) was used for all LC experiments.
Tryptic fragments were eluted using a linear gradient of methanol containing 0.1% acetic
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acid that increased from 5% to 90% methanol over 30 min at a flow rate of 0.250
mL/min. The LC effluent was split at a ratio of 1:4 with the smaller fraction of the split
flow being fed into the mass spectrometer.

2.2.5 Mass Spectrometry
Mass spectra were acquired on a Bruker Esquire-LC (Billerica, MA) quadrupole
ion trap mass spectrometer equipped with an electrospray ionization source. Typically,
the electrospray needle voltage was kept at 3-3.5 kV, and the capillary temperature was
set to 300 oC. A voltage of 30-40 V was applied to skimmer 1, and the capillary offset
voltage was between 50 and 60 V. For direct injection experiments similar source
conditions were used, but sample was delivered at 1 µL/min using a syringe pump.
Tandem mass spectra were acquired using isolation widths of 1.0 Da and excitation
voltages between 0.6 and 1.0 V. Peptide sequences were determined from the MS/MS
data via de novo sequencing or with the help of BioToolsTM (Bruker Daltonics, Billerica,
MA). The sequence coverage for cytochrome c and β2m was 100%, while the sequence
coverage for myoglobin was approximately 90%.

2.2.6 Determination of Solvent Accessibility
The 3D structures of cytochrome c and myoglobin were examined using the
structures from the Protein Data Bank (PDB) (1AKK for cytochrome c and 1DWR for
myoglobin).

Solvent

accessibility

was

calculated

using

GETAREA

(http://curie.utmb.edu/getarea.html) [19]. A probe radius of 1.4 Å, representing the van
der Waals sphere of water, was used.
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2.2.7 Fluorescence Measurements
Fluorescence spectra were acquired with a Photon Technology International
Quantamaster-4 SE. Tryptophan fluorescence measurements were obtained using slit
widths of 2 nm and an excitation wavelength of 280 nm. Protein solutions (100 µM, 50
mM ammonium acetate at pH 7) were initially incubated at 37 oC for 30 min prior to
addition of DEPC. Emission scans from 300-390 nm were taken at different time points
after the addition of DEPC. Fluorescence intensity measurements immediately before and
1 to 5 min after the addition of DEPC were performed to determined the effect of DEPC
modification on protein structure. The fluorescence measurements are reported as
Average Emission Fluorescence Wavelength, <λ>, as shown in equation 1 [20]:

2.2.8 Circular Dichroism (CD) Experiments
CD experiments were performed at 37 oC using a Jasco-710 spectropolarimeter.
All experiments were done in 50 mM ammonium acetate at pH 7. Spectra were measured
with a sample cell having a 0.1 cm path length and at a scan resolution of 0.2 nm, a scan
rate of 50 nm/min, and a response time of 4 s.
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2.3 Results and Discussion
2.3.1 Carbethoxylation of Histidine, Tyrosine, Serine and Threonine
Diethylpyrocarbonate (DEPC) reacts somewhat specifically with histidine
residues at near-physiological pHs (Figure 2.1), but it can also react with tyrosine,
cysteine, and lysine residues [9,21,22]. Covalent modification experiments with DEPC
are usually performed for 30-120 min at pH ~ 7 [21-23]. In our experiments a 1 min
reaction time was chosen to minimize the effect of DEPC hydrolysis on the kinetics of
the modification reactions. DEPC hydrolysis is known to occur with a reaction half-life
of 9 min at 25 °C and pH = 7 [24]. In addition, a short reaction time was used to improve
the temporal resolution of the modification procedure and decrease the possibility of
protein structural changes during modification. The reagent dose was also kept relatively
low to minimize any structural changes caused by the reagent.
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Figure 2.1 Reactions of histidine, tyrosine, threonine, and serine with DEPC.

Under our reaction conditions, LC-MS/MS data (e.g. Figure 2.2) show that many
solvent exposed His, Tyr, Ser and Thr residues are modified by DEPC (Tables 2.1 and
2.2). Most of the modified amino acids have solvent accessible surface area (SASA)
percentages above 30. Figure 2.2 shows the MS/MS spectra of the 16 modified peptides
which confirm the modification sites that are reported in Tables 2.1 and 2.2. These
spectra also demonstrate that modifications can be readily determined with single amino
acid resolution. For example, unmodified y3, y4, y5, and y6 product ions along with
modified y7 ion indicate that His13 is the modified residue in the Ser11-Lys19 fragment

44

of β2m (Figure 2.2B). Similarly, unmodified b ions from b9 through b14, a modified b15
ion, and a complete series of modified y2 to y13 ions indicate that Ser117 is the modified
residue in the Tyr103-Lys119 fragment of myoglobin (Figure 2.2Q).

Table 2.1 DEPC modification rate coefficients for histidine residues.
Protein

Cytochrome
C

Myoglobin

β2m

SASA of
Nε2 (Ǻ2)a
3.9

pKab

His18

% SASA
Ratioa
15

4.3

kc
(M-1 s-1)
0

His26

34

6.8

6.5

0.069 ± 0.004

His33

49

0.3

6.4

0

His24

3

0

4.6

0

His36

33

11.7

6.1

0.070 ± 0.007

His48

65

6.4

6.7

0.067 ± 0.003

His64

27

5.9

4.5

0.009 ± 0.001

His81

89

18.8

7.4

0.053 ± 0.002

His82

45

0

7.1

0

His93

35

17.1

4.4

0

His97

43

13.5

6.4

0.036 ± 0.003

His113

43

9.9

6.2

0

His116

44

0.6

6.4

0

His119

20

0

6.2

0

His13

56

15.7

7.4

0.041 ± 0.003

His31

25

11.5

7.2

0.010 ± 0.001

His51

44

10.2

6.2

0.036 ± 0.003

His84

0

0

7.3

0

Residue

a

Solvent accessible surface area (SASA) calculated using GETAREA 1.1. 1.4 Å is used
as the probe radius, and the calculated SASA is compared to the surface area of the side
chain in a Gly-X-Gly tripeptide generating a % ratio. Residues with % ratio below 20 are
typically considered buried whereas those with ratios above 30% are regarded as solvent
exposed
b
pKa calculated using PROPKA
c
Rate coefficients from dose-response plots like those shown in Figure 2.5
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DEPC is known to react with Tyr residues in addition to His residues, but the
modification of Ser and Thr residues is previously unreported. Like Tyr residues, Ser and
Thr have weakly nucleophilic alcohol groups capable of reacting with DEPC. We find
that the reactivity of Ser and Thr residues is mostly limited, though, to those residues that
are highly exposed (i.e. SASA % ratios > 50%), and so only 21% and 5% of the Ser and
Thr residues, respectively, are modified in the three proteins studied here. Nonetheless,
this observation dramatically expands the potential of DEPC as a probe of protein
structure. Histidine and tyrosine residues cover only 2.2% and 3.3%, respectively, of the
sequence of a typical protein [25]. In contrast, Ser and Thr cover 7.4% and 6.0% of the
sequence of a typical protein [25]. Indeed, Ser is the third most abundant residue in
proteins. Because Lys (5.8% frequency) and Cys (1.8% frequency) can also be modified
by DEPC, this reagent has the potential to cover about 25% of the sequence of a typical
protein. This degree of coverage could make DEPC a very general surface mapping
reagent for those proteins having typical numbers of His, Tyr, Ser, Thr, Lys, and Cys
residues.
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Table 2.2
residues.

DEPC modification rate coefficients for tyrosine, serine and threonine

Protein

Cytochrome
C

Myoglobin

β2m

Residuea

SASA of
Nε2b
30.9

pKac

Tyr48

% SASA
Ratiob
26

9.8

kd
(M-1 s-1)
0.050 ± 0.006

Tyr67

10

9.0

12.5

0.017 ± 0.002

Tyr74

27

8.5

10.2

0.015 ± 0.001

Tyr97

8

7.9

10.9

0

Tyr103

15

17.1

11.9

0

Tyr146

4

0

10.1

0

Ser3

64

3.6

--

0.031 ± 0.003

Ser117

51

31.5

--

0.028 ± 0.003

Thr4

63

25.8

--

0.078 ± 0.004

Ser33

43

25.2

--

0.008 ± 0.002

Ser88

97

25.7

--

0.021 ± 0.005

a

All Tyr residues are included for each protein, but only modified Ser and Thr residues
are included.
b
SASA calculated using GETAREA 1.1. 1.4 Å is used as the probe radius, and the
calculated SASA is compared to the surface area of the side chain in a Gly-X-Gly
tripeptide generating a % ratio. Residues with % ratio below 20 are typically considered
buried whereas those with ratios above 30% are regarded as solvent exposed
c
pKa calculated using PROPKA
d
Rate coefficients from dose-response plots like those shown in Figure 2.5
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This figure is continued on the next page.
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This figure is continued on the next page.
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This figure is continued on the next page.
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This figure is continued on the next page.
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This figure is continued on the next page.
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Figure 2.2 MS/MS spectra of β2m (A-F), cytochrome C (G-J), and myoglobin (K-Q)
showing modification of: (A) Thr4 (fragment Thr4-Tyr10), (B) His13 (fragment Ser11Lys19), (C) His31 (fragment Val27-Lys41)*, (D) Ser33 (fragment Val27-Lys41)*, (E)
His51 (fragment Val49-Trp60), (F) Ser88 (fragment Val82-Lys94), (G) His26 (fragment
His26-Arg38), (H) Tyr48 (fragment Thr40-Lys55), (I) Tyr67 (fragment Gly56-Lys72),
(J) Tyr74 (fragment Lys73-Lys79), (K) N-terminus or Ser3 (fragment Gly1-Lys16), (L)
His36 (fragment Leu32-Lys45), (M) His48 (fragment His48-Lys50), (N) His64 (fragment
Lys63-Lys77), (O) His81 (fragment Gly80-Lys96), (P) His97 (fragment His97-Lys102),
and (Q) Ser117 (fragment Tyr103-Lys118)).
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The failure to see more modified Ser and Thr residues might be due to two
reasons. First, residues that are modified at very low extents can be difficult to detect
under normal LC-MS conditions. Second, covalent modification by DEPC is known to be
reversible for His and Tyr. For example, the dissociation reaction of modified His has a
t1/2 of 55 hr at pH = 7 [16]. The modifications of Ser and Thr might also be reversible and
could conceivably have shorter t1/2, making them even more difficult to detect. To test
this second possibility, the reversibility of this reaction was tested for six model peptides
that each had at least one Ser, His, or Thr residue (Table 2.3). After reaction of these
peptides with DEPC for 1 min, the solutions were stored at 37 oC for 22 hr to mimic the
digestion conditions. The samples then were stored at -10 oC for the remaining time to
mimic the storage conditions used for all the peptides shown in Tables 2.1 and 2.2.
Aliquots of these reaction mixtures were analyzed at different time periods. Figure 2.3
clearly shows that the extents of modification of the Ser- and His-containing peptides do
not decrease for up to 60 hours, but the extents of modification to the Thr-containing
peptides start to decrease after about 10 to 12 hours before leveling off when the samples
are frozen. These data suggest that the reaction of DEPC with Thr is reversible and may
explain why only a small percentage (~ 5%) of modified Thr residues is detected. Further
work is needed to fully characterize the reversibility of this reaction, and methods to
avoid this situation will be important in order to expand the practical sequence coverage
possible with DEPC.
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Table 2.3 Peptides used for investigating reversibility of DEPC modification.
Amino acid
modified
Ser

Peptide sequence

Peptide mass

CH3-GRGDSP

601.6

Peptide + DEPC
masses
673.6

LRRASLG

771.9

843.9

IARDHPYFL

1172

1244

DRVYIHPFHL

1296

1368

VAITVLVK

842.1

914.1

GRGDTP

601.6

673.6

His

Thr

LRRASLG

% DEPC Modification

60
GRGDSP

50
DRVYIHPFHL

40
IARDHPYFL

30

VAITVLVK
GRGDTP

20
0

10

20

30

40

50

60

Time (hr)
Figure 2.3 Changes in DEPC modification percentages over time for peptides containing
Ser, His, and Thr residues. Each plot is labeled with the sequence of the peptide that
corresponds to the data. The lines are not mathematical fits of the data but are included to
help visualize the qualitative trend. The thicker lines are for the peptides containing Thr.
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2.3.2 Dose-Response Curves as Indicators of Changes in Protein Structure
Structural information from surface mapping experiments is reliable only if the
protein structure is preserved during the reaction. Some previous surface mapping studies
have used spectroscopic methods such as CD or fluorescence spectroscopy to monitor the
effect of modification on the protein structure. Some have assumed that as long as the
number of modifications is kept low the protein’s structure will not be affected by the
label. These approaches may make identification of modified residues difficult by
limiting the average number of modifications and may lead to errors. CD, for example,
provides only the population-weight average properties of a protein sample and may not
be sensitive to local structural changes or intra- and intermolecular interactions between
protein molecules. Fluorescence spectroscopy can provide local structural information
but usually only around Trp residues. Finally, the assumption that limiting the number of
modifications will ensure protein integrity may be too simplistic. Some proteins may be
able to suffer multiple modifications to surface exposed amino acids without disrupting
structure, while the structures of other proteins might be significantly altered by a single
modification at a particular site.
Monitoring the extent of protein modification as a function of reagent
concentration should be a sensitive method for ensuring that a protein’s structure is
maintained during the modification reaction. Under the conditions that we use, the
reaction of DEPC with a protein is a second-order reaction, and ensuring that this
reaction order is maintained at low reagent doses can serve as the means by which protein
structural integrity is assured. A second-order reaction is described by equations 2 and 3,
where [P]o is the initial concentration of unmodified protein, [X]o is the initial
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concentration of DEPC, [P] is the unmodified protein concentration at time t, [X] is the
DEPC concentration at time t, and k is the second-order rate coefficient.

If a reaction is second order, then a plot of ln([P][X]o)/([P]o[X]) vs. [X]o (or t) will
result in a straight line. We assume that the second-order modification rate coefficient
will be constant as long as the protein’s structure remains unchanged, and such a doseresponse plot will thus remain linear. Deviations from linearity or changes in the plot’s
slope will indicate a change in the reaction dynamics that are likely caused by changes in
a residue’s microenvironment. Thus, these plots should be very sensitive to any
modification-induced structural changes that occur.
The reaction time with DEPC was kept constant at 1 min to minimize DEPC
hydrolysis over time, and different DEPC concentrations were used to generate the
second-order reaction plots. At low DEPC concentrations, linear relationships are
observed between the unmodified protein and the DEPC concentrations, suggesting
second-order kinetics and the proteins’ 3D structures are maintained during the covalent
modification reactions of cytochrome c and myoglobin (Figure 2.4). Deviations from
linearity occur at DEPC concentrations above 0.6 mM and 0.4 mM for cytochrome c and
myoglobin, respectively, indicating that the proteins’ structures are disrupted during 1
min reactions with DEPC above these concentrations. Figure 2.5 shows expanded views
of the mass spectra of cytochrome c and myoglobin after reactions with 0.6 mM and 0.4
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mM DEPC, respectively. Up to 3 and 4 DEPC adducts are possible for cytochrome c and
myoglobin before deviations from linearity are noted. At these DEPC concentrations, the
average numbers of modifications per molecule are 1.48 and 0.91 for cytochrome c and
myoglobin, respectively. In addition, the modification rate coefficient, k, obtained from
the slope of the lines in Figure 2.4 indicates that myoglobin is more reactive with DEPC
than cytochrome c. This is most likely due to the greater number of exposed His residues
in myoglobin.
While second-order reaction plots of the whole protein data indicate that global
changes to protein structure occur above certain DEPC concentrations, an assessment of
local changes in protein structure can be obtained by generating second-order reaction
plots for individual proteolytic fragments of the proteins. LC-MS analysis of the tryptic
peptides of these proteins reveal that the labeling reactions follow second-order kinetics,
but there are differences for each fragment both in the concentration at which deviations
from linearity are observed and in the modification rate coefficients (Figure 2.6). These
observations are important for two reasons. First, deviations from linearity at different
DEPC concentrations indicate that certain regions of a protein lose their native structure
more readily than others upon reactions with DEPC. Second, the rate coefficients are
quantitative indicators of a residue’s reactivity and might correlate with a residue’s
SASA, thus providing more precise structural insight.

58

Figure 2.4 Dose-response plots for the reactions of DEPC with (A) cytochrome c and (B)
myoglobin. The plot for each protein is produced from the ESI-MS data of the DEPCtreated proteins. The [P]/[P]0 ratio is obtained by dividing the peak area for the
unmodified protein by the sum of the peak areas for the modified and unmodified protein.
The difference between the [P] and [P]o is used to determine the concentration of DEPC,
[X]. The k values are obtained by dividing the measured slopes by the reaction time.

59

Figure 2.5 Expanded view of mass spectrum showing the extent of DEPC modification
for the (A) +15 charge state of cytochrome c and (B) +21 charge state of myoglobin. CEt
refers to a carbethoxy group, which is added upon reaction with DEPC.
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Figure 2.6 Dose-response plots for selected proteolytic fragments of myoglobin after
reactions with DEPC. (A) Proteolytic fragment Leu32-Lys45, which contains His36; (B)
Proteolytic fragment His48-Lys56; (C) Proteolytic fragment Lys79-Lys96, which
contains His81; (D) Proteolytic fragment Gly1-Lys16 which contains Ser3. The plot for
each reactive residue is produced from LC-MS data of the proteolytic digests of the
modified protein. The ion abundances for the modified and unmodified peptide fragments
containing the residue of interest are used to determine [P], [P]o, [X] and [X]o in a manner
similar to that described in the caption of Figure 2.4.
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2.3.3 A Comparison with Structural Information from Spectroscopic Techniques
The information obtained from the dose-response plots is compared to CD and
fluorescence data in order to (1) check whether the dose-response plots are valid
approaches for testing the maintenance of structural integrity and (2) confirm our
hypothesis that the dose-response plots are more sensitive to local structural changes in a
protein. Tryptophan fluorescence, far-UV CD, and near-UV CD measurements of
cytochrome c and myoglobin were made as a function of reagent concentration.
Tryptophan fluorescence is commonly used to monitor structural changes in a protein
because the fluorescence intensity of this amino acid residue is very sensitive to local
structural changes. In this work, the red shift in emission was determined by calculating
the average emission fluorescence wavelength, <λ> [20]. Because it is an integral
measurement, the <λ> is less prone to instrumental noise than is the peak maximum. It is
also a more sensitive value because it arises from a calculation involving the entire
spectrum, thus, it reflects changes in the shape of the spectrum as well as in position.
Fluorescence measurements (Figure 2.7) of the proteins are consistent with the
MS data in Figure 2.4. Changes in the fluorescence intensity of cytochrome c and
myoglobin at 1.5 and 0.8 mM DEPC, respectively, suggest that there are structural
changes in the proteins at these concentrations. Even though the structural changes
monitored by fluorescence occur at higher DEPC concentrations than are observed in
Figure 2.4, a comparison of the data from proteolytic fragments containing a Trp residue
is most relevant. The DEPC concentration (0.6 mM) at which the fluorescence of
myoglobin changes is similar to the concentration at which the linearity of the doseresponse plot for the proteolytic fragment Gly1-Lys16 changes (Figure 2.6D). This

62

peptide fragment contains myoglobin’s two Trp residues at positions 7 and 14, and the
DEPC-modified Ser residue in this fragment is at position 3. Evidently, the extent of
modification that occurs on myoglobin at DEPC concentrations > 0.8 mM is enough to
cause a structural change in the N-terminal region of the protein that is reflected in both
the fluorescence and MS data. DEPC-modified fragments containing Trp residues were
not detected for cytochrome c, so this comparison could not be done for this protein.
Even though it is only one comparison, the consistency between the MS and fluorescence
data for fragment 1-16 supports the idea that the dose-response plots can act as indicators
of protein structural changes. Moreover, the fluorescence data can only provide
information about the microenvironment of Trp, which is the least commonly occurring
amino acid residue. The dose-response plots from LC-MS analyses, on the other hand,
enables monitoring changes in multiple sites in a protein. This appears to be essential for
both proteins studied here as the dose-response plots indicate that structural changes
occur for some regions of the protein at lower DEPC concentrations than the fluorescence
data indicate.
CD spectroscopy is another method that is used to monitor protein structural
changes, but this method is much less sensitive to local structural changes. When the farUV (Figure 2.8) spectra of the proteins in the presence of DEPC are obtained, the results
are almost identical to the CD spectra of the native proteins, even for DEPC
concentrations up to 2 mM (50-fold excess). For comparison, CD spectra of the proteins
in the presence of the denaturant urea are shown to indicate spectral differences that can
occur upon changes in protein structure. These results indicate that CD spectroscopy is
not as sensitive as the dose-response curves for detecting structural changes that occur
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upon covalent modification.

Several studies have used CD spectroscopy to check

changes in protein structure during covalent labeling experiments [9,14-16,26], but our
results suggest that CD spectroscopy may not always be a reliable approach for ensuring
protein structural integrity during the modification reactions.

Figure 2.7 Fluorescence measurements of (A) cytochrome c and (B) myoglobin after
reactions with different concentrations of DEPC. The fluorescence measurements are
reported as average fluorescence emission wavelength calculated as described in Section
2.2.7.
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Figure 2.8 Far-UV CD spectra of (A) cytochrome c and (B) myoglobin acquired under
native conditions (dotted black line), after a 1 min reaction with a 50-fold excess (5 mM)
of DEPC (solid light gray line), in the presence of 1 M urea (dashed black line), and in
the presence of 9 M urea (dashed gray line).
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2.3.4 Concentration Effects
Because the reaction with DEPC is second-order, the initial protein concentration
plays a role in the extent of modification observed. Modification with 10 µM and 100 µM
cytochrome c results in different degrees of modification. The average numbers of
modifications per cytochrome c molecule are 0.07 and 0.38 for the 10 µM and 100 µM
solutions, respectively, at 0.6 mM DEPC. However, we do not expect the rate coefficient
to vary with any change in protein concentration. The modification rate coefficients
obtained for the two cytochrome c solutions are identical within experimental error with a
k = 0.027 ± 0.001 for the 10 µM solution and a k = 0.0268 ± 0.0004 for the 100 µM
solution (Figure 2.9). In addition, the range where linearity holds for the 10 µM solution
of cytochrome c is higher when compared to the 100 µM solution. In the 10 µM case, the
linearity of the plot holds at 10-fold molar excesses of DEPC whereas linearity is lost in
the 100 µM solution at molar excesses above 6-fold. These results are not surprising as
the higher concentrations of protein and DEPC increase the rate of the reaction, while not
changing the rate coefficient for the reaction. A greater number of modifications occur
after 1 min in the 100 µM solution, and modification-induced structural changes thus
occur at lower DEPC ratios under these conditions. The relevance of these concentration
studies has become apparent because of a recent oxidative labeling study [27]. This
covalent labeling study using hydroxyl radicals showed that protein concentration has a
critical impact on the level of modification, and if not accounted for correctly, data
interpretation ambiguities can occur in oxidative labeling studies of protein-protein
interactions [27]. Our results clearly show that the second-order plots account for protein
concentrations adequately in our covalent labeling studies.
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Figure 2.9 Dose-response plot showing the effect of protein concentration on the DEPC
modification rate. The modification rate coefficients, k, are 0.027 ± 0.001 for 10 µM
(black straight line) and 0.0268 ± 0.0004 for 100 µM (gray dashed line). The k values are
obtained by dividing the measured slope by the reaction time.

2.3.5 Factors Affecting the Reactivity of Functional Groups
In addition to providing the range of DEPC concentrations over which a protein’s
structural integrity is maintained, the dose-response curves provide reaction rate
coefficients that allow quantitative comparisons between the reactivity of different
residues. Previous studies have shown that reactivity is influenced mainly by the solvent
accessibility of the amino acid and of the reactive atom [19,23,28,29]. The rate
coefficients in Tables 2.1 and 2.2 indicate that there is not a simple correlation between
the modification rates and the solvent accessibility of the entire side chain. The % SASA
ratio does not seem to always correlate with the reaction rates. For example, His33 of
cytochrome c is not reactive with DEPC despite its high SASA. A better indicator of
reactivity appears to be the solvent accessibility of the reactive atom, which is the Nε2
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atom in His residues. In cytochrome c, for example, His26 is more reactive with DEPC
than His33 despite its lower overall SASA. This is probably due to the higher
accessibility of its Nε2 atom.

This could also explain why Tyr48 and Tyr74 of

cytochrome c do not have the same reactivity with DEPC even though these residues
have similar % SASA ratios. Tyr48 is more reactive because its hydroxyl group is more
solvent accessible than the hydroxyl group of Tyr74. The lower reactivity of Tyr67,
despite a similar OH group SASA as Tyr74, is due to its location in the heme pocket of
myoglobin. GETAREA does not calculate SASA with the heme present, so the actual
SASA of Tyr67 is surely lower. Similar reasoning explains the lack of reactivity of His93
and His64 of myoglobin and His18 of cytochrome c; the SASA of these residues are
artificially high because the heme is not included in the SASA calculation. When the
modification rate coefficients for all 18 of the histidine residues from the three proteins in
this study are considered, it is clear that only those His residues with Nε2 SASA above 6
Å2 are modified (Tables 2.1) with the exception of 2 His residues. The failure of these
two His residues (His93 and His113 from myoglobin) to react with DEPC despite Nε2
SASA above 6 Å2 is actually enlightening about the factors that affect His reactivity.
His93 is bound to the heme in myoglobin, so as mentioned above its calculated SASA is
incorrect. His113 is probably unreactive because of its close proximity (~ 3.3 Å) to
Arg31. This nearby Arg residue might form a H-bond with His113 or its positive charge
might hinder the reaction of His113 with DEPC by influencing the partial positive
character of the reactive carbonyl carbon of DEPC. The only other His residue in the
three proteins that is also close (< 8 Å) to an Arg residue is His31 in β2m. This His
residue is reactive, but the modification rate coefficient for this residue is much lower
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(0.010 M-1s-1) than expected based on its relatively high Nε2 SASA (11.5 Å2). The effect
of a nearby charged residue might also be used to explain the lack of reactivity of Tyr103
from myoglobin. Despite its hydroxyl group having a very high SASA, the electrostatic
effect of nearby Glu38 (~ 4.3 Å) may lower Tyr103’s reactivity. The other Tyr residues
do not have charged residues nearby. The relatively few Ser and Thr residues that are
reactive make it difficult to assess the factors that affect the reactivity of these residues.
Even stronger quantitative correlations between modification rate coefficients and
the accessibility of the reactive atom are difficult to obtain because of the other potential
factors that affect reactivity, such as ionization state, H-bonding, and electrostatic effects
of nearby residues. Examples of possible electrostatic effects were briefly mentioned
above for His113 and Tyr103 of myoglobin and His31 of β2m. A good example of the
effect of ionization state is observed upon considering the reactivity of His81 in
myoglobin. Despite having the highest Nε2 SASA, the modification rate coefficient of
this residue is modest (0.053 M-1s-1). Not coincidentally, this His residue also has the
highest calculated pKa of all the His residues, indicating that under the experimental
conditions His81 is protonated in most of the protein molecules. Histidine reacts with
DEPC only when deprotonated. Because of the many factors that can influence DEPC
reactivity, any quantitative description will clearly require the study of a greater number
of proteins.
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2.4 Conclusions
An improved method of protein surface mapping using covalent modification in
conjunction with MS has been described in this chapter. Results demonstrate that DEPC
can react with Ser and Thr residues in addition to His and Tyr residues, which
dramatically expands the sequence coverage possible with this reagent. Given the
prevalence of Ser and Thr residues in proteins, DEPC may be able to compete with nonspecific reagents like hydroxyl radicals as a standalone reagent for protein surface
mapping. The lesser number of possible products from DEPC modification makes
identification of its modification sites more straightforward when compared to hydroxyl
radicals that react with many amino acid residues, generating a variety of possible
oxidation products. Another advantage of DEPC over hydroxyl radicals is that it does not
require the use of expensive synchrotron or other X-ray sources. Further improvements to
the method will be necessary to fully access this potential. Improvements such as better
detection of modified Ser and Thr residues will expand the practical sequence coverage
possible with DEPC.
This work in this chapter also establishes a reliable approach for ensuring protein
structural integrity during the modification reactions. Most amino acid-specific covalent
labeling studies fail to do this. Dose-response plots are shown to be a useful approach for
making sure that the intact structure of a protein is being monitored during the covalent
modification reactions. By generating these plots for individual peptide fragments, any
small-scale or local perturbations caused by the covalent label can be readily identified
and avoided. Furthermore, these plots are more reliable and generally applicable than CD
and fluorescence spectroscopies. The dose-response plots provide the added benefit of
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quantitative information about residue reactivity, which could possibly provide more
precise structural information. While our results cannot currently provide a quantitative
description of all the factors that affect reactivity, modification rate coefficients seem to
reflect both the reactive atom’s solvent accessibility and amino acid microenvironment.
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CHAPTER 3
COPPER BINDING AND BINDING-INDUCED CONFORMATIONAL
CHANGES IN β-2-MICROGLOBULIN
This chapter is part of papers published as: Srikanth, R., Mendoza, V. L., Bridgewater, J.
D., Zhang, G., and Vachet, R. W. (2009) Copper binding to β-2-microglobulin and its
pre-amyloid oligomers. Biochemistry 48, 9871-9881 and Mendoza, V.L., Antwi, K.,
Baron-Rodriguez, M.A., Blanco, C., and Vachet, R.W. (2009) Structure of the preamyloid dimer of β-2-microglobulin from covalent labeling and mass spectrometry.
Biochemistry 49, 1522-1532.

3.1 Introduction
The cause of β-2-microglobulin (β2m) amyloid formation in vivo is not precisely
known, but several means of causing fibril formation in vitro have been identified. β2m
amyloid fibrils can be generated under acidic conditions (pH < 3.6) [1], by removing the
first six N-terminal amino acids [2], by mixing the protein with collagen at pH = 6.4 [3],
by sonicating the protein in the presence of sodium dodecyl sulfate at pH = 7.0 [4], and
by incubating the protein at physiological conditions in the presence of stoichiometric
amounts of Cu(II) [5,6].
The latter means of initiating β2m fibril formation is interesting for a number of
reasons. Several proteins are known to form amyloid fibrils in the presence of divalent
metals, especially Cu(II), thus, Cu(II)-protein interactions seem to represent one of the
general motifs for stimulating amyloid formation [7-11]. For β2m, the case has been
made that Cu(II) could be the initiating factor in vivo because of the elevated Cu(II)
concentrations that hemodialysis patients experience (i.e. dialysate and dialysis
membrane) [5,12]. The conditions necessary to stimulate β2m fibril formation in the
presence of Cu(II) are also arguably more similar to physiological conditions than other
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methods used to stimulate β2m fibril formation in vitro. In addition, a catalytic role for
Cu(II) is suggested by recent studies that found Cu binding to be essential for initiating
oligomer formation under near-physiological conditions (i.e. pH 7.4, 37 ºC, 150 mM
ionic strength) in vitro but not essential for maintaining the stability of tetramers or
hexamers and completely absent in the eventual amyloid fibrils [13,14]. While an in vivo
role for Cu(II) in β2m amyloid formation is not confirmed, the metal does represent a
discrete way to trigger amyloid formation so that the intermediates that precede the fibrils
can be more easily studied. The added appeal of studying Cu(II) as a trigger is that the
structural changes brought about by Cu binding are subtle and the pre-fibril oligomers
have native-like structures [15]. Intriguingly, very similar divalent metals, such as Ni(II),
do not cause β2m to self assemble [15], indicating that the mode of Cu(II) binding is
unique enough to cause just the right structural changes to facilitate oligomerization and
fibril formation.
Given the importance of β2m fibril formation and the unique ways in which
Cu(II) catalyzes this reaction, the structural details of how Cu(II) binds the monomer and
causes the necessary structural changes for oligomerization are important to determine. In
this chapter, covalent labeling with mass spectrometric detection is used to determine the
Cu(II) binding site in β2m and any conformational changes induced by metal binding.
These covalent labeling methods provide information about protein structure and
interactions by comparing the reactivity of amino acid side chains in solution under
different conditions (i.e. with and without Cu). The covalent labeling reactions can be
used to identify Cu(II) binding sites because reactivity with these reagents is significantly
decreased when residues are bound to Cu [16,17].
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3.2 Experimental Procedure
3.2.1 Materials
Human β2m was obtained from Fitzgerald Industries International, Inc. (Concord,
MA). Diethylpyrocarbonate (DEPC), 2,3-butandeione (BD), sulfo-N-hydroxysuccinimide
acetate (NHSA), imidazole, dithiothreitol (DTT), copper-(II) sulfate (CuSO4), 3morpholinopropanesulfonic acid (MOPS), potassium acetate, arginine, ubiquitin from
bovine erythrocytes, equine heart cytochrome c, equine skeletal muscle myoglobin,
chicken egg white ovalbumin, human hemoglobin, and bovine transferrin were purchased
from Sigma-Aldrich (St. Louis, MO). Tris(hydroxymethyl)-aminomethane (Tris) was
purchased from EM Science (Gladstone, NJ). Urea was purchased from Mallinckrodt
Chemicals (Phillipsburg, NJ). Trypsin was from Promega (Madison, WI), and
chymotrypsin was purchased from Roche Diagnostics (Indianapolis, IN). Centricon
molecular weight cutoff (MWCO) filters were obtained from Millipore (Burlington,
MA). Deionized water was prepared from a Millipore (Burlington, MA) Simplicity 185
water purification system.

3.2.2 β2m Solutions
100 µM β2m in 200 mM potassium acetate, 500 mM urea, and 25 mM MOPS
(pH 7.4) with 200 µM copper(II) sulfate at 37 °C. All components were equilibrated at 37
°C prior to Cu(II) addition, and immediately returned to 37 °C after mixing. The covalent
labels were added to the incubated β2m 2 minutes after addition of Cu(II).
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3.2.3 Carbethoxylation with DEPC
Stock solutions of DEPC were prepared in acetonitrile. The DEPC reactions of
β2m were performed for 1 min at 37 °C and were initiated by adding 0.25 mM DEPC.
The total reaction volume for the experiments was 30 µL, and the total amount of
acetonitrile added was ~ 1.5 %. The reactions were quenched after 1 min by adding 10
mM imidazole.

3.2.4 Acetylation with NHSA
Stock solutions of NHSA were prepared in water. The labeling of β2m with 0.30
mM NHSA was carried out for 1 min at 37 °C. The total reaction volume for the
experiments was 30 µL. The reactions were quenched by adding 10 mM Tris.

3.2.5 BD Modification
Stock solutions of BD were prepared in water. The reactions of β2m with 35 mM
BD were performed in the dark for 1 min at 37 °C. Reactions were carried out in the dark
to avoid possible photoactivation of the label, which could enhance nonspecific reactions
with residues other than arginine [18,19]. The total reaction volume for the experiments
was 30 µL. The reactions were quenched by adding 100 mM arginine.

3.2.6 Proteolytic Digestion
Before proteolytic digestion, all modified samples were purified using a 10,000
MWCO filter and reconstituted with deionized water to a final concentration of 300 µM.
Purified β2m samples in 25 mM Tris-HCl (pH 7) and 1 mM CaCl2 were first reacted with
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10 mM DTT at 37 °C for 45 min to reduce the disulfide bonds. This was followed by
addition of acetonitrile and incubation at 37 °C for 45 min. Trypsin and chymotrypsin (1
µg/µL) were then added to DEPC-modified samples to yield a final enzyme/substrate
ratio of 1:20. For the NHSA- and BD-modified β2m samples, only chymotrypsin (1
µg/µL) was added. Although trypsin is the most reliable and robust protease,
chymotrypsin was used instead because trypsin can no longer cleave proteins after
acetylated lysine and modified arginine residues. All samples were digested at 37 °C for
16 h. The enzymes were inactivated by adding 2 µL of acetic acid, and the samples were
immediately analyzed.

3.2.7 Instrumentation
The amount of modification was determined by removing an aliquot of the
purified β2m and analyzing the samples using a Bruker Esquire-LC quadrupole ion trap
mass spectrometer (Billerica, MA) equipped with an ESI source. The ESI source was
operated at a spray voltage of 3.5 kV, and the capillary temperature was set at 300°C. The
voltages for the transfer optics between the ESI source and the ion trap were optimized
for maximum signal, with typical skimmer 1 and capillary offset values of 30-35 V and
50-60 V, respectively.
The proteolytic fragments were separated by an Agilent HP1100 (Wilmington,
DE) HPLC system with a C18 column (15 cm x 2.1 mm, 5 µm particle size, Supelco, St.
Louis, MO) for on-line analysis by MS and MS/MS. The fragments of NHSA- and BDmodified β2m were eluted using a linear gradient of methanol that increased from 5 to
70% over 20 min and 70 to 100% over the final 2 min at a flow rate of 0.250 mL/min.
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For the fragments of DEPC-modified β2m, a linear gradient of methanol that increased
from 5 to 70% over 30 min and 70 to 100% over the final 3 min was used. For both
gradient conditions, water comprised the balance of the solvent, and a total of 0.1% acetic
acid was present. The LC effluent was fed into the mass spectrometer with similar ESI
source conditions as described above. Tandem mass spectra were acquired using collision
induced dissociation (CID) with isolation widths of 1.0 Da and excitation voltages
between 0.6 and 1.0 V. Peptide sequences were determined from the MS/MS data via de
novo sequencing or with the help of BioTools (Bruker Daltonics, Billerica, MA).
Sequencing of β2m to identify the specific amino acids modified by BD is not
possible using CID, so electron transfer dissociation (ETD) was used to identify the
specific modification sites. In the CID process the BD label is readily lost without any
associated information about its location in the sequence. The ETD experiments were
carried out using a Bruker HCT ETD II (Billerica, MA) equipped with an ESI source.
ETD was performed using total reaction time of 25 ms and low mass cutoff of 100.
Accumulation times for the fluoranthene radical anion, which was used as the ETD
reagent, were typically between 3 and 5 ms.

3.2.8 Amino Acid Modification Percentage
The percent modification of each labeled amino acid was determined by
comparing the LC-MS intensities of modified and unmodified proteolytic peptide
fragments containing the amino acid of interest. For each peptide fragment, the modified
form eluted after the unmodified form with the difference in retention times ranging from
1-12 minutes. The ion intensities of both modified and unmodified peptides were
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determined from extracted ion chromatograms (EIC). As an example, Figure 3.1 shows
the EIC of the unmodified (m/z 623.4) and modified (m/z 644.4 and 665.4) forms of the
fragment Ile1-Tyr10 in the absence of Cu(II). The EIC for all peptides is averaged over a
0.4 min time range to determine the ion intensities. The percent modification was
obtained by dividing the ion intensity of the modified fragment (Imodified) by the sum of
the ion intensities for the modified (Imodified) and unmodified (Iunmodified) fragments as
shown in equation 1. The errors are reported as the standard error of the mean using the
data from three separate modification reactions. Because ion intensity ratios were used,
low modification levels could be accurately determined.
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Figure 3.1 Extracted ion chromatograms (EIC)of the unmodified (m/z 623.4) and
modified (m/z 644.4 and 665.4) forms of the fragment Ile1-Tyr10 in the absence of
Cu(II). Each trace represents one trial. The peaks at ~14 min and ~15 min are the Lys6and N-terminus-modified fragments, respectively. The peaks at ~18.2 min are the dimodified fragments.
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3.3 Results and Discussion
The reactivity of monomeric β2m in the absence and presence of Cu(II) was
monitored using three covalent labeling reagents – diethylpyrocarbonate (DEPC), sulfoN-hydroxysuccinimide acetate (NHSA), and butanedione (BD). DEPC can react with
solvent exposed His, Lys, Tyr, Thr, and Ser residues [20], but this reaction is
significantly slowed when these residues, especially His, are bound to Cu(II) [16,17].
Likewise, NHSA and BD can react with amino and guanidinium groups, respectively,
when these sites are solvent exposed [20], but its reactivity is reduced when these
residues are protected, for example, by metal binding. Moreover, amino acid-specific
information about β2m’s structural changes can be inferred from differential reactivity
patterns of individual amino acids.

3.3.1 Covalent Labeling with NHSA
NHSA can react with amino groups such as the ε-NH2 of lysine residues and the
N-terminal α-NH2. First, the optimum reaction time and molar ratio of NHSA were
determined. As described previously [20,21] and in chapter 2, plots of the 2nd order
reaction kinetics for the modified peptide fragments can be used to ensure that the
covalent label itself does not disrupt the structure of β2m near a particular reactive amino
acid residue (Figures 3.2A and 3.2B). For monomeric β2m, deviations from linearity,
which are indicators of label-induced structural perturbations, occur at a 4-fold molar
excess of NHSA for most of the modified proteolytic peptide fragments. Hence, a 3-fold
molar excess of the label was added to the β2m samples to avoid label-induced protein
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structural changes. Upon modification with 3-fold excess of NHSA for 1 min at 37 oC,
addition of up to three acetyl groups is reproducibly observed, with the average number
of modifications to the whole protein around one (Figure 3.2C).
Identification of the modified amino acids was achieved by proteolytic digestion
and LC-MS/MS analyses. LC-MS/MS analyses indicate that the N-terminus, almost all
of the lysines (Lys6, Lys19, Lys41, Lys58, Lys75, Lys91, and Lys94), and Asn83 are
labeled to different degrees. The unmodified and modified fragments containing the
lysine residues were detectable at t=0 and t=2min after addition of Cu(II). Modification
of an Asn residue, Asn83, is unprecedented as NHSA has only been reported to react
with N-terminal amines and lysine residues [22], but the tandem mass spectrum of the
modified fragment Ala79-Leu87 unambiguously identifies Asn83 as the modified amino
acid.
When the covalent labeling reactions with NHSA are performed in the absence
and presence of Cu(II), the modification extents of some residues change (Table 3.1).
Because the percent modification is determined using the ion intensity ratios of the
unmodified and modified peptide fragments, small changes in modification levels can be
accurately and precisely determined. From the data in Table 3.1, we find that the levels of
modification of all but two of the residues remain approximately the same after the
addition of Cu(II). The reactivity of the N-terminus and Lys91 decrease by 25% and
18%, respectively, after addition of Cu(II).
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Figure 3.2 (A) Dose-response plot for Lys6 (fragment Thr4-Tyr10) after reaction with
NHSA. (B) Dose-response plot for Lys75 (fragment Tyr67-Tyr78) after reaction with
NHSA. The plot for each reactive residue is produced from LC-MS data of the
proteolytic digests of the modified protein. The [P]/[P]o ratio is obtained by dividing the
peak area for the unmodified fragment by the sum of the peak areas for the modified and
unmodified fragments. The difference between the [P] and [P]o values is used to
determine the concentration of NHSA, [X]. (C) Expanded view of mass spectrum
showing the extent of acetylation for the +12 charge of β2m at t=0. The second peak of
each doublet is due to a fraction of the protein being oxidized at Met99. This residue is
easily oxidized during protein storage. The portion of the protein molecules that are
oxidized is typically about 20 to 30% of the total protein.
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3.3.2 Covalent Labeling with DEPC
DEPC reacts readily with histidine residues but can also react with amine and
hydroxyl groups at neutral pH [20,21 and chapter 2]. The DEPC experiments were
performed in much the same way as the lysine acetylation studies. Based on 2nd order
kinetics plots of each modified peptide, a 2.5-fold molar excess of DEPC was used to
minimize DEPC-induced β2m structural changes (Figure 3.3A and 3.3B). As was the
case with the NHSA reactions, the reaction time was kept short (1 min) to avoid
modification-induced structural change and to minimize DEPC hydrolysis by water.
Under the experimental conditions used, the addition of up to four carbethoxy (CEt)
groups to the protein was observed, and the average number of modification was between
one and two (Figure 3.3C). Proteolytic digestion of the protein and LC-MS/MS analyses
indicate that DEPC reacted with the N-terminus, Thr4, Lys6, His13, Lys19, Tyr26,
Ser28, His31, Ser33, Lys41, His51, Ser57/Lys58, Tyr63, Tyr67, Lys75, Ser88, and
Lys94. These modifications were observed at t=0 and t=2min after addition of Cu(II), but
the level of modification for some residues changed over time (vide infra). In all cases
but one (Ser57/Lys58), the specific amino acids that were modified could be determined
unambiguously from the MS/MS data.
The reactions with DEPC reveal that some residues change in reactivity upon
addition of Cu(II) (Table 3.1). LC-MS data reveal that the percent modifications of six
residues decrease after Cu(II) binding. These residues are the N-terminus, Ser28, His31,
Ser33, Tyr63, and Tyr67. His31 undergoes the most significant change in reactivity, with
about a 61% decrease in modification when Cu(II) is present. A decrease in extent of
modification between 30 and 40% was observed for the N-terminus, Ser28, Ser33, and
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Tyr63. Tyr67 showed the least drop in reactivity, ~17% in the presence of Cu(II). The
changes in reactivity observed for the N-terminus, Lys6, Lys19, Lys41, Lys58, Lys75,
and Lys94 with DEPC agree with the NHSA data described above.

3.3.3 Covalent Labeling with Butanedione
Unlike DEPC, which reacts with many nucleophilic groups, BD reacts
specifically with arginine. The reaction is reversible at pH < 9, so higher reagent doses
are necessary to improve the product yield. The excess reagent allows pseudo 1st order
kinetic plots to be used to ensure the structural integrity of the protein (Figure 3.4A).
Based on these plots, 350 fold molar excess (i.e. 35 mM) was chosen. Under our reaction
conditions, up to two modifications were detected with an average number of
modification of less than one (Figure 3.4B). The LC/MS and ETD data indicate that BD
reacts with Arg3, Arg12, Arg45, and Arg97 but not Arg81.
The reactions of BD with β2m reveal that three of the four reacting arginine
residues undergo changes in reactivity after the addition of Cu(II) (Table 3.1). The
reactivities of Arg3 and Arg97 dramatically increase (about >70%) immediately after
Cu(II) is added. In contrast, the level of modification of Arg12 decreased by 23%.
A summary of the extent of modification for each of the modified amino acids in
the absence and presence of Cu(II) is shown in Table 3.1.
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Figure 3.3 (A) Dose-response plot for His13 after reaction with DEPC. (B) Doseresponse plot for Tyr26 after reaction with DEPC. The plot for each reactive residue is
produced from LC-MS data of the proteolytic digests of the modified protein. The
[P]/[P]o ratio is obtained by dividing the peak area for the unmodified fragment by the
sum of the peak areas for the modified and unmodified fragments. The difference
between the [P] and [P]o values is used to determine the concentration of DEPC, [X]. (C)
Expanded view of mass spectrum showing the extent of carbethoxylation for the +12
charge of β2m at t=0. The second peak of each doublet is due to a fraction of the protein
being oxidized at Met99. This residue is easily oxidized during protein storage. The
portion of the protein molecules that are oxidized is typically about 20 to 30% of the total
protein.
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Figure 3.4 (A) Dose-response plot for β2m after reaction with BD. The plot is produced
from the ESI-MS data of the BD-treated proteins. The [P] is the remaining concentration
of β2m after reaction with BD. (B) Expanded view of mass spectrum showing the extent
of modification for the +12 charge of β2m at t=0. The second peak of each doublet is due
to a fraction of the protein being oxidized at Met99. This residue is easily oxidized during
protein storage. The portion of the protein molecules that are oxidized is typically about
20 to 30% of the total protein.

Table 3.1 Summary of the percentage changes for the modified amino acids of β2m in
the absence and presence of Cu(II).
Residue

apo-β2m

Cu(II)

% Change

NHSA
N-terminus

81 ± 3

60.5 ± 0.7

- 29

Lys6

20 ± 1

19 ± 1

0

Lys19

7.0 ± 0.4

6.9 ± 0.4

0

Lys41

13.6 ± 0.7

15 ± 1

0

This table is continued on the next page.
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Lys58

16.1 ± 0.7

16 ± 3

0

Lys75

1.6 ± 0.2

1.3 ± 0.1

0

Asn83

1.50 ± 0.04

1.4 ± 0.1

0

Lys91

27 ± 1

22 ± 1

- 18

Lys94

3.1 ± 0.2

3.4 ± 0.3

0

N-terminus

99 ± 1

68 ± 1

- 43

Thr4

86.7 ± 0.7

87 ± 2

0

Lys6

8.07 ± 0.05

8.0 ± 0.1

0

His13

47 ± 2

46 ± 3

0

Lys19

22 ± 1

19 ± 2

0

Ty26

0.75 ± 0.07

0.79 ± 0.05

0

Ser28

0.24 ± 0.01

0.17 ± 0.02

- 29

His31

1.8 ± 0.1

0.7 ± 0.1

- 61

Ser33

1.7 ± 0.1

1.1 ± 0.1

- 35

Lys41

0.32 ± 0.04

0.33 ± 0.03

0

His51

61 ± 3

61 ± 4

0

Ser57/Lys58

43 ± 2

42 ± 3

0

Tyr63

7.1 ± 0.5

4.3 ± 0.3

- 39

Tyr67

2.1 ± 0.1

1.75 ± 0.06

- 17

Lys75

0.36 ± 0.04

0.33 ± 0.02

0

Ser88

63 ± 3

65 ± 3

0

Lys94

30 ± 2

29 ± 2

0

Arg3

0.6 ± 0.1

1.05 ± 0.05

+ 75

Arg12

1.3 ± 0.1

1.00 ± 0.05

- 23

Arg45

3.8 ± 0.3

3.6 ± 0.1

0

Arg97

2.8 ± 0.4

4.8 ± 0.2

+ 71

DEPC

BD
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3.3.4 Copper Binding to Monomeric β2m
Studies have shown that in vitro interactions of β2m with stoichiometric amounts
of Cu(II) under near physiological conditions result in fibril formation [6,15]. The exact
structural changes undergone by the protein as a result of Cu(II) binding, however, are
unclear. To gather some insight into possible structural changes associated with Cu(II)
binding, the reactions of NHSA, DEPC, and BD with β2m in the presence and absence of
Cu(II) were performed. Several factors affect the covalent labeling efficiency of amino
acid side chains, but solvent accessibility is the most important [20]. Consequently,
covalent labeling is especially effective at identifying residues involved in ligand binding
because the solvent accessibilities of such residues typically undergo noticeable changes.
Thus, by monitoring the modification extents of different residues within 2 min after
addition of Cu(II) we can obtain some insight into the residues that are involved in
binding Cu(II) as well as those that undergo changes in solvent accessibility.
The β2m residues that react with NHSA, DEPC, and BD are widely distributed
along the polypeptide chain and on the surface of the protein. Thus, we cover most
regions of the protein. The structural data obtained covers 24 of the protein’s 99 residues
and ~30% of the surface-exposed residues (Figure 3.5). For the three covalent labels,
linear relationships are observed at the concentrations used. At these reagent
concentrations the protein’s global structure is maintained for both native β2m (Figures
3.1-3.3) and β2m in the presence of Cu(II) (Figure 3.6). The extent of β2m modification
decreased upon addition of Cu(II) for all the different NHSA and DEPC concentrations
used. This observation is consistent with previous studies of other proteins that show that
Cu(II) binding protects residues from DEPC modification [16,17].
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Figure 3.5 (A) Ribbon representation of monomeric β2m (PDB ID: 2D4F). Amino acids
modified by the covalent labels are shown as sticks. (B) Amino acid sequence of β2m
showing strand nomenclature [23]. Black lines show amino acids on each β strand. The
internal disulfide bond is shown in blue. The amino acids probed by the covalent labels
are shown in red.
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Figure 3.6 Dose-response plots for β2m after reaction with (A) DEPC, (B) NHSA, and
(C) BD. The plots show that the concentration range in which the protein’s global
structure is maintained is the same for both native β2m and β2m in the presence of
Cu(II).
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Out of the 24 modified residues, only 10 amino acids are found to change in
reactivity, namely, the N-terminus, Arg3, Arg12, Ser28, His31, Ser33, Tyr63, Tyr67,
Lys91, and Arg97. This suggests that there are significant structural changes in the
immediate regions surrounding these amino acids. These observations are consistent with
previous studies that indicate that the N-terminus and His31 are part of the Cu(II) binding
site in β2m [6,24]. The N-terminus and His31 showed the greatest decrease in reactivity,
indicating that these residues are protected by Cu(II) from modification (Figure 3.7).

Figure 3.7 Structure of β2m showing the Cu(II) binding site at the N-terminal region of
the protein. This structure was generated from molecular mechanics calculations of the
protein, beginning with the crystal structure of the apo-protein (PDB 1LDS) [25] and
after adding Cu(II) to the known binding sites.

Figure 3.8 shows that most of the remaining eight residues that change in
reactivity are localized at the N-terminal region and the ABED β-sheet of β2m. The
reduced reactivity of Ser33 might simply be explained by the nearby binding of Cu(II) to
His31, which prevents ready access of DEPC to this amino acidic side chain.
Alternatively, others have reported that Cu(II) binding induces a cis to trans backbone
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isomerization of the Pro32 residue [26]. A β2m mutant (P32A) that closely resembles this
isomerized structure was designed and its atomic structure was solved using X-ray
diffraction (PDB 2F8O). In this crystal structure, the protein adopts a slightly different
conformation that places Ser33 closer to the suspected Cu(II) binding site, which would
make it less accessible and therefore less reactive. Thus, the drop in Ser33’s reactivity
observed in our studies may be caused by a similar structural change upon binding
Cu(II).

Figure 3.8 Ribbon representation of monomeric β2m (PDB ID 2D4F) [27]. Amino acids
that decrease (green) and increase (orange) in modification extent upon interaction with
Cu(II) are shown as sticks.

Our data also suggests that Cu(II) binding to monomeric β2m repositions Arg3.
The increased reactivity of Arg3 might be explained by the repulsion of the positively
charged side chain by Cu(II). Recently, a crystal structure of the H13F mutant of β2m in
the presence of Cu(II) was solved, and it was found to form a hexamer with Cu(II) bound
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at the N-terminal region of all β2m subunits [28]. Examination of one subunit of the
H13F hexamer shows that the guanidinium group of Arg3 is pointing away from Cu(II)
by approximately 11 Å (Figure 3.9). In the crystal structure of wild-type protein without
Cu(II), Arg3 is located very close to His31 and where Cu(II) ultimately binds in the
monomer. The location of Arg3 in the H13F hexamer suggests that Cu(II) binding forces
this residue to be repositioned. Moreover, Arg3 is now located about 3.8 Å from Glu16 of
another protein subunit, suggesting that these residues probably form an intermolecular
salt bridge. Interestingly, this is not the only intermolecular salt bridge created by Cu(II)
binding. A recent study using metal-catalyzed oxidation (MCO) revealed that Asp59 is
part of the Cu(II) binding site. In both NMR and crystal structures of monomeric β2m
[25,29], the side chain of Asp59 points away from the N-terminal strand. However, upon
binding Cu(II) this residue must be repositioned to point toward the N-terminal amine
and the amide between Ile1 and Gln2 to effectively bind Cu(II). A close examination of
the crystal structure of the H13F hexamer of β2m [28] reveals that the side chain of
Asp59 has rotated greater than 100º and is located closer to the N-terminus than in the
monomer. Furthermore, inspection of the subunit contacts between chains B and C in the
crystal structure of the H13F hexamer of β2m reveals that Asp59 of one protein subunit is
about 2.8 Å from Lys19 of another protein subunit. The interactions of Arg3/Glu16 and
Asp59/Lys19 are symmetric, thereby giving rise to a pair of salt bridges that are probably
important for the stability of the β2m dimer. The formation of these salt bridges is highly
probable because electrostatic interactions are usually important contributors to the
specificity and stability of protein-protein complexes [30-32].
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Figure 3.9 A comparison of the crystal structure of monomeric β2m (green, PDB 2D4F)
and one of the subunits from the H13F hexamer (blue, PDB 3CIQ) that illustrates the
repositioning of Arg3.

Lastly, four residues on the ABED β-sheet of β2m decreased in reactivity upon
Cu(II) binding, namely, Arg12, Ser28, Tyr63, and Tyr67. In addition to the possible
intermolecular salt bridges formed by Arg3/Glu16 and Asp59/Lys19, the rearrangements
of these four residues on the ABED β-sheet likely help facilitate dimer formation of β2m.
In a previous work, we have shown that a better indicator of reactivity appears to be the
solvent accessibility of the reactive atom (i.e. hydroxyl group for Ser and Tyr and
guanidinium group for Arg) [21]. The decrease in reactivity of these residues suggest that
the side chains move after Cu(II) binding such that their reactive atoms become less
solvent accessible. This movement probably exposes their hydrophobic part to the
solvent, and together with the surrounding nonpolar residues, creates a hydrophobic facen
on the ABED β-sheet. Studies of other amyloidogenic proteins showed that hydrophobic
interactions play a decisive role in the formation of amyloid fibrils [33-35]. Hence, we
hypothesize that this hydrophobic region can promote dimerization by interaction with
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another ABED β-sheet to minimize solvent exposed hydrophobic groups. Examination of
the subunit contacts between chains B and C in the H13F hexamer shows that these
residues have indeed moved > 2Ǻ relative to the wild-type apo β2m (PDB ID 2D4F) and
that they formed hydrophobic interactions with the ABED β-sheet of an adjacent
monomer.
The decrease and increase in reactivity of Lys91 and Arg97, respectively, are
difficult to explain. The increase in modification of Arg97 indicates that it becomes more
solvent accessible and that the C-terminal strand possibly becomes frayed upon Cu(II)
binding. This is consistent with a study wherein β2m was shown to populate partially
unfolded states under acidic conditions that display significant destabilization of the Cterminal strand [36] with the fraying of the C-terminal strand.
The fact that the reactivity of His51 is the same in the absence and presence of
Cu(II) is also informative. The literature is contradictory with regards to His51’s
interaction with Cu(II). Our group and others [6,24] have found no evidence for Cu(II)
binding to His51, whereas an NMR study [37] implies that Cu(II) does bind His51 based
on the broadening of resonances associated with this residue. The present work provides
additional evidence that Cu(II) does not interact with His51, perhaps indicating that the
previous NMR results could simply be due to increased conformational flexibility at this
residue when Cu(II) binds to β2m.
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3.4 Conclusions
In conclusion, this study shows that the combination of selective covalent
modification with mass spectrometric detection is well suited for the characterization
metal binding and binding-induced conformational changes. Initial application of this
method to study Cu(II)-β2m interactions provides additional insight into the effect of
Cu(II) on this protein’s structure. The NHSA and DEPC reactivity of β2m in the presence
of Cu(II) confirms the involvement of the N-terminus and His31 in the binding site and
further rules out the interaction of His51 with Cu(II).
The results described here also give us additional insight into how Cu(II)
facilitates the β2m structural changes that lead to oligomer formation. In the monomer,
Cu(II) binds to the N-terminus and His31. Binding to these residues causes several
structural changes. We propose that movement of Arg3 allows a dimer-stabilizing salt
bridge to be formed with Glu16 of an adjacent β2m. The movement of Arg12, Ser28,
Tyr63, and Tyr67 on the ABED β-sheet possibly creates a hydrophobic face that can
promote dimerization via interaction with another hydrophobic sheet of an adjacent
monomer. Rearrangement of these residues, along with the cis-trans isomerization of
Pro32, may therefore be part of the switch that enables Cu(II) to initiate dimer formation
[26,38].
Lastly, the results in this chapter provide some additional details about the
molecular role that Cu(II) can play in amyloid-forming systems. Divalent transition
metals, especially Cu(II), appear to be one of the general ways to cause protein amyloid
formation. Prior work shows that proteins such as α-synuclein, immunoglobulin light
chain, Aβ, and even possibly the prion protein form amyloid aggregates in the presence
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of metal ions. In the present work we find that metal binding to certain residues and
repulsion of other residues can perturb protein structure in a way that enables
aggregation. Further studies of Cu(II)-β2m interactions and the resulting aggregation may
provide even more insight into the possible roles that divalent metals play in protein
aggregation.
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CHAPTER 4
STRUCTURE OF THE PRE-AMYLOID DIMER OF β-2-MICROGLOBULIN
FROM COVALENT LABELING AND MASS SPECTROMETRY
This chapter is part of a paper published as: Mendoza, V.L., Antwi, K., Baron-Rodriguez,
M.A., Blanco, C., and Vachet, R.W. (2009) Structure of the pre-amyloid dimer of β-2microglobulin from covalent labeling and mass spectrometry. Biochemistry 49, 15221532.

4.1 Introduction
The Cu(II)-induced amyloid formation of β-2-microglobulin (β2m) is preceded by
the formation of discrete, oligomeric intermediates [1,3]. The formation of discrete
oligomers as prefibrillar intermediates has been observed for several other amyloidogenic
proteins too [4-6], and indeed acid-induced (pH = 2.5) amyloid formation of β2m has
been found to be preceded by discrete oligomers [7]. Delineating the mechanism of the
early stages of β2m fibrillogenesis and the structural properties of these oligomeric
intermediates may be critical for developing therapeutic strategies against DRA.
Furthermore, recent studies of other amyloid systems suggest that prefibrillar
intermediates might be responsible for cellular toxicity rather than the amyloid fibrils
[8,9]. Consequently, any methods or results that give insight into intermediates that
precede β2m fibrils may be useful for understanding other amyloid systems as well.
In this chapter, we used Cu(II) as a trigger to initiate β2m amyloid formation, and
then studied the structure of the dimer, which is the first pre-amyloid oligomer formed
[1,3]. Previous work has shown that incubation of β2m with Cu(II) under near
physiological conditions results in the formation of dimers in the first 30 minutes with
tetramers and hexamers not forming for > 12-24 hours [1,3]. Because the dimer is an
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intermediate and is always present as a mixture with the monomer and eventually other
higher order oligomers, obtaining residue-specific information about the dimer is very
challenging by traditional approaches. One recently used approach to solve this problem
has been to construct β2m mutants that are capable of crystallizing as oligomers [10,11].
In this way, it has been found that the P32A mutant of β2m forms a dimer in the absence
of Cu and the H13F mutant forms a stable hexamer in the presence of Cu. These crystal
structures have then been used to support hypotheses about the structural changes
necessary for β2m oligomer and amyloid formation.

While these crystal structures

provide high resolution atomic-level information, they cannot provide a complete picture
of β2m oligomer structure. The β2m mutants do not form fibrils, and so the crystallized
oligomers unlike the wild-type oligomers contain structural features that prevent further
aggregation. Moreover, it is possible that the selected mutations initiate the formation of
oligomers that differ completely from the ones formed by the wild-type protein.
As a complementary approach to these crystallographic studies, we describe here
the use of covalent labeling along with mass spectrometry (MS) to gather insight into the
structure of the wild-type β2m dimer. This method relies on amino acid specific reactions
of solvent exposed amino acid side chains, and tandem MS (MS/MS) to identify the
modified residues. Covalent labeling combined with MS and MS/MS has been used to
map protein surfaces, identify ligand-binding sites, study protein-protein and proteinnucleic acid complexes, and detect ligand-induced conformational changes [12]. These
covalent labeling methods provide information about protein structure and interactions by
comparing the reactivity of amino acid side chains in solution under two or more
different conditions. MS/MS is then used to identify the specific amino acids that
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undergo significant changes in reactivity. This approach is well suited for providing
insight into the dimeric intermediate of β2m because amino acid side chains are usually
buried upon formation of new protein-protein interfaces, and buried amino acids are
much less reactive than exposed amino acids. Furthermore, the specificity of MS allows
this information to be obtained even under conditions in which a mixture of β2m forms is
present.

4.2 Experimental Procedure
4.2.1 Materials
The same materials were used as described in Section 3.2.1.

4.2.2 Formation of β2m Oligomers
Reports have shown that discrete oligomers precede β2m amyloid fibrils when
monomeric β2m is incubated under near-physiological conditions in the presence of
Cu(II) [1,3]. Amyloid fibrils were formed by incubation of 100 µM β2m in 200 mM
potassium acetate, 500 mM urea, and 25 mM MOPS (pH 7.4) with 200 µM copper(II)
sulfate at 37 °C. All components were equilibrated at 37 °C prior to Cu(II) addition, and
immediately returned to 37 °C after mixing. The covalent labels were added to aliquots of
incubated β2m taken at several time points after initiating the amyloid fibril formation
reaction.
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4.2.3 Covalent Labeling Reactions
The covalent labeling reactions were done in a manner identical to that described
in Sections 3.2.3-3.2.5.

4.2.4 Proteolytic Digestion
The proteolytic digestions were performed in a manner identical to that described
in Section 3.2.6.

4.2.5 Desalting
Desalting of the protein samples just prior to electrospray ionization (ESI) mass
spectrometry (MS) analyses was performed using a 5 ml HiTrap desalting column from
Amersham Biosciences (Piscataway, NJ). The column was first equilibrated with 30 ml
of the mobile phase (10 mM ammonium acetate, pH = 7.4) at a flow rate of 5 mL/min.
Then, between 100 and 150 µL of incubated sample was injected onto the column via a
sample loop attached to a home-made setup. The oligomeric intermediates were eluted at
a flow rate of 10 ml/min using 10 mM ammonium acetate (pH = 7.4), which was filled
into a syringe and delivered by a syringe pump. The β2m fraction eluting from the
column was collected between 20 and 22 seconds and analyzed immediately by ESI-MS.

4.2.6 Instrumentation
The amount of modification was determined by removing an aliquot of the
purified β2m and analyzing the samples using a Bruker Esquire-LC quadrupole ion trap
mass spectrometer (Billerica, MA) equipped with an ESI source. The ESI source was
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operated at a spray voltage of 3.5 kV, and the capillary temperature was set at 300°C. The
voltages for the transfer optics between the ESI source and the ion trap were optimized
for maximum signal, with typical skimmer 1 and capillary offset values of 30-35 V and
50-60 V, respectively.
The proteolytic fragments were separated by an Agilent HP1100 (Wilmington,
DE) HPLC system with a C18 column (15 cm x 2.1 mm, 5 µm particle size, Supelco, St.
Louis, MO) for on-line analysis by MS and MS/MS. The fragments of NHSA- and BDmodified β2m were eluted using a linear gradient of methanol that increased from 5 to
70% over 20 min and 70 to 100% over the final 2 min at a flow rate of 0.250 mL/min.
For the fragments of DEPC-modified β2m, a linear gradient of methanol that increased
from 5 to 70% over 30 min and 70 to 100% over the final 3 min was used. For both
gradient conditions, water comprised the balance of the solvent, and a total of 0.1% acetic
acid was present. The LC effluent was fed into the mass spectrometer with similar ESI
source conditions as described above. Tandem mass spectra were acquired using collision
induced dissociation (CID) with isolation widths of 1.0 Da and excitation voltages
between 0.6 and 1.0 V. Peptide sequences were determined from the MS/MS data via de
novo sequencing or with the help of BioTools (Bruker Daltonics, Billerica, MA).
Sequencing of β2m to identify the specific amino acids modified by BD is not
possible using collision induced dissociation (CID), so electron transfer dissociation
(ETD) was used to identify the specific modification sites. In the CID process the BD
label is readily lost without any associated information about its location in the sequence.
The ETD experiments were carried out using a Bruker HCT ETD II (Billerica, MA)
equipped with an ESI source. The voltages for the transfer optics between the ESI source
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and the ion trap were optimized for maximum signal. ETD was performed using reaction
time of 25 ms and low mass cutoff of 100. Accumulation times for the fluoranthene
radical anion, which was used as the ETD reagent, were typically between 3 and 5 ms.
A JMS-700 MStation (JEOL, Tokyo, Japan) double-focusing mass spectrometer
equipped with a standard ESI source was used to acquire mass spectra of the β2m
oligomers after desalting the incubation solution. The ESI source conditions that were
o

used are the following: desolvating plate temperature, 100 C; orifice temperature, 140
o

C; orifice potential, 60 V; ring lens potential, 100 V. ESI-MS experiments of the
desalted protein samples were used to measure the average charge states of these
oligomers and to estimate their surface areas using a method described previously by
Kaltashov and co-workers [13]. The spectra were acquired by scanning the magnet at a
rate of 5 s/decade.

4.2.7 Amino Acid Modification Percentage
The amino acid modification percentages were calculated in a manner identical to
that described in Section 3.2.8.

4.2.8 Determination of Solvent Accessibility
The 3D structures of β2m that were examined were obtained from the Protein
Data Bank: 2D4F for monomeric β2m [14], 2F8O for the P32A dimer [10], and 3CIQ for
the H13F hexamer [11]. The solvent accessible surface areas (SASA) of individual amino
acid side chains were calculated from the PDB coordinate files using GETAREA
(http://curie.utmb.edu/getarea.html) [15]. For these SASA calculations, a 4.0 Å probe
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radius was used because the radii of the covalent labels used in this study range from
~3.5-4.5 Å. To determine the surface area of the whole protein for comparison with the
ESI-MS results, a 1.4 Å probe radius was used.

4.2.9 Docking Calculations
All simulations were performed using the β2m subunit taken from the crystal
structure of human MHC-I complex (PDB ID: 1DUZ) [16], which contains 99 amino
acid residues. Met0 was eliminated from the original set of coordinates in order to
resemble the wild-type protein used in the labeling experiments. Hydrogen atoms were
explicitly added to the protein model and His residues were considered to be neutral, as
shown in nuclear magnetic resonance (NMR) studies by Esposito and co-workers [17].
Water molecules, as a TIP3P model [18], were also added until a cubic simulation cell of
side length 7.8 nm was achieved.
Five ns molecular dynamics (MD) simulations were performed to determine the
most probable conformation of wild-type β2m. The MD simulations were run at 310 K
with periodic boundary conditions in an nPT ensemble and with the AMBER94 force
field [19,20] implemented in GROMACS [21-23]. Protein structures were selected every
1 ps, and those structures that had root-mean-squared displacements of the backbone less
than 0.05 nm were clustered together. The final structure that was used in the docking
calculations was chosen from the largest cluster of structures.
The docking of two wild-type monomeric β2m molecules was performed to
evaluate possible dimer interfaces. The docking search optimizes desolvation, grid-based
shape complementarity, and electrostatics using a Fast Fourier Transform algorithm
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ZDOCK2.3 [24,25] and provides a score for all possible docked conformations. The
structures of the ten top-scoring dimers were then energy-minimized with solvent present
using the AMBER94 force field. The Adaptive Poisson-Boltzmann Solver [26] within the
AMBER force field was used to evaluate the free energy binding (∆∆G) of each dimer.
4.3 Results and Discussion
All covalent labeling experiments were performed on wild-type protein under
solution conditions in which β2m forms amyloid fibrils. In previous studies, dynamic
light scattering, size-exclusion chromatography, and MS showed that β2m oligomers are
formed sequentially with the dimer first appearing between 30 min and 1 h and the initial
form of the tetramer appearing after approximately 12-24 h [3]. These previous studies
also showed that the smaller oligomers are in equilibrium with one another and can
therefore dissociate to lower-order oligomers or to the monomer. Because complete
isolation of the dimer was not possible without some dissociation back to the monomer,
the chemical modification reactions were performed at different times before (t = 0 min)
and after (t = 2 min, 0.5 h, 1 h, 1.5 h, and 2 h) adding Cu(II) to initiate the amyloidforming reaction. The dimer percentage at time points after the addition of Cu(II)
increases from 0 to 20% based on ESI-MS measurements of the desalted sample under
amyloid-forming conditions, as described previously [3].

4.3.1 Covalent Labeling with NHSA
Amino groups such as the ε-NH2 of lysine residues and the N-terminal α-NH2 can
react with NHSA. Identifying the amino acids that are acetylated is necessary to pinpoint
the specific residues that become less reactive as the dimer concentration increases, and
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this identification was achieved by proteolytic digestion and LC-MS/MS analyses. LCMS/MS analyses indicate that the N-terminus, almost all of the lysines (Lys6, Lys19,
Lys41, Lys58, Lys75, Lys91, and Lys94), and Asn83 are labeled to different degrees.
The unmodified and modified fragments containing the lysine residues were detectable at
all time points; however, the level of modification for some residues changed over time
(vide infra). When the covalent labeling reactions with NHSA are performed at different
time points after initiating the formation of the dimer, the modification extents of some
residues change as the concentration of the dimer increases in solution (Figure 4.1). The
data in these figures are obtained by measuring the modification percentage, as described
in the experimental section, for the peptide fragments containing the indicated residues.
For each time point, the modification reaction was repeated three times. Because the
percent modification is determined using the ion intensity ratios of the unmodified and
modified peptide fragments, small changes in modification levels can be accurately and
precisely determined.
From the data in Figure 4.1, we find that the levels of modification of Lys58,
Lys75, and Lys94 increase by about 20%, 20%, and 40%, respectively, from before
Cu(II) is added to 2 h after Cu(II) is added. In contrast, the reactivity of the N-terminus,
Lys6, and Lys91 decrease after addition of Cu(II). The N-terminus has the greatest drop
in extent of modification, decreasing 30% immediately upon addition of Cu(II). The
reactivity of this residue, however, does not change anymore as the dimer forms in
solution. Like the N-terminus, the reactivity of Lys91 initially decreases, about 20%, after
addition of Cu(II); however, there is a small 5% increase in the extent of modification
from 2 min to 2 h as the dimer’s concentration increases in solution. Lys6 behaves
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differently than the N-terminus and Lys91 in that its reactivity does not drop immediately
upon addition of Cu(II) but instead decreases as the dimer’s concentration increases
(Figure 4.1B). The reactivity of Lys19, Lys41, and Asn83 remain approximately constant
up to 2 h after the addition of Cu(II).
In summary, the NHSA reactivity data indicate that of the nine modified residues
in β2m four of them undergo a notable change in reactivity as the dimer is formed in
solution. The modification extents of Lys58, Lys75, and Lys94 increase, whereas the
reactivity of Lys6 decreases. The N-terminus and Lys91 also decrease in reactivity, but
their lower reactivity appears to be mostly due to Cu binding rather than the formation of
dimer.
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This figure is continued on the next page.
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Figure 4.1 Extent of NHSA modification throughout the course of dimer formation. (A)
N-terminus. (B) Lys6. (C) Lys19. (D) Lys41. (E) Lys58. (F) Lys75. (G) Ans83. (H)
Lys91. (I) Lys94.

4.3.2 Covalent Labeling with DEPC
DEPC reacts readily with histidine residues but can also react with amine and
hydroxyl groups at neutral pH. Proteolytic digestion of the protein and LC-MS/MS
analyses indicate that DEPC reacted with the N-terminus, Thr4, His13, Lys19, Tyr26,
Ser28, His31, Ser33, His51, Ser57/Lys58, Tyr63, Tyr67, Lys75, Ser88, and Lys94. These
modifications were observed at all time points, but the level of modification for some
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residues changed over time (vide infra). In all cases but one (Ser57/Lys58), the specific
amino acids that were modified could be determined unambiguously from the MS/MS
data.
The reactions with DEPC reveal that some residues change in reactivity as the
dimer’s concentration increases in solution (Figure 4.2). LC-MS data reveal that the
percent modifications of six residues increase upon dimer formation. These residues are
Thr4, His51, Ser57/Lys58, Lys75, and Lys94. Thr4 undergoes the least significant
change in reactivity, with about a 3% increase when about 20% dimer is present. His51
and either Ser57 or Lys58 increase in reactivity by about 10%. The increased reactivity of
Ser57 or Lys58 is consistent with the increased reactivity of Lys58 in the NHSA
experiments described above. The reactivity of Lys75 and Lys94 increase the most, 25%
and 30%, respectively, as the dimer’s concentration increases. The significantly increased
reactivities of Lys75 and Lys94 agree with the NHSA data described above. Finally, the
reactivity trend of Ser88 is somewhat unclear. For all but the last time point (2 h), this
residue reacts with DEPC in a fairly constant manner.
The modification extents of nine amino acids drop after Cu is added, but only five
of these residues show decreased reactivity as the dimer’s concentration increases. The
reactivities of the N-terminus, His31, Ser33, and Tyr67 drop upon Cu(II) binding but
change little or none as the dimer forms. Lys6, His13, Lys19, Tyr26, Ser28, and Tyr63,
however, do decrease in reactivity as more and more dimer is formed.

115

This figure is continued on the next page.
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This figure is continued on the next page.
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Figure 4.2 Extent of DEPC modification throughout the course of the dimer formation.
(A) N-terminus. (B) Th4. (C) Lys6. (D) His13. (E) Lys19. (F) Tyr26. (G) Ser28. (H)
His31. (I). Ser33. (J) Lys41. (K) His51. (L) Ser57/Lys58. (M) Tyr63. (N) Tyr67. (O)
Lys75. (P) Ser88. (Q) Lys94.
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The results from the DEPC reactions are consistent with the NHSA experiments,
except for the reactivity trend of Lys19. In contrast to the constant modification of
fragment Ser11-Phe22 with NHSA during the course of the dimer forming reaction, this
fragment showed a 10% decrease in modification of Lys19 with DEPC over time (Figure
4.2E). This slight discrepancy might be due the microenvironment around Lys19, which
could influence the reactivity of the two differently-charged labels to an unequal extent.
In summary, our results indicate that the reactivities of DEPC with His13, Lys19,
Tyr26, Ser28, and Tyr63 decrease as the dimer is formed, whereas the reactivities of
Thr4, His51, Ser57/Lys58, Lys75, and Lys94 increase as the dimer is formed. The
modification extents for the N-terminus, His31, Ser33, and Tyr67 also decrease, but their
lower reactivity appears to be due to Cu binding rather than the formation of dimer.

4.3.3 Covalent Labeling with Butanedione
Unlike DEPC, which reacts with many nucleophilic groups, BD reacts
specifically with arginine. The LC/MS and ETD data indicate that BD reacts with Arg3,
Arg12, Arg45, and Arg97 but not Arg81. The reactions of BD with β2m reveal that each
of the four reacting arginine residues undergoes changes in reactivity after the addition of
Cu(II) (Figure 4.3). The reactivities of Arg3 and Arg97 dramatically increase (about
80%) immediately after Cu(II) is added but do not change much as the dimer’s
concentration increases. The reactivity trends of Arg12 and Arg45, however, do change
as the dimer is formed. The modification extent of Arg12 decreases over time, whereas
the modification extent of Arg45 gradually increases.
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Figure 4.3 Extent of BD modification throughout the course of the dimer formation. (A)
Arg3. (B) Arg12. (C) Arg45. (D) Arg97.

A summary of the percentage changes for each of the modified amino acids
monitored at t=0 and t=2 hours is shown in Table 4.1.
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Table 4.1 Summary of the percentage changes for the modified amino acids from t=0 to
t=2 hours after the addition of Cu(II).
Residue

t=0

t = 2 hours

% Change

N-terminus

84 ± 3

60.7 ± 0.3

-28

Lys6

18.31 ± 0.04

17.9 ± 0.1

-2

Lys19

7.1 ± 0.2

7.2 ± 0.2

0

Lys41/Lys48

13.2 ± 0.7

13.2 ± 0.8

0

Lys58

16.1 ± 0.7

19.0 ± 0.1

+18

Lys75

1.37 ± 0.07

1.62 ± 0.08

+18

Asn83

1.48 ± 0.04

1.46 ± 0.03

0

Lys91

27 ± 1

24.0 ± 0.4

-11

Lys94

3.2 ± 0.3

4.4 ± 0.2

+38

N-terminus

99 ± 3

68.1 ± 0.6

-31

Thr4

86.5 ± 0.7

89.5 ± 0.6

+3

Lys6

8.07 ± 0.05

7.64 ± 0.02

-5

His13

45 ± 1

40.0 ± 0.7

-11

Lys19

13.0 ± 0.9

11.5 ± 0.6

-12

Tyr26

0.74 ± 0.06

0.45 ± 0.06

-39

Ser28

0.24 ± 0.01

0.11 ± 0.01

-54

His31

1.6 ± 0.2

0.8 ± 0.2

-50

Ser33

1.74 ± 0.06

1.19 ± 0.06

-32

Lys41

0.32 ± 0.04

0.34 ± 0.02

0

His51

61 ± 2

66 ± 2

+8

Ser57/Lys58

39 ± 2

47 ± 2

+21

Tyr63

6.3 ± 0.3

3.3 ± 0.2

-48

NHSA

DEPC

This table is continued on the next page.
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Tyr67

2.2 ± 0.2

1.5 ± 0.1

-32

Lys75

0.31 ± 0.04

0.38 ± 0.02

+23

Ser88

66 ± 2

72 ± 1

+9

Lys94

28 ± 2

36 ± 2

+29

Arg3

0.5 ± 0.2

1.01 ± 0.04

+100

Arg12

1.3 ± 0.1

0.64 ± 0.06

-51

Arg45

3.8 ± 0.3

6.5 ± 0.5

+71

Arg97

2.7 ± 0.5

4.9 ± 0.2

+81

BD

4.3.4 Determination of Surface Area of β2m Oligomers
ESI-MS experiments were performed to measure the average charge states of
β2m oligomers and estimate their surface areas from these measurements using a method
recently described by Kaltashov and co-workers [13]. That group recently demonstrated
that the average charge state of a protein in its ESI mass spectrum is related to its surface
area. Using mass spectral data for six proteins with accurately known surface areas
(Table 4.2), we generated a calibration curve by plotting the natural log of the measured
average charge state as a function of the natural log of the protein surface area (Figure
4A). The resulting plot has a slope of 0.68 ± 0.02, which compares favorably with the
theoretically expected slope of 0.75 and a slope of 0.69 ± 0.02 measured by Kaltashov
and co-workers [26]. To obtain the average charge state of each protein, a Gaussian fit of
relative abundance of each charge state for the protein in the mass spectrum versus the
measured charge states was used (Figure 4B).

122

Table 4.2 Proteins used to generate the charge-surface area calibration plot.
Protein

PDB ID

Surface Area (Å2)

Average Charge

Ubiquitin

1UBQ

4758

5.5

Cytochrome C

1HRC

6232

7.3

Myoglobin

1WLA

8017

8.2

Ovalbumin

1OVA

15586

14.2

Hemoglobin

1A3N

24548

17.3

Transferrin

1JNF

27395

18.5
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Figure 4.4 (A) Calibration plot obtained from mass spectra of the proteins in Table 4.1,
which is used to measure the surface areas of the β2m oligomers. (B) A plot of ion
intensity as a function of charge state for the β2m dimer. A Gaussian fit is used to
determine the average charge state.

This approach for estimating oligomer surface area was used at different points
after adding Cu(II) to initiate the amyloid forming reaction. The average charge states of
the monomer and oligomers of β2m ions were determined from ESI mass spectra and
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these values were used to estimate their surface areas (Table 4.3). The estimated surface
areas of the monomer, dimer, tetramer, and hexamer are 6590 ± 140, 11430 ± 150, 21110
2

± 190, and 24960 ± 110 Å , respectively.

Table 4.3 Measured surface areas of β2m oligomers.
Measured Surface Area (Å2)

Days of
Incubation

Monomer

Dimer

Tetramer

Hexamer

0

6515

11586

--

--

1

6743

11546

21248

--

3

6655

11435

20843

25050

5

6660

11370

21110

24982

7

6393

11211

21228

24837

4.3.5 Pre-amyloid β2m Dimer
The goal of the current study is to obtain structural information about the β2m
dimer that is formed after the protein binds Cu and before it proceeds to form amyloid
fibrils. Our group and others have shown that β2m forms dimers, tetramers, and hexamers
[1,3]. Because no odd-numbered oligomers are observed, the dimer is likely the basic unit
of the tetramer and hexamer. Hence, characterizing the dimeric intermediate will not only
help to delineate the early steps of β2m fibrillogenesis but will also aid in determining the
structures of the tetramer and hexamer.
Our approach in this work has been to use covalent labeling along with MS
detection because of the utility of this method for studying protein-protein interactions in
solution. Two mutant β2m oligomer crystal structures are available [10,11], and these

125

structures provide convenient high resolution information to which our data can be
compared. These crystal structures, however, are not of the wild-type protein, and the
specific mutations in each case prevent the protein from forming amyloid fibrils. This
fact means that our labeling experiments provide more relevant information about the
structural changes necessary for wild-type β2m to form amyloid-competent oligomers.
Several factors affect the covalent labeling efficiency of amino acid side chains,
but solvent accessibility is the most important [12]. Consequently, covalent labeling is
especially effective at identifying residues that mediate protein-protein interactions
because the solvent accessibilities of such residues typically undergo noticeable changes.
In the case of β2m, complete isolation of the dimer is not possible without some
dissociation back to the monomer, so the covalent labeling experiments had to be
performed at different times after adding Cu(II) to initiate the amyloid-forming reaction.
Our previous work has shown that an appreciable amount of dimer is formed within 30
minutes and no tetramer is formed until after 12 hours. Thus, by monitoring the
modification extents of different residues for the first 2 h after the addition of Cu(II), we
can obtain some insight into the residues that undergo changes in solvent accessibility
over time, suggesting that they are important for mediating dimer formation. As shown
in Chapter 3, the β2m residues that react with NHSA, DEPC, and BD are widely
distributed along the polypeptide chain and on the surface of the protein. Thus, we cover
most regions of the protein. The structural data obtained covers 25 of the protein’s 99
residues and ~30% of the surface-exposed residues.
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Most of the amino acids probed by the covalent labels undergo a change in
reactivity after Cu(II) is added, but we will focus our discussion on those amino acids that
undergo changes as the dimer forms in solution. Of the 24 modified residues, only three
amino acids, Lys41, Asn83, and Ser88, have no significant change in reactivity after
Cu(II) is added and the amyloid-forming reaction has proceeded for 2 h. No change in
reactivity suggests that these residues retain a similar chemical environment upon Cu
binding and dimer formation. The residues that undergo a change in reactivity upon
Cu(II) binding, but change little or none as the dimer forms, are the N-terminus, Arg3,
His31, Ser33, Tyr67, Lys91, and Arg97. The changes in reactivity associated with these
residues are important because they provide some insight into the structural changes
caused by Cu binding that enable the protein to dimerize; however, the focus of this work
is the identification of the amino acids that are involved in mediating the interactions
between protein units in the dimer. The remaining 14 residues, including Thr4, Lys6,
Arg12, His13, Lys19, Tyr26, Ser28, Arg45, His51, Lys58 (and/or Ser57), Tyr63, Lys75,
and Lys94, undergo changes in their labeling extent as the dimer’s concentration
increases in solution. Because solvent accessibility is the key factor controlling the
relative reactivity of these residues, the protection from modification of some of these
residues in the dimer suggests that these residues are at or near the dimer interface and
implies that they may perhaps contribute to the stability of the dimer.
Previous reports showed that the β2m oligomers are native-like in structure [2], so
the known structure of the Cu-free monomer is a useful reference point for interpreting
our data. In addition, the recent crystal structures of two mutant β2m oligomers, the P32A
dimer (PDB ID: 2F8O) [10] and the H13F hexamer (PDB ID: 3CIQ) [11], also provide a
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very useful basis for comparison to our data. The symmetry of the H13F hexamer is such
that each protein unit interfaces with two other protein units in distinct ways. Thus,
together the P32A dimer and the H13F hexamer provide three dimer interfaces to which
we can compare our data. The overall fold of β2m changes little in these mutant
oligomers, which is consistent with the expected native-like structure of the wild-type
oligomers. Upon comparing our data with the mutant oligomers and the wild-type
monomer, three important observations are made: (1) dimer formation via D-D strand
interactions as seen in the P32A structure and one of the subunit contacts in the H13F
structure is improbable; (2) the CFG β-sheet is not part of the dimer interface; and (3) the
ABED β-sheet is part of the dimer interface.
Considering the possibility of the D-D β-strand interaction in the dimer, we find
that two of the residues expected to be buried by this interaction increase in reactivity as
the dimer is formed. The interfaces formed by the interaction of D strands from two
monomeric units as seen in the P32A dimer and one of the dimer units (AB chains) in
H13F hexamer are shown in Figure 4.5. The two crystal structures show that the
interaction surfaces of the anti-parallel D strands span primarily the amino acids Glu50Lys58. These interfaces predict reduced solvent accessibility of His51 on the D strand
and Ser 57 and Lys58 on the DE loop. The calculated SASA of His51 decreases from 93
Å2 in the monomeric protein (PDB ID: 2D4F) to 33 Å2 and 2 Å2 in the P32A dimer and
AB dimer in the H13F hexamer, respectively. Similarly, the SASA of Lys58 in the
monomer decreases from 214 Å2 to ~167 Å2 in the P32A and 88 Å2 in the AB dimer,
respectively. For Ser57, the SASA decreases from 58 Å2 in the monomer to 0 Å2 in the
P32A dimer but increases slightly to 65 Å2 in the AB dimer of the H13F hexamer.
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Hydrogen-bonding likely occurs between the side chain of His51 and the backbone of
Phe56 in the anti-parallel D-D strand interaction of the AB chains of H13F mutant
(Figure 4.5B). In addition, in both the P32A and H13F crystal structures, Lys58 can form
a salt bridge with Glu50 (Figure 4.5B). These interactions protect residues His51, Ser57,
and Lys58 from solvent, and thus, if the dimer interface involves the D strands from two
monomers, one would expect these residues to drop in reactivity as the dimer is formed.
In our experiments, however, we find that His51, Lys58, and possibly Ser57 increase in
reactivity as the dimer’s concentration increases, suggesting that these interactions are not
present in the wild-type dimer. From studies of the oligomerization properties of a series
of β2m mutants in which the four His residues were replaced by different residues, Blaho
and Miranker [27] recently speculated that His51 is an important residue at the interface
of the tetramer, and therefore not part of the dimer interface. Our results are consistent
with this suggestion and provide additional evidence that His51 is not buried upon dimer
formation.
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Figure 4.5 Dimers formed by D-D strand interactions. Amino acids Glu50-Lys58 are
shown as spheres. (A) D-D strand interface of the crystallographic dimer of P32A. (B)
Interaction of adjacent D strands in one of the dimer units (AB chains) in the H13F
hexamer. Inter-strand interactions of the side chains of Glu50 and His51 of one monomer
with the side chain of Lys58 and the backbone of Phe56, respectively, of another
monomer are shown.
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The decreased reactivities of other residues provide further evidence against a
dimer formed via the D-D strands and give support for a dimer involving the ABED βsheet. The amino acids that exhibit a decrease in extent of modification upon dimer
formation are shown in Figure 4.6A. All of these residues are located on the A, B, and E
strands of β2m. Hence, the measured reactivity patterns are consistent with a dimer
structure wherein the ABED sheet is part of the dimer interface.

Figure 4.6 The probed amino acids that are located on the (A) ABED and (B) CFG
sheets of β2m.

The decreased reactivity of these seven residues are consistent with both an antiparallel ABED-ABED arrangement as is formed by the B and C chains of the hexameric
H13F mutant and a parallel ABED-ABED arrangement (Figure 4.7). Analysis of the BC
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dimer from the crystal structure of the hexameric H13F mutant reveals that all residues
predicted to occur inside the dimer interface, Lys6 on the A strand, Arg12, His13, and
Lys19 on the AB loop, Tyr26 and Ser28 on the B strand, and Tyr63 on the E strand, drop
in reactivity after the onset of dimer formation. These data also correlate well with the
decrease in calculated SASAs of most of these residues when comparing the monomeric
structure to that of the BC dimer of the H13F mutant; Lys6: 199 to 0 Å2; Arg12: 159 to
20 Å2; Lys19: 316 to 90 Å2; Tyr26: 73 to 0 Å2; and Tyr63: 45 to 32 Å2. The SASAs of
His13 in the monomer and Phe13 in the BC dimer are 106 Å2 and 0 Å2, respectively. For
Ser28, the SASA for monomeric β2m and the BC dimer are both 0 Å2.
Many of these residues form new contacts in the BC chains of the H13F crystal
structure that may help stabilize the dimer. For example, Arg12 is very close to Tyr63,
and the three carbon chain of Arg’s side chain probably forms a hydrophobic interaction
with Tyr. Lys19 can form a salt bridge with Asp59 of another monomer in the antiparallel arrangement (Figure 4.8), which was recently postulated as one of the important
interactions caused by Cu binding to monomeric β2m [28]. Indeed, several structural and
mutational analyses reveal a crucial role for electrostatic interactions in protein–protein
interactions [29,30]. In addition to experimental data, computational studies show that
electrostatic interactions can substantially enhance the stability of protein-protein
complexes [31,32]. Lys19 is also in close proximity to Glu16, indicating that Lys19
might form a complex salt bridge with Glu16 of the same protein unit and Asp59 of
another protein unit. Such networks involving two or more ion pairs are common at
protein-protein interfaces and contribute more to protein stability than isolated ion pairs,
which predominate in intramolecular interactions [33-35].
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Figure 4.7 Two possible dimers formed via ABED-ABED inter-sheet interactions. (A)
Anti-parallel ABED-ABED arrangement as seen in the dimer formed by the B and C
chains of the H13F mutant (PDB ID: 3CIQ). (B) Parallel ABED-ABED arrangement as
calculated by the docking of two energy-minimized Cu-free β2m monomers obtained
from the MHC complex (PDB ID: 1DUZ).
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Figure 4.8 Interface between the chains B and C in an anti-parallel arrangement in the
H13F hexamer (PDB ID: 3CIQ), showing the inter-subunit salt bridges involving Asp59
and Lys19 and the complex salt bridge involving Glu16.

Detailed structural information is not available for a dimer with a parallel ABEDABED interface, but we have used protein docking to test the viability of this potential
dimer interface. Docking calculations involving two β2m monomers reveal that the dimer
with the highest docking score has a parallel ABED-ABED interface with a crossing
angle of ~35o (Figure 4.7B). Analysis of this docked dimer structure indicates that the
residues that experimentally decrease in reactivity are also part of the dimer interface,
with the exception of Lys19. The calculated SASAs for the residues in the docked dimer
structure when compared to the monomeric crystal structure are: Lys6: 199 to 19 Å2;
Arg12: 159 to 0 Å2; His13: 106 to 78 32 Å2; Lys19: 316 to 194 Å2; Tyr26: 73 to 0 Å2;
Ser 28: 0 to 0 Å2; and Tyr63: 45 to 0 Å2. The decrease in SASA of Lys19 in the parallel
dimer structure may be a consequence of forming a salt bridge with Glu16 of the same
monomeric unit. Even though the drop in SASAs of most of these residues is consistent
with the experimentally determined reactivities, close inspection of this docked dimer
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structure does not reveal any favorable salt bridge interactions between the two
monomeric units. Indeed, calculations of the electrostatic component of the binding free
energy indicate that the parallel arrangement has a slightly unfavorable electrostatic
component. Because our previous work demonstrated the importance of salt bridges in
dimer formation [30], we conclude that this parallel ABED-ABED interface is less likely
than the anti-parallel one.
The anti-parallel ABED-ABED arrangement is also consistent with the measured
surface area of the β2m dimer. The measured surface area of the monomer (6590 ± 140
Å2) compares well with the surface area (6500 Å2) obtained from the monomeric crystal
structure of β2m. The surface areas of the crystallographic dimer of the P32A dimer, the
AB dimer of the H13F mutant, the BC dimer of the H13F mutant, and the parallel
ABED-ABED arrangement from the docking calculations are 11988 Å2, 12093 Å2,
11524 Å2, and 11095 Å2, respectively. The measured surface area for the dimer (11430 ±
150 Å2) compares most favorably with the surface area of the anti-parallel ABED-ABED
arrangement as seen in the BC chains of the H13F mutant.
There are two other possible dimer forms with an ABED β-sheet interaction: (1) a
parallel 3-stranded (CFG) and 4-stranded (ABED) interaction, and (2) an anti-parallel
CFG-ABED interaction. Only four residues in the CFG sheet are probed by the covalent
labels: His31, Arg45, Lys75, and Asn83 (Figure 4.7B). If the inter-sheet interaction
involves the CFG sheet together with an ABED sheet, these four residues are expected to
decrease in reactivity as the dimer forms. Our data clearly shows, though, that the
reactivity of Arg45 on the CD loop and Lys75 on EF loop increase upon dimer formation
indicating that these residues are more solvent accessible. There is no significant change
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in the reactivity of Asn83 on the F strand, suggesting that this residue is not part of the
dimer interface. His31 on the BC loop had an initial drop in reactivity after the addition
of Cu(II), but its reactivity remains constant during dimer formation. Hence, the
reactivity pattern of these residues suggests that a dimer formed by the interaction of a
CFG from one protein unit with an ABED sheet of another protein unit is unlikely.
Overall, our data support a β2m dimer interface that involves an antiparallel
ABED-ABED interaction. As described above, the seven residues that are found at this
interface all decrease in reactivity upon dimer formation. There are, however, seven other
residues, Thr4, Arg45, His51, Ser57, Lys58, Lys75, and Lys94, that increase in reactivity
as the dimer’s concentration increases in solution. Are the reactivities of these residues
consistent with the proposed dimer structure? The increased reactivity of five of these
residues can be rationalized by comparing the monomeric structure and the crystal
structure of the BC chains of the H13F hexamer. The increased reactivity of Arg45
might be explained by the breaking of a salt bridge interaction with Asp38 that is
probably present in the monomer but not in the BC dimer of the H13F mutant. Arg45’s
SASA also increases slightly from 109 to 118 Å2. Similarly, Lys94 probably forms a salt
bridge with Glu77 in the monomer, but these two residues are much further apart in the
BC dimer of the H13F mutant. The increased reactivities of His51, Lys58 and Lys75
correlate reasonably well with the increase in SASAs of these residues in the BC chains
of the H13F mutant relative to the monomer: His51: 93 to 113 Å2; Lys58: 214 to 327 Å2;
and Lys75: 245 to 302 Å2.
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4.4 Conclusions
In conclusion, our covalent labeling data indicate that the β2m dimer, which is
formed prior to the β2m amyloid fibrils, has an interface that involves the antiparallel
arrangement of ABED sheets from two monomers. Our confidence in this assignment
comes from labeling data that covers almost one-half of the amino acids that are at the
interface of the dimer and from comparison to the crystal structure of the hexameric
H13F mutant, which appears to include many of the interactions present in the wild-type
dimer. Our data clearly indicate that the dimer interface present in the P32A mutant of
β2m is not the interface present in the wild-type dimer. Because β2m also forms
tetramers and hexamers and not odd-ordered oligomers, the knowledge gained in this
study about the dimer interface will serve as important foundational information for
characterizing these larger oligomers. Information about these oligomeric intermediates
should be useful for the development of therapeutics against DRA. More broadly
speaking, covalent labeling along with MS detection appears to be a useful method for
probing protein–protein interactions in situations where more than one protein species is
present in solution. This ability could make this method useful for other amyloid forming
systems in which discrete oligomers precede fibril formation. For some amyloid forming
proteins, these small prefibrillar oligomers are thought to be responsible for cellular
toxicity rather than the amyloid fibrils themselves [8,9], indicating the importance of
studying their structures.
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CHAPTER 5
STRUCTURE OF THE PRE-AMYLOID TETRAMER OF
β-2-MICROGLOBULIN FROM COVALENT LABELING AND MASS
SPECTROMETRY
This chapter is part of a paper in preparation: Mendoza, V.L., Baron-Rodriguez, M.A.,
Blanco, C., and Vachet, R.W. (2010) Structure of the pre-amyloid tetramer of β-2microglobulin from covalent labeling and mass spectrometry.

5.1 Introduction
The formation of discrete oligomers as prefibrillar intermediates has been
observed for several proteins including β2m [1-5]. The fact that amyloidogenic proteins
form oligomeric intermediates prior to fibril formation may be important because the
oligomers themselves might be therapeutic targets for preventing amyloid fibril formation
Indeed, recent studies of other amyloid systems suggest that prefibrillar intermediates
might be responsible for cellular toxicity rather than the amyloid fibrils [6,7].
Our previous work has shown that Cu(II)-induced β2m amyloid formation is
preceded by the formation of discrete, oligomeric intermediates, including dimers,
tetramers, and hexamers [4]. In our proposed model, monomeric β2m binds Cu(II) and is
destabilized. Cu(II)-bound β2m forms a dimer which subsequently forms tetramer I.
Tetramer I undergoes a conformational change, releases Cu(II), and undergoes
rearrangement to form tetramer II. Tetramer II associates with a dimer that presumably
releases its bound Cu(II) and forms the hexamer. Several studies have attempted to
characterize these pre-amyloid oligomers, but this task is very challenging because the
oligomers are present as a mixture of species and, as intermediates, are only transiently
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populated. One successful approach to obtain structural information about the oligomers
has been to create β2m mutants that are stable enough to crystallize as oligomers [8,9]. In
this way, it has been found that a P32A mutant of β2m forms a dimer in the absence of
Cu(II) and an H13F mutant forms a hexamer in the presence of Cu(II). These crystal
structures provide high resolution atomic-level information about possible β2m oligomer
structures, but they do not provide a complete picture about oligomer structure because
these mutants do not ultimately form amyloid fibrils.
As a complement to these crystallographic studies, covalent labeling with mass
spectrometric method is used to study the oligomeric intermediates. We recently used this
method to gain insight into the structure of the dimer formed by wild-type β2m [10] and
found that the dimer interface is formed by the anti-parallel stacking of ABED β-sheets
from two β2m monomers. In this chapter, we applied this covalent labeling/MS approach
to characterize the tetrameric form of β2m that follows formation of the dimer. Using the
covalent labeling data along with molecular dynamics calculations, we are able to then
build a model of the tetramer that indicates how the protein can continue to form higher
order oligomers.

5.2 Experimental Procedure
5.2.1 Materials
The same materials were used as described in Section 3.2.1.
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5.2.2 Formation of β2m Oligomers
The formation of β2m oligomers was done in a manner identical to that described
in Section 4.2.2.

5.2.3 Covalent Labeling Reactions
The covalent labeling reactions were done in a manner identical to that described
in Sections 3.2.3-3.2.5.

5.2.4 Proteolytic Digestion
The proteolytic digestions were performed in a manner identical to that described
in Section 3.2.6.

5.2.5 Instrumentation
The amount of modification was determined by removing an aliquot of the
purified β2m and analyzing the samples using a Bruker Amazon quadrupole ion trap
mass spectrometer (Billerica, MA) equipped with an ESI source. The ESI source was
operated at a spray voltage of 4.5 kV, and the capillary temperature was set at 220°C. The
voltages for the transfer optics between the ESI source and the ion trap were optimized
for maximum signal.
The proteolytic fragments were separated by an Agilent HP1100 (Wilmington,
DE) HPLC system with a C18 column (15 cm x 2.1 mm, 5 µm particle size, Supelco, St.
Louis, MO) for on-line analysis by MS and MS/MS. The fragments of NHSA- and BDmodified β2m were eluted using a linear gradient of methanol that increased from 5 to
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70% over 20 min and 70 to 100% over the final 2 min at a flow rate of 0.250 mL/min.
For the fragments of DEPC-modified β2m, a linear gradient of methanol that increased
from 5 to 70% over 30 min and 70 to 100% over the final 3 min was used. For both
gradient conditions, water comprised the balance of the solvent, and a total of 0.1% acetic
acid was present. The LC effluent was fed into the mass spectrometer with similar ESI
source conditions as described above. Tandem mass spectra were acquired using collision
induced dissociation (CID) with isolation widths of 1.0 Da and excitation voltages
between 0.6 and 1.0 V.

5.2.6 Amino Acid Modification Percentage
The amino acid modification percentages were calculated in a manner identical to
that described in Section 3.2.8.

5.2.7 Molecular Dynamics Simulations
All molecular dynamics simulations were initiated using a dimer, the B and C
chains, from the H13F mutant hexamer crystal structure (PDB ID: 3CIQ) [9], which
contains 98 amino acid residues. Met0 was eliminated from the original set of
coordinates. Two dimers were added together before the simulations began in order to
produce a tetramer structure that was consistent with the covalent labeling data. This
tetramer structure was then energy-minimized, using an explicit model of the solvent,
with the AMBER94 force field [11,12] implemented in GROMACS [13-15]. During the
energy minimization hydrogen atoms were explicitly added to the tetramer model and His
residues were considered to be neutral, as shown in nuclear magnetic resonance (NMR)
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studies by Esposito and co-workers [16]. Water molecules were simulated using a TIP3P
model [17] and molecules were added until a cubic simulation cell of side length 9.6 nm
was achieved.

5.3 Results and Discussion
Structural studies of the oligomeric intermediates that precede β2m amyloid
formation are challenging because these oligomers are transient, present as a mixture, and
can dissociate back into the monomer during isolation. We reported previously that β2m
oligomers are formed via the discrete addition of dimer units [4]. The dimer first appears
within 1 hour after adding Cu(II), a first form of the tetramer appears within 12-24 hours,
a second Cu(II)-free form of the tetramer appears after approximately 3 days, and the
hexamer appears soon after the Cu(II)-free tetramer. Since complete isolation of the
tetramer is not possible without some dissociation back to the dimer and monomer,
covalent labeling experiments were performed at different times before (t = 0 min) and
after (t = 2 min, 2 hrs, 0.5 day, 1 day, 1.5 days, 2 days, and 2.5 days) adding Cu(II) to
initiate the amyloid fibril-forming reaction. At time points between 0.5 and 2.5 days, the
mixture contains monomer, dimer, and the first form of the tetramer. The percentage of
tetramer at time points after the addition of Cu(II) increases from 0 to 15% based on ESIMS measurements of the desalted sample under amyloid-forming conditions, as
described previously [4]. Also, the percentage of dimer increases from 0 to 28% from 0
to 2.5 days. In recent covalent labeling studies of the β2m dimer, we identified 20 amino
acids that undergo changes in labeling reactivity, relative to the monomer, after Cu(II)
binding and dimer formation (Figure 5.1) [10].
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Figure 5.1 (A) Ribbon representation of monomeric β2m (PDB ID: 2D4F), Cu(II)-bound
β2m, and the formation of the dimer by stacking of two antiparallel ABED sheets.
Amino acids modified by the covalent labels are shown as green sticks. The amino acids
found in the dimer interface (ABED β-sheet) are shown as red sticks. (B) Amino acid
sequence of β2m showing strand nomenclature [18]. Black lines show amino acids on
each β strand. The internal disulfide bond is shown in blue. The amino acids probed by
the covalent labels are shown in green.

In the current study, we sought to identify residues that only undergo changes in
labeling reactivity as the tetramer is formed. To do this the covalent labeling data that is
obtained when the tetramer is present (0.5-2.5 days) is compared to the data acquired
when only dimer and monomer are present in solution (0.5-2 hours). Any residues that
undergo new changes in reactivity after 0.5 days are then residues that undergo changes
in solvent accessibility, and thus are likely important for the formation of the tetramer.
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5.3.1 Covalent Labeling with NHSA
Amino groups such as the ε-NH2 of lysine residues and the N-terminal α-NH2 can
react with NHSA, but information from such surface mapping experiments is reliable
only if the structural integrity of a protein is preserved during the reaction. Previously, we
have reported that reaction of β2m with a 3-fold molar excess of NHSA for 1 min at 37
o

C does not induce any protein structural changes [10]. The reaction time was kept short

(1 min) to avoid tetramer dissociation.
Proteolytic digestion and LC-MS analyses are necessary to identify the amino
acids that change in reactivity as the tetramer concentration increases. Under solution
conditions in which β2m forms amyloid fibrils, LC-MS/MS analyses show that the Nterminus, almost all of the lysines (Lys6, Lys19, Lys41, Lys58, Lys75, Lys91, and
Lys94), and Asn83 are labeled to different degrees. The unmodified and modified
fragments containing these amino acids are detectable at all time points; however, the
level of modification for some residues changes over time (vide infra). In our previous
study, definitive MS/MS data could not be obtained for the fragment Lys41-Leu54 [10].
Here, the better sensitivity of the quadrupole ion trap used in these experiments allowed
identification of Lys41 as the modification site.
The reactions with NHSA at different time points after formation of the tetramer
reveal that the modification extents of some residues change as the concentration of the
tetramer increases in solution (Figure 5.2). The percentage modification for the peptide
fragments containing the indicated residues were determined from the LC-MS intensities
of the modified and unmodified fragments, as described in the Materials and Methods
section. For each time point, the modification reaction was repeated three times. Because
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ion intensity ratios of the unmodified and modified peptide fragments are used to
determine the extent of modification, small changes in modification levels can be
accurately and precisely determined, as we demonstrated in our previous work [10].
Of all the residues acetylated by NHSA, only the N-terminus (Figure 5.2A) does
not change in the extent of modification from 0.5 to 2.5 days after addition of Cu(II). The
levels of modification of Lys75 (Figure 5.2F) and Asn83 (Figure 5.2G) increase from 0.5
days after Cu(II) is added to 2.5 days after the metal is added. In contrast, the reactivity of
Lys6, Lys19, Lys41, Lys58, Lys91, and Lys94 clearly decrease as the tetramer’s
concentration increases in solution. The extent of modification of Lys6 decreases slightly
within 2 hours after adding Cu(II), and the reactivity of this residue continues to decrease
up to 2.5 days. In our previous covalent labeling studies on the dimer, we concluded that
Lys6 was part of the dimer interface, and so its continual decrease in reactivity is
consistent with the dimer’s concentration continuing to increase in solution over time.
The rest of the lysine residues, Lys19, Lys41, Lys58, Lys91, and Lys94, behave
differently. The reactivity of these five lysine side chains also decrease as the tetramer
concentration increases, but their reactivities either do not change or increase prior to
tetramer formation. For example, Lys94 increases in reactivity as the dimer’s
concentration increases in solution, but as soon as the tetramer begins to significantly
populate the solution, Lys94 decreases in reactivity. On the other hand, Lys41 undergoes
no change in reactivity as the dimer is formed, whereas it decreases in reactivity as the
tetramer’s concentration increases in solution.
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This figure is continued on the next page.
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Figure 5.2 Extent of NHSA modification throughout the course of tetramer formation.
(A) N-terminus. (B) Lys6. (C) Lys19. (D) Lys41. (E) Lys58. (F) Lys75. (G) Ans83. (H)
Lys91. (I) Lys94. The changes in modification during the dimer formation are shown
(points before red line) as reference points.

In summary, our results indicate that the reactivity of NHSA with the N-terminus
does not change as the tetramer is formed in solution. In contrast, the reactivities of
Lys75 and Asn83 increase as the tetramer is formed, whereas the reactivities of Lys6,
Lys19, Lys41, Lys58, Lys91, and Lys94 decrease as the tetramer’s concentration
increases in solution. Importantly, the modification extent for Lys6 decreases within the
first 2 h after adding Cu(II), which suggests that its continuing drop in modification
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extent is due to the formation of more dimer in solution rather than the formation of
tetramer. Tetramer formation is then likely responsible for the decreased reactivity of the
remaining lysine residues (i.e. Lys19, Lys41, Lys58, Lys91, and Lys94).

5.3.2 Covalent Labeling with DEPC
DEPC reacts readily with histidine residues but can also react with amine and
hydroxyl groups at neutral pH. As was demonstrated previously, a 2.5-fold molar excess
of DEPC is sufficient to label several amino acids in β2m while minimizing any DEPCinduced structural changes to the protein [10]. As was the case with the NHSA reactions,
the reaction time was kept short (1 min) to avoid tetramer dissociation but also to
minimize DEPC hydrolysis by water.
Proteolytic digestion of the protein and LC-MS/MS analyses indicate that DEPC
reacts with the N-terminus, Thr4, Lys6, His13, Lys19, Tyr26, Ser28, His31, Ser33,
Lys41, His51, Ser57/Lys58, Tyr63, Tyr67, Lys75, Ser88, and Lys94. These
modifications are observed at all time points, but the level of modification for some
residues changes over time (vide infra). In all cases but one (Ser57/Lys58), the specific
amino acids that are modified could be determined unambiguously from the MS/MS data.
When the covalent labeling reactions with DEPC are performed at different time
points after the tetramer begins to form, the modification levels of 13 of the 17 labeled
residues change as the tetramer’s concentration increases in solution (Figure 5.3). The
labeling data reveal that only Lys75 (Figure 5.3O) shows an increase in modification
extent upon tetramer formation. The level of modification of seven residues, Lys6, His13,
Lys19, Tyr26, Ser28, Tyr63, and Tyr67, initially decrease within 2 hours after adding
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Cu(II) and continue to decrease up to 2.5 days. Five residues, Thr4, Lys41, His51,
Ser57/Lys58, and Lys94, increase within 2 hours after adding Cu(II) but then decrease as
the tetramer concentration increases in solution. Four residues, the N-terminus, His31,
Ser33, and Ser88, undergo no change in reactivity as the tetramer is formed. In
comparing the DEPC and NHSA reactivity for those residues that react with both
reagents, we find complete consistency for the N-terminus, Lys6, Lys41, Lys58, Lys75,
and Lys94. Only the reactivity of Lys19 is slightly different.
In summary, the reactions with DEPC indicate that 13 residues undergo a notable
change in reactivity as the tetramer is formed in solution. The modification extent of
Lys75 increases whereas the reactivity of the other 12 amino acids decreases. The
decrease in modification extents for Lys6, His13, Lys19, Tyr26, Ser28, Tyr63, and Tyr67
within 2 h after adding Cu(II) suggests that the continual drop in the extents of
modification for these residues is due to formation of more dimer in solution rather than
the formation of tetramer. Consequently, tetramer formation is then likely responsible for
the reactivity changes of Thr4, Lys41, His51, Ser57/Lys58, Lys75, and Lys94.
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This figure is continued on the next page.
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This figure is continued on the next page.
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Figure 5.3 Extent of DEPC modification throughout the course of the tetramer
formation. (A) N-terminus. (B) Th4. (C) Lys6. (D) His13. (E) Lys19. (F) Tyr26. (G)
Ser28. (H) His31. (I). Ser33. (J) Lys41. (K) His51. (L) Ser57/Lys58. (M) Tyr63. (N)
Tyr67. (O) Lys75. (P) Ser88. (Q) Lys94. The changes in modification during the dimer
formation are shown (points before red line) as reference points.

155

5.3.3 Covalent Labeling with Butanedione
Unlike DEPC, which reacts with many nucleophilic groups, BD reacts
specifically with arginine. The reaction is reversible at pH < 9, so higher reagent doses
are necessary to improve the product yield. As determined previously, a reagent excess of
350 is suitable to avoid any modification-induced structural changes as well as to obtain
readily detectable modifications [10]. The LC-MS data indicate that BD reacts with Arg3,
Arg12, Arg45, and Arg97 but not Arg81. The reactions of BD with β2m reveal that only
Arg3 and Arg12 undergo any notable changes in reactivity upon formation of the
tetramer (Figure 5.4). The modification levels of Arg3 and Arg12 decrease as the
tetramer’s concentration increases in solution, but because the reactivities of these
residues also decrease before 0.5 days their continual decreases in reactivity are likely
due to formation of more dimer in solution rather than the formation of tetramer. The
unchanged reactivity of Arg45 and Arg97 is curious since both of these residues increase
in reactivity up to 2 h as the dimer’s concentration increases in solution. It is likely that
these residues slightly decrease in reactivity as the tetramer is formed, but this decrease is
counterbalanced by the increase in reactivity as the dimer’s concentration continues to
increase in solution up to day 2.5.

Overall, the BD reactivity suggests that Arg3 and

Arg12 undergo no significant changes in reactivity as the tetramer is formed but Arg45
and Arg97 might.
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Figure 5.4 Extent of BD modification throughout the course of the tetramer formation.
(A) Arg3. (B) Arg12. (C) Arg45. (D) Arg97. The changes in modification during the
dimer formation are shown (points before red line) as reference points.

A summary of the reactivity changes for all of the modified amino acids
monitored at t=2 h and t=2.5 days is shown in Table 5.1.
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Table 5.1 Summary of the modification percentages for the modified amino acids at 2
hours (t=2 hours) after the addition of Cu(II) and 2.5 days (t=2.5 days) after the addition
of Cu(II).
Residue

t = 2 hours

t = 2.5 days

% Change

N-terminus

60.7 ± 0.3

61 ± 1

0

Lys6

17.9 ± 0.1

14.2 ± 0.2

-

Lys19

7.2 ± 0.2

6.42 ± 0.09

-

Lys41

8.2 ± 0.8

6.1 ± 0.2

-

Lys58

19.0 ± 0.1

13.9 ± 0.5

-

Lys75

1.62 ± 0.08

2.33 ± 0.02

+

Asn83

1.46 ± 0.03

1.6 ± 0.1

+

Lys91

24.0 ± 0.4

21.0 ± 0.3

-

Lys94

4.4 ± 0.2

3.40 ± 0.08

-

N-terminus

68.1 ± 0.6

67 ± 2

0

Thr4

89.5 ± 0.6

61 ± 2

-

Lys6

7.64 ± 0.02

5.9 ± 0.2

-

His13

40.0 ± 0.7

34.2 ± 0.8

-

Lys19

11.5 ± 0.6

10.1 ± 0.2

-

Tyr26

0.45 ± 0.06

0.35 ± 0.02

-

Ser28

0.11 ± 0.01

0.078 ± 0.008

-

His31

0.8 ± 0.2

0.89 ± 0.05

0

Ser33

1.19 ± 0.06

1.36 ± 0.09

0

Lys41

0.34 ± 0.02

0.24 ± 0.01

-

His51

66 ± 2

49 ± 1

-

Ser57/Lys58

47 ± 2

33 ± 2

-

Tyr63

3.3 ± 0.2

2.7 ± 0.6

-

NHSA

DEPC

This table is continued on the next page.
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Tyr67

1.5 ± 0.1

1.21 ± 0.04

-

Lys75

0.38 ± 0.02

0.54 ± 0.02

+

Ser88

72 ± 1

71 ± 2

0

Lys94

36 ± 2

28 ± 1

-

Arg3

1.01 ± 0.04

0.86 ± 0.07

-

Arg12

0.64 ± 0.06

0.48 ± 0.07

-

Arg45

6.5 ± 0.5

6.6 ± 0.3

0

Arg97

4.9 ± 0.2

5.1 ± 0.1

0

BD

5.3.4 Pre-amyloid β2m Tetramer
The goal of this study is to obtain structural insight into the pre-amyloid tetramer
that is formed by β2m after adding Cu(II) at near physiological conditions. Our group has
previously shown that Cu(II)-induced β2m amyloid formation is preceded by the
formation of dimers, tetramers, and hexamers [4]. No odd-numbered oligomers are
observed, indicating that the oligomeric intermediates form via the assembly of dimers.
In addition, our previous work suggests that the first tetramer species that is formed has
Cu(II) bound to it, but as the amyloid fibril-forming reaction proceeds, Cu(II) is lost from
this first tetramer before forming Cu(II)-free tetramers, hexamers, and eventually amyloid
fibrils. In a recent study, we showed that the pre-amyloid dimer is formed by the
interaction of anti-parallel ABED β-sheets from two monomers [10]. This dimer structure
provides a starting point for gaining insight into the structure of the Cu(II)-bound
tetramer.
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Covalent modification with detection by MS was selected to probe the tetramer as
this method has been effective in mapping protein surfaces, identifying ligand-binding
sites, detecting ligand-induced conformational changes, and studying protein-protein
complexes, including the β2m dimer [10,19]. As described in our previous studies [10],
care was taken to select optimal reaction times and stoichiometries for each covalent
labeling reagent to ensure that the amount of label added and the resulting modification
do not disrupt the protein structure. A total of 24 residues in β2m are probed by NHSA,
DEPC, and BD, and these residues are widely distributed along the polypeptide chain and
on the surface of the protein, representing about 30% of the surface amino acids (see
monomer in Figure 5.1A). Changes in the reactivity of amino acid side chains reflect
changes in their solvent accessibility. Hence, patterns of modification during the course
of the amyloid fibril-formation reaction permit us to build a low-resolution map of the
protein and identify residues involved in mediating tetramer formation. Having baseline
labeling data for the monomer and dimer allow us to readily identify those residues
involved in tetramer formation, even though monomer, dimer, and tetramer are present
simultaneously. In addition, being able to perform these reactions on wild-type β2m
under amyloid fibril-forming conditions makes the resulting structural information
relevant for understanding native β2m amyloid assembly.
The amino acid side chains probed by the covalent labels can be grouped in three
categories, namely, residues with (1) unchanged reactivity, (2) decreased reactivity, and
(3) increased reactivity from 2 h after adding Cu(II) to 2.5 days when the first form of the
tetramer is present. The covalent labeling experiments reveal that six of the 24 modified
amino acids, the N-terminus, His31, Ser33, Arg45, Ser88, and Arg97, maintain the same
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reactivity with their respective labeling reagents at time points from 2 h to 2.5 days. Four
of these residues, the N-terminus, His31, Ser33, and Ser88 have the same reactivity in the
dimer and tetramer, indicating that these residues retain similar microenvironments in
both these oligomers. Therefore, these residues are not likely part of the tetramer
interface. The unchanged reactivities of the N-terminus and His31 are consistent with
these residues remaining Cu(II) binding sites in the monomer, dimer, and tetramer [20].
The unchanged reactivity of Ser33 is also consistent with steric hindrance caused by
nearby Cu(II) binding in the monomer and oligomers. Others have reported that Cu(II)
binding induces a cis-to-trans backbone isomerization of Pro32. In the crystal structures
of the P32A mutant dimer and the dimeric unit in the H13F mutant hexamer, which both
show this cis-trans isomerization, Ser33 has low accessibility to solvent [8,9]. Persistence
of this structural feature in the tetramer due to Cu(II) binding would maintain the
microenvironment around Ser33 in such a way that its reactivity does not change. The
unchanged reactivity of Ser88 suggests that it remains solvent accessible in the monomer,
dimer, and tetramer. The reactivity of Arg45 and Arg97 is essentially different than the
N-terminus, His31, Ser33, and Ser88. These residues increase in reactivity as the dimer is
formed but then their reactivities level off as the tetramer is formed. This behavior
suggests that they decrease in reactivity as the tetramer is formed, thereby
counterbalancing their increased reactivity as the dimer continues to populate the
solution. Thus, we consider Arg45 and Arg97 as residues that decrease in reactivity as the
tetramer is formed.
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Including Arg45 and Arg97, 18 residues decrease in reactivity as the tetramer’s
concentration increases. Nine of these residues, Arg3, Lys6, Arg12, His13, Lys19, Tyr26,
Ser28, Tyr63, and Tyr67, were found previously to decrease in reactivity as the dimer is
formed, and their continued decrease in reactivity is consistent with the dimer’s
continued increase in concentration up to 2.5 days. The remaining nine residues, Thr4 on
the A strand, Lys41 on the C strand, Arg45 on the CD loop, His51 on the D strand,
Ser57/Lys58 on the DE loop, Lys91, Lys94, and Arg97 on the G strand, only decrease in
reactivity once the tetramer is formed. Because solvent accessibility is the main factor
that affects the reactivity of the amino acid side chains, decreases in reactivity suggests
that these latter nine amino acids may mediate interactions in the tetramer.
Even though no crystal structure of a wild-type or mutant β2m tetramer is
available to which we can compare our covalent labeling data, several lines of evidence
help us arrive at a model for the pre-amyloid tetramer of the wild-type protein. (1)
Previous reports have shown that the β2m oligomers are native-like in structure [21],
indicating that the tetramer will have many of the structural features present in the wildtype monomer for which several crystal structures exist [22,23]. (2) Previous covalent
labeling experiments from our group determined the structure of the wild-type β2m
dimer, which has essentially the same structural features as the dimer unit formed by the
B and C chains of the H13F mutant hexamer of β2m [10]. This dimer structure (see
Figure 5.1) serves as a convenient starting point for constructing a model of the tetramer
since the tetramer very likely arises from the assembly of two dimers. (3) The H13F
mutant hexamer contains another oligomeric interface (chains C and D) that could
represent the interface of the wild-type tetramer and so our labeling data can be directly
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compared to the interface of these two chains. (4) The P32A mutant dimer, which was
previously ruled out as a possible dimer interface for wild-type β2m, could represent the
interface of the wild-type tetramer and our labeling data can be compared to this structure
too.
In comparing our labeling data with the oligomeric interface of chains C and D of
the H13F hexamer (Figure 5.5), we find that only three of the nine residues that decrease
in reactivity are found at the CD interface. The interface of these two chains should result
in reduced solvent accessibility for His51, Ser57, and Lys58, and we observe
experimentally that these residues decrease in reactivity upon tetramer formation. In
contrast, the other six residues (i.e. Thr4, Lys41, Arg45, Lys91, Lys94, and Arg97) that
decrease in reactivity and thus are likely at the tetramer interface, are all solvent
accessible when considering the CD interface of the H13F hexamer (Figure 5.5C). This
collective observation alone strongly suggests that the interface of the C and D chains of
the H13F mutant does not reflect the tetramer interface in wild-type β2m. Indeed, no
interface in the H13F hexamer is consistent with our covalent labeling data for the wildtype tetramer. This conclusion is not too troublesome, though, as the H13F hexameric
mutant cannot form amyloid fibrils, whereas the wild-type protein can form tetramers,
hexamers and eventually amyloid fibrils. Evidently, the wild-type protein forms a
tetramer species capable of continuing on to form amyloid fibrils, whereas the H13F
mutant cannot form such an interface and therefore does not progress to form amyloid
fibrils.
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Since studies have shown that the H13F mutant has a very similar structure,
stability, and Cu(II) binding constant compared to wild-type β2m [24], the inability of
H13F mutant to form amyloid fibrils indicates that His13 is important in the formation of
pre-amyloid oligomers of wild-type β2m. The exact role that His13 plays is not clear, but
the presence of a Cu-bound and a Cu-free tetramer [4] along with the metal-binding
capabilities of histidine residues might provide a clue. It is possible that transiently
binding of His13 by Cu(II) may provide the necessary stabilization to allow release of
Cu(II) from the N-terminal region, thus enabling the formation of the Cu(II)-free tetramer
that eventually proceeds to form the Cu(II)-free amyloid fibrils. Replacement of His by
Phe in the H13F mutant may hinder the formation of the Cu(II)-free tetramer, which is
necessary for eventual fibril formation.
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Figure 5.5 Possible tetramer formed by two dimer units with anti-parallel ABED
interface as seen in the H13F hexamer [9]. The side chains involved in the interface are
shown as spheres. (A) Possible tetramer formed by D strands and BC loops from two
dimer units in the crystal structure of H13F hexamer. One dimer unit (chains BC) is
shown in gray and the other (chains DE) is shown in green. Chains C and D, which form
tetramer interface, are shown in dark gray and dark green, respectively. (B) Interaction of
adjacent D strands. Inter-strand interactions of the side chains of Glu50 and His51 of one
monomer with the side chain of Lys58 and the backbone of Phe56, respectively, of
another monomer are shown. These interactions make Ser57 less exposed to solvent. (C)
Six of the amino acids that decrease in reactivity upon tetramer formation, namely, Thr4,
Lys41, Arg45, Lys91, Lys94, and Arg97, are solvent accessible in the H13F structure.
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The P32A mutant also forms an oligomeric interface with which we can compare
our labeling data (Figure 5.6). Like the interactions seen in the CD chains of the H13F
hexamer, the interaction of the anti-parallel D strands in P32A span primarily the amino
acids Glu50-Lys58 (Figure 5.6B). These interfaces predict reduced solvent accessibility
of His51 on the D strand and Ser57 and Lys58 on the DE loop. These interactions protect
residues His51, Ser57, and Lys58 from solvent, which possibly explains why we see a
decrease in the reactivity of these residues. Like the H13F mutant, though, Thr4, Lys41,
Arg45, Lys91, Lys94, and Arg97 are solvent accessible in the P32A dimer, which is not
consistent with the observed decrease in their reactivity upon tetramer formation. This
result indicates that an interaction involving D strands from two protein sub-units does
not represent the tetramer interface in wild-type β2m.
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Figure 5.6 Interface formed by D-D strand interactions in P32A. (A) Crystallographic
dimer formed by P32A. (B) Amino acids Glu50-Lys58 on the D strands are shown as
spheres. Inter-strand interactions of the side chains of Glu50 and His51 of one monomer
with the side chain of Lys58 and the backbone of Phe56, respectively, of another
monomer are shown.

In arriving at a viable model for the tetramer, it is helpful to map the amino acids
that decrease in reactivity upon tetramer formation. In doing so, it is clear that the
residues that decrease in reactivity are localized on the edge strands A, D, C and G
strands of β2m (Figure 5.7). This observation suggests a tetramer interface that involves
an anti-parallel arrangement of D and G strands from two dimers (Figure 5.8). In this
tetramer model, two D strands from one dimer unit and two G strands from an adjacent
dimer form the interface (Figure 5.8A and 5.8B). More specifically, a D strand from one
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monomer in a dimer and a D strand from the other monomer in the same dimer interact
with the G strands from each of the monomers the other dimer. Analysis of such a model,
which was computationally constructed and energy minimized as described in the
experimental section, reveals that seven out of the nine residues that drop in reactivity as
the tetramer is formed are found at the interface of the D and G strands of adjacent
dimers. These seven residues are Thr4, His51, Ser57/Lys58, Lys91, Lys94, and Arg97
(Figure 5.8C). The two amino acids that increased in reactivity upon tetramer formation,
Lys75 and Asn83, are both solvent accessible in the tetramer model. In this model, His51,
Lys58, Lys91, Lys94, and Arg97 are involved in mediating the interactions at the
tetramer interface, whereas Ser57 is protected from solvent by these interactions and
Thr4 is enclosed by the D and G strands. Glu50 and His51 form salt bridges with Arg97
and Asp96, respectively. Such electrostatic interactions can substantially enhance the
stability of protein-protein complexes [25,26], and the involvement of His51 in one of
these interactions is consistent with a study by Blaho and Miranker in which they found
from mutagenesis studies that His51 is a critical residue in mediating the interface [27].
Asp53 is in close proximity to both Lys91 and Lys94, indicating that this residue can
form a complex salt bridge with both of these lysine residues. Such complex salt bridges
at protein-protein interfaces contribute significantly to protein complex stability [28-30].
In addition, Lys58 is in close enough proximity to hydrogen bond with Gln89. Moreover,
several hydrophobic residues are buried in this model structure, including Pro32, Leu54,
Phe56, Ile92, and Val93 (residues not shown). In this model, Arg45 decreases in
reactivity but is not buried at the interface. In this case, the orientation of the D strand is
altered such that Arg45 can form a salt bridge with Glu47 (Figure 5.8D), which could
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explain its decreased reactivity with BD. These interactions might also alter the
orientation of the D strand such that Lys41 becomes protected from solvent, and thus
decrease in reactivity upon tetramer formation.
A final important feature of our proposed model for the pre-amyloid tetramer is
the likely ability of this tetramer to further propagate into higher order oligomers. In our
previous studies, we found that the tetramer can progress to form hexamers. As shown in
Figure 5.8, interaction of D strands of one dimer and the G strands of a second dimer to
form the tetramer leaves the G strands of the first dimer and the D strands of the second
dimer available for further interaction with another dimer unit. Such unfulfilled
interactions would presumably allow formation of a hexamer via another D-G interaction.

Figure 5.7 The probed amino acids that decrease in modification upon tetramer
formation (shown as red sticks) are located on the edge strands, A, C, D and G.
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Figure 5.8 Proposed model structure for the wild-type β2m tetramer. (A) Tetramer
formed by the interaction of two D strands from one dimer unit (dark and light gray) and
two G strands of another dimer unit (dark and light). (B) Top-view of the tetramer model.
(C) Amino acids Thr4 on the N-terminal strand, Glu50-Lys58 on the D strand, and
Gln89-Arg97 on the G strand are shown as spheres. Several interactions are shown: salt
bridge between Glu50 and Arg97, salt bridge between His51 and Asp96, complex salt
bridge between Asp53 and Lys94 and Lys91, and H-bonding between Gln89 and Lys58.
(D) These interactions alter the orientation of the D strand such that Arg45 can form a
salt bridge with Glu47.
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5.4 Conclusions
Using a combination of selective covalent labeling and mass spectrometric
detection, we identify structural features of the pre-amyloid tetramer of β2m, which is
generated by incubation with Cu(II) under physiologically relevant conditions. The
covalent labeling data allows us to develop a model for the tetramer in which the
interface is mediated by interactions between D strands of one dimer unit and the G
strands of another dimer unit. Our model, therefore, differs from previous suggestions
that the tetramer is mediated by interactions between D strands on separate dimer units.
Covalent labeling data that covers about 30% of the amino acids that are at the interface
of the proposed tetramer structure provide strong support for our model. Future studies
will further test this model, and more structural information about this pre-amyloid
tetramer might be useful for the development of therapeutics against DRA. More broadly
speaking, covalent labeling along with MS detection should have applicability to other
amyloid-forming systems, especially those in which mixtures of pre-amyloid oligomers
are formed. This approach could then take on greater importance since in several amyloid
diseases the pre-amyloid oligomers may represent the species responsible for cellular
toxicity rather than the amyloid fibrils themselves [31,32].
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CHAPTER 6
DELINEATING THE METAL-SPECIFIC STRUCTURAL CHANGES IN
β-2-MICROGLOBULIN AND THEIR EFFECT ON ITS AGGREGATION

6.1 Introduction
Prior work shows that endogenous metals other than Cu, such as Fe and Zn, are
involved in the pathogenesis of a variety of aggregation and amyloid diseases. Reports
have shown that Cu(II) and Zn(II) modulate the aggregation of the prion peptide PrP106126 from Creutzfeldt-Jakob disease [1]. It has been shown that Aβ aggregation is greatly
influenced by Zn(II) at pH 7.4. Cu(II) and Fe(III), which have much lower affinities for
the protein, can induce limited Aβ aggregation, but their effect can be further exaggerated
by slightly acidic conditions [2,3]. Studies have shown that α-synuclein from Parkinson’s
is able to interact with Zn(II), Cu(II), and Fe(III) and that these interactions lead to
protein aggregation and crosslinking [4,5]. The amyloidogenic immunoglobulin light
chain (LC) or SMA forms granular aggregates upon exposure to Cu leading to LC
deposition disease [6]. This previous work demonstrates that transition metals can
influence protein amyloid formation and raises the question about the effect of other
transition metals on β2m aggregation.
As shown in the previous chapters, interaction of β2m with Cu(II) results in
destabilization, oligomerization and subsequent amyloid formation. In this chapter, the
effect of interactions with other first-row transition metals, specifically Zn(II) and Ni(II),
on β2m will be investigated. Previous studies show that Zn(II) and Ni(II) also bind to
β2m but with much lower affinities (KdCu = 2.7 µM, KdNi = 400 µM and KdZn = 1500 µM)
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[7]. Importantly, the binding of Ni(II) and Zn(II) to β2m does not lead to amyloid fibril
formation, but Zn(II) does induce the formation of oligomers [8]. In addition to native
state binding, urea titration experiments shows that the destabilization of β2m is specific
for Cu(II) over Zn(II) and Ni(II) [7,9]. Taken as a whole, these previous reports indicate
that Cu(II) exerts a unique effect by stimulating β2m amyloid formation. It is therefore
interesting to compare the differences that each metal (Cu(II), Ni(II), and Zn(II)) exerts
on the structure of the β2m monomer as a way to obtain deeper insight into the specific
structural changes that are necessary for Cu(II) to induce β2m amyloid formation.

6.2 Experimental Procedure
6.2.1 Materials
Human β2m was obtained from Fitzgerald Industries International, Inc. (Concord,
MA). Diethylpyrocarbonate (DEPC), 2,3-butanedione (BD), sulfo-N-hydroxysuccinimide
acetate (NHSA), copper(II) sulfate (CuSO4) pentahydrate, zinc sulfate (ZnSO4)
heptahydrate, nickel sulfate (NiSO4) heptahydrate, 3-morpholinopropanesulfonic acid
(MOPS), imidazole, dithiothreitol (DTT), potassium acetate, arginine, carbonic
anhydrase, equine skeletal muscle myoglobin, and bovine serum albumin were purchased
from Sigma-Aldrich (St. Louis, MO). Tris(hydroxymethyl)-aminomethane (Tris) was
purchased from EM Science (Gladstone, NJ). Urea was purchased from Mallinckrodt
Chemicals (Phillipsburg, NJ). Trypsin was from Promega (Madison, WI), and
chymotrypsin was purchased from Roche Diagnostics (Indianapolis, IN). Centricon
molecular weight cutoff filters were obtained from Millipore (Burlington, MA).
Deionized water was prepared from a Millipore Simplicity 185 water purification system.
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6.2.2 Formation of β2m Oligomers
Oligomers were formed by incubation of 100 µM β2m in 200 mM potassium
acetate, 500 mM urea, and 25 mM MOPS (pH 7.4) with the divalent metal salt of interest
at 37 °C. The concentrations of the metal salts used were: 200 µM CuSO4, 400 µM
ZnSO4, and 16 mM NiSO4. All components were equilibrated at 37 °C prior to metal salt
addition, and immediately returned to 37 °C after mixing. The covalent labels were added
to aliquots of incubated β2m taken at 2 minutes after addition of the metal salt. Five µL
aliquots of the incubated β2m were taken at several time points after addition of the metal
salt for analysis by size-exclusion chromatography (SEC).

6.2.3 Covalent Labeling Reactions
The covalent labeling reactions were done in a manner identical to that described
in Section 3.2.3-3.2.5.

6.2.4 Proteolytic Digestion
The proteolytic digestions were done in a manner identical to that described in
Section 3.2.6.

6.2.5 Instrumentation
The determination of the amount of modification of the whole protein and
proteolytic fragments were performed the same way as described in Section 3.2.7. For
online SEC-MS analyses, a Bruker Amazon quadrupole ion trap mass spectrometer
equipped with a standard ESI source was used. The ESI source was operated at a spray
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voltage of 4.5 kV, and the capillary temperature was set at 220°C. The voltages for the
transfer optics between the ESI source and the ion trap were optimized for maximum
signal.

6.2.6 Amino Acid Modification Percentage
The amino acid modification percentages were determined in a manner identical
to that described in Section 3.2.8.

6.2.7 Circular Dichroism (CD)
CD measurements were made at 37 oC using a Jasco-710 spectropolarimeter. The
metal salts (same concentrations used as in section 6.2.2) were added to a solution
containing 20 µM β2m, 500 mM Urea, 25 mM MOPS and 150 mM potassium acetate.
Spectra were acquired with a sample cell having a 0.1 cm path length and at a scan
resolution of 0.2 nm, a scan rate of 50 nm/min, and a response time of 4 s.

6.2.8 Thioflavin T Fluorescence
Fluorescence experiments to monitor the rate of β2m oligomer formation were
performed using a QuantaMaster 4 SE spectrofluorometer (Photon Technology
International, Lawrenceville, NJ). A solution containing 100 µM β2m, 80 µM thioflavin
T (ThT), 500 mM Urea, 25 mM MOPS and 150 mM potassium acetate was initially
equilibrated at 37 oC, and after the addition of the divalent metal salt, the fluorescence
shift of ThT was measured. Measurements were taken at excitation and emission
wavelengths of 437 and 483 nm, respectively.
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6.2.9 Size Exclusion Chromatography
To determine any β2m oligomers formed upon addition of the divalent metals,
the incubated solutions were separated using a Superdex 75 PC 3.2/30 column (GE
Healthcare Biosciences, Piscataway, NJ) installed on an Agilent HP1100 series highperformance liquid chromatography system (Wilmington, DE). Before analysis of the
sample, the SEC column was first equilibrated with a 20 mM ammonium acetate mobile
phase (pH = 7.4) at 0.06 mL/min flow rate for 1 hour. During the analysis, 5 µL of an
incubated sample solution was injected into the sample loop. A variable wavelength
detector set at 214 nm was used for detection, except in cases where mass spectrometric
detection was performed. For the molecular weight (MW) calibration, a solution
containing a mixture of the following proteins was used: 1.5 µM bovine serum albumin
(MW = 66,000), 3 µM carbonic anhydrase (MW = 29,040), 3 µM myoglobin (MW =
16951), and 3 µM β2m (MW = 11732).

6.2.10 Transmission Electron Microscopy (TEM)
TEM images were obtained on a JEOL JEM-100CX electron microscope
operating at 100 keV. Before analysis, a solution containing insoluble material was
centrifuged (14,000g) for 8 min and decanted, and the solid material was resuspended in
10 mL of the supernatant. The resulting solution was then applied to carbon-coated
copper grids and allowed to air-dry for 5 min. The sample was then stained with 1%
phosphotungstic acid, airdried for 12 h, and then viewed.
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6.3 Results and Discussion
The Cu(II) and Ni(II) concentrations used for the incubation experiments were
calculated from the reported Kd values such that 97% of β2m is bound to the metal of
interest. The concentration that was initially used for Zn(II) was also calculated from the
reported Kd; however, we observe aggregation/precipitation of β2m when greater than a
5-fold molar excess of Zn(II) is used. Hence, a 4-fold molar excess (400 µM) was chosen
for the experiments involving Zn, resulting in 20% loading of the protein by the Zn(II).

6.3.1 Effect on β2m Structure
Assessment of the β2m structure in the presence of the three divalent metal ions
was first performed using far- and near-UV CD. All peaks in the far-UV spectrum
demonstrate weak negative ellipticity, which is characteristic of a β-sheet fold (Figure
6.1A). The spectrum shows a slightly more negative ellipticity in the presence of Cu(II)
and Zn(II) at 220 nm compared to apo-β2m. This may be attributed to the breaking of one
or more hydrogen bonds upon binding of these two metals, resulting in small changes in
the secondary structure. In the near-UV CD, positive bands were observed at 260 nm and
290 nm for all samples (Figure 6.1B), indicating that the protein is folded and has very
similar arrangements of aromatic residues when each of the metals is bound. These bands
arise from the packing of aromatic groups into well-defined and fixed conformations.
With Cu(II) and Zn(II), there are slight variations from the apo-protein at ~270 and ~ 280
nm, indicating that there might be small changes in the atomic arrangement of the
aromatic groups. Overall, the CD data suggest that the global structure of β2m remains
mostly unchanged upon interaction with all three divalent metal ions.
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Figure 6.1 CD spectra of β2m in the absence (black) and presence of divalent metal ions:
Cu(II) (blue), Ni(II) (green), and Zn(II) (orange). (A) Far-UV CD spectra. (B) Near-UV
CD spectra.

6.3.2 Effect on Oligomerization of β2m
The oligomerization of β2m in the presence of the divalent metal ions was
monitored using two methods: (1) thioflavin T (ThT) fluorescence and (2) SEC. Upon
binding to amyloid-like species, the characteristic fluorescence spectrum of ThT changes
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[10]; although, we and others have shown that the spectrum of ThT also changes upon
formation of the β2m dimer [8,11,12]. Figure 6.2 shows the ThT fluorescence in the
absence and presence of the metal ions. No significant change in ThT fluorescence was
found in the control experiment (i.e. no metal ion present) for up to 7 hours. ThT
fluorescence in the presence of Ni(II) was similar to that of the control, indicating that
oligomerization does not occur with Ni(II), which is consistent with previous studies
[13]. In contrast, ThT fluorescence in the presence of Cu(II) and Zn(II) increased
immediately after addition of the metal ion. For the Cu-containing solution, the increase
in ThT fluorescence enhancement occurs at a rate of 1.38 x 10-1 s-1, and the signal levels
off after about 5 hours. In the presence of Zn(II), the ThT fluorescence increases
exponentially with a rate of 4.49 x 10-1 s-1, and the signal levels off after 1 hour. This
indicates that kinetics of oligomerization is much faster in the presence of Zn(II)
compared to Cu(II). Although a change in the fluorescence of ThT is observed within 1
hour for both Cu(II) and Zn(II), no insoluble material is observed from these samples for
up to seven hours. Changes in ThT fluorescence by upon binding Cu(II) and Zn(II)
indicate that both metals induce the formation of oligomers that are able to bind ThT in a
similar manner, whereas Ni either does not induce oligomerization or produces oligomers
that are unable to change the fluorescence characteristics of ThT.
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Figure 6.2 Oligomerization of β2m in the absence (black) and presence of divalent metal
ions: Cu(II) (blue), Ni(II) (green), and Zn(II) (orange) monitored by thioflavin T (ThT)
fluorescence at 483 nm. The ThT fluorescence maximum shifts from 450 nm to 483 nm
upon binding to β2m oligomers or amyloid-like species in solution. The trend lines
associated with the plots of the metal-containing samples are from non-linear curve
fitting of the data.

The oligomerization of β2m was also monitored by SEC in order to follow the
kinetics and identities of the oligomeric species that are formed. SEC analyses indicate
that no oligomers are formed when β2m is incubated with Ni(II) over the course of two
weeks (Figure 6.2). Based on comparison to a calibration curve, the compound that elutes
at ~27 min is the monomer. Over the course of two weeks a small drop in the monomer
intensity is observed because the protein adheres to the surface of the tubes during
incubation over such long periods of time.
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Figure 6.3 β2m oligomerization in the presence of Ni(II) monitored by SEC. The
monomer peak is observed at ~27 min.

In the presence of Cu(II), monomers, dimers, tetramers, and hexamers are
observed within six days of incubation (Figures 6.4A and 6.4B), which is perfectly
consistent with previous studies by our group [12]. Based on a calibration curve, the
molecular weights (MW) of the compounds that elute at 20, 21, 25, and 27 min are
11,750 Da, 21,780 Da, 45,240 Da, and 68,310 Da, respectively,. The peak at 27 min with
a MW of 11,750 matches very well the expected MW of the monomer (11,731 Da). This
assignment was also confirmed by online SEC-MS analysis (data not shown). The
expected MW of the dimer (23,462) is close to the MW of the peak at 25 min. Online
SEC-MS analysis of this peak confirms that this compound is the β2m dimer (Figure
6.4C). The peak at 21 min has an estimated MW of 45,240 Da which is very close to the
expected MW of the tetramer (46,924 Da). The peak that elutes at 20 min is assigned to
the hexameric form of β2m, which has an expected MW of 70,386. Unfortunately, the
assignments of the tetramer and hexamer peaks could not be confirmed by SEC-MS.
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Figure 6.4
SEC and SEC-MS analyses of β2m incubated with Cu(II). (A)
Chromatograms for a control (black) and samples incubated with Cu(II) for 1 day (red), 3
days (blue), and 6 days (green). Monomer (M), dimer (M2), tetramer (M4), and hexamer
(M6) are observed. (B) Temporal progression of the oligomers measured by SEC. (C)
SEC-ESI mass spectrum of the chromatographic peak eluting at ~25 min after 6 days of
incubation, confirming that this peak corresponds to the β2m dimer. The charge state of
each mass spectral peak is labeled.
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Figure 6.5 show that β2m also forms oligomers upon interaction with Zn(II).
Unlike with Cu(II), in which there is a gradual decrease in the abundance of the monomer
(27 min), the abundance of the monomer in the presence of Zn(II) drops by ~50% after 1
day (Figure 6.5A). This is consistent with the higher rate of oligomerization seen in the
ThT fluorescence experiments with Zn(II) (see Figure 6.2). The peak at 23 min has an
estimated MW of ~27,000 which is about 3500 more than the expected MW of the dimer
but 8000 less than the expected MW of the trimer. SEC-MS analysis confirms that the
oligomer eluting at 23 min is the dimer (Figure 6.5C). The oligomer with an elution time
of 18 min has a MW of ~79,000 which is about 8600 more than the expected MW of the
hexamer and 3000 less than the expected MW of the heptamer. Definitive assignment of
this oligomer is difficult because this MW is near the exclusion limit of the SEC column
and its identity could not be confirmed by SEC-MS. An interesting observation that is
evident in Figure 6.5A is that the retention times of the compounds shift over time. This
phenomenon could occur because different oligomers are formed over time or because
the oligomers are somewhat unstable and dissociate during the chromatographic process.
Overall, the SEC experiments indicate that the β2m oligomers that are formed in
the presence of Cu(II) include dimers, tetramers, and hexamers (Figure 6.4B). The
oligomers form via the assembly of dimers since no odd-numbered oligomers were
observed. This is consistent with previous SEC and dynamic light scattering experiments
[12]. In contrast, β2m immediately forms a dimer upon interaction with Zn(II) and
subsequently forms oligomers larger than a hexamer. Thus, in comparison to Cu(II),
binding of Zn(II) to β2m causes subtle but different changes in the structure of β2m that
result in the formation of slightly different oligomeric forms.
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Figure 6.5
SEC and SEC-MS analyses of β2m incubated with Zn(II). (A)
Chromatograms for a control (black) and samples incubated for 1 day (red), 3 days
((blue), and 6 days (green). Monomer (M), dimer (M2), oligomers bigger than a hexamer
are observed. (B) Temporal progression of the oligomers measured by SEC. (C) SEC-ESI
mass spectrum of the chromatographic peak eluting at ~23 min after 6 days incubation,
confirming that this is the β2m dimer. The charge state of each mass spectral peak is
labeled.
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6.3.3 Effect on Amyloid Formation of β2m
Sodium dodecyl sulfate (SDS) dissolution was used to determine if the aggregates
formed in the presence of Cu(II) and Zn(II) are amyloid in nature. One characteristic
feature of amyloid-like aggregates as opposed to amorphous aggregates is that they do
not readily dissolve in 2% SDS. The aggregates were filtered and added to a 2% solution
of SDS at 37°C. The aggregates in the samples incubated with Cu(II) for 4 weeks did not
dissolve after 24 h, in the presence of SDS, indicating that they were amyloid-like
aggregates. In contrast, the insoluble material formed after 4-week incubation with Zn(II)
dissolved in 2% SDS suggesting that they are amorphous aggregates.
We have shown previously that after 1 month of incubation with Cu(II), the vast
majority of the aggregates are long and straight, which are hallmarks of amyloid fibrils
[12]. On the other hand, TEM images of the aggregates taken after incubation with Zn(II)
for 1 month shows that the aggregates formed with Zn(II) do not have well-defined
structures (Figure 6.6). Taken as a whole, the SDS dissolution experiments and TEM
images suggest that amyloid formation is observed with Cu(II) but not with Zn(II).
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Figure 6.6 (A) Transmission electron micrograph images obtained from β2m after
incubation with Zn(II) for 1 month. Dimensions of image is 200 nm x 325 nm. (B) The
TEM image for β2m incubated with Cu(II) for 1 month is adapted from reference 12.

6.3.4 Covalent Labeling
The results above reveal that binding to Ni(II) and Zn(II) causes noticeable
differences in oligomerization and amyloid formation of β2m when compared to Cu(II)
binding. We hypothesize that these differences are due to differences in binding sites and
binding-induced conformational changes. The structural changes caused by the binding
of each metal ion were investigated by covalent labeling and MS. The reactivity of three
covalent labeling reagents with β2m in the presence of each selected metal ion before it
formed any oligomers was performed. The three labeling agents that were used (i.e.
DEPC, NHSA, and BD) were the same ones described in previous chapters of this
dissertation. DEPC can react with solvent exposed His, Tyr, Thr, Lys, and Ser residues
[14], but the reactions with this reagent are significantly slowed when these residues,
especially His, are bound to metal ions [15,16]. Likewise, NHSA and BD can react with
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amino and guanidinium groups, respectively, when these sites are solvent exposed [17],
but its reactivity is reduced when these residues are protected, for example, by metal
binding. Moreover, increases or decreases in the reactivity of specific amino acids,
relative to the apo-protein, can also reflect differences in solvent exposure caused by
metal-binding induced conformational changes. All covalent labeling experiments were
performed when only monomeric β2m was present. A list of the experimentallydetermined modification percentages for each of the modified amino acids reacted in the
absence (i.e. apo- β2m) and presence of the divalent metal ions is shown in Table 6.1.

Table 6.1 Modification percentagesa for each modified amino acid in the absence of
metal and the presence of Cu(II), Ni(II), and Zn(II).
Residue

apo-β2m

Cu(II)

Ni(II)

Zn(II)

N-terminus

81 ± 3

60.5 ± 0.7

74 ± 3

71 ± 2

Lys6

20 ± 1

19 ± 1

26.9 ± 0.9

19.1 ± 0.7

Lys19

7.0 ± 0.4

6.9 ± 0.4

5.1 ± 0.4

6.9 ± 0.3

Lys41

13.6 ± 0.7

15 ± 1

13 ± 0.8

13.4 ± 0.9

Lys58

16.1 ± 0.7

16 ± 3

11.8 ± 0.5

14.5 ± 0.6

Lys75

1.6 ± 0.2

1.3 ± 0.1

1.60 ± 0.04

2.3 ± 0.2

Asn83

1.50 ± 0.04

1.4 ± 0.1

1.3 ± 0.2

2.6 ± 0.2

Lys91

27 ± 1

22 ± 1

29 ± 1

24 ± 1

Lys94

3.1 ± 0.2

3.4 ± 0.3

3.8 ± 0.1

4.9 ± 0.2

N-terminus

99 ± 1

68 ± 1

92 ± 1

90 ± 1

Thr4

86.7 ± 0.7

87 ± 2

86 ± 3

86 ± 5

Lys6

7.57 ± 0.05

7.5 ± 0.1

7.93 ± 0.07

7.6 ± 0.1

NHSA

DEPC

This table is continued on the next page.
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His13

47 ± 2

46 ± 3

46 ± 2

46 ± 3

Lys19

22 ± 1

19 ± 2

18.0 ± 0.7

24 ± 2

Ty26

0.75 ± 0.07

0.79 ± 0.05

1.10 ± 0.05

0.75 ± 0.03

Ser28

0.24 ± 0.01

0.17 ± 0.02

0.35 ± 0.02

0.26 ± 0.01

His31

1.8 ± 0.1

0.7 ± 0.1

1.6 ± 0.1

1.40 ± 0.05

Ser33

1.7 ± 0.1

1.1 ± 0.1

1.11 ± 0.06

1.6 ± 0.1

His51

61 ± 3

61 ± 4

72 ± 2

81 ± 4

Ser57/Lys58

43 ± 2

42 ± 3

19.9 ± 0.8

46 ± 2

Tyr63

7.1 ± 0.5

4.3 ± 0.3

3.6 ± 0.3

5.4 ± 0.3

Tyr67

2.1 ± 0.1

1.75 ± 0.06

2.4 ± 0.1

2.01 ± 0.08

Lys75

0.36 ± 0.04

0.33 ± 0.02

0.35 ± 0.04

0.52 ± 0.04

Ser88

63 ± 3

65 ± 3

60 ± 1

74 ± 1

Lys94

30 ± 2

29 ± 2

39 ± 3

39.7 ± 0.5

Arg3

0.6 ± 0.1

1.05 ± 0.05

0.48 ± 0.07

0.64 ± 0.04

Arg12

1.3 ± 0.1

1.00 ± 0.05

0.51 ± 0.08

0.9 ± 0.1

Arg45

3.8 ± 0.3

3.6 ± 0.1

3.3 ± 0.1

4.40 ± 0.06

Arg97

2.8 ± 0.4

4.8 ± 0.2

4.9 ± 0.4

1.7 ± 0.4

BD

a

The percent modification of each labeled amino acid was determined from the ion
intensities of both modified and unmodified proteolytic peptide fragments containing the
amino acid of interest in a manner identical to that described in Section 3.2.8.

When the covalent labeling reactions were performed 2 minutes after addition of
Cu(II), the extent of modification of 10 residues changed when compared to the protein
in the absence of any metal. The residues that change in reactivity are localized at the Nterminus region and the ABED sheet (Figure 6.7A). As discussed in Section 3.3.4, the Nterminus and His31 are part of the Cu(II) binding site. Of the 24 modifiable residues in
β2m, these two amino acids had the biggest drop in reactivity in the presence of Cu(II).
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The other six residues that decrease in reactivity in the presence of Cu(II) are Arg12,
Ser28, Ser33, Tyr63, Tyr67, and Lys91. There are only two amino acids that increase in
reactivity upon interaction with Cu(II), namely, Arg3 and Arg97. The possible reasons
for these structural changes are discussed in Chapter 3.
The reactivity pattern is different when β2m binds Ni(II). Figure 6.7B shows that
few residues decrease in reactivity at the N-terminal region of the protein, and several
residues increase in reactivity at the ABED β-sheet in the presence of Ni(II). The seven
residues that decrease in modification extent after interaction with Ni(II) include the Nterminus, Arg12, Lys19, Ser33, Arg45, Lys58 (and possibly Ser57), and Tyr63. Unlike
with Cu(II) where a ~30% decrease in modification extent was observed for the Nterminus, the change in reactivity with Ni(II) was only ~7%. In addition, there is no
change in the extent of modification of His31. These results suggest that Ni(II) might
bind to a different region of the protein. The extent of modification of Arg12, Lys19,
Ser33, Arg45, Lys58, and Tyr63 decrease by 30, 22, 34, 13, 40, and 49%, respectively;
however, these residues are not likely to bind Ni(II). Several residues increase in
modification extent, namely, Tyr26 (45%), Ser28 (45%), His51 (18%), Lys94 (26%), and
Arg97 (97%), indicating that these residues are more accessible after interaction with
Ni(II). The conformational changes responsible for these reactivity changes are clearly
very different from those observed with Cu(II), which may be the reason why no β2m
oligomerization or amyloid formation is observed in the presence of Ni(II).
The amino acids that change in reactivity upon interaction with Zn(II) are shown
in Figure 6.7C. Five residues have lower reactivity, namely, the N-terminus, His31,
Tyr63, Arg12, and Arg97. The N-terminus and His31 decreased in modification by 11
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and 22%, respectively. These modest drops in reactivity may suggest that Zn (II) binds at
the N-terminal region in a fashion similar to Cu(II). In contrast to Cu(II), though, Zn(II)
binding to the N-terminal region of the protein does not induce any reactivity changes to
Ser28, Ser33, and Arg3. The modification extents of Tyr63, Arg12, and Arg97 decrease
by 23, 30, and 39%, respectively. In the presence of Cu(II), Tyr63 and Arg12 also
decrease in reactivity but the modification extent of Arg97 increased. In addition, we find
the levels of modification of Arg45, His51, Lys75, Asn83, Ser88, and Lys94 increase by
about 15, 32, 44, 73, 17, and 45%, respectively, in the presence of Zn(II). In contrast, the
reactivity of these five residues remain the same in the presence of Cu(II).
Taken together, the covalent labeling data indicates that Cu(II) and Zn(II) may
have the same binding site (i.e. N-terminal region), whereas Ni(II) may bind elsewhere.
The similarity in binding sites between Cu(II) and Zn(II) might explain why β2m
oligomerization is observed for both of these metal ions but not Ni(II). The smaller
decrease in modification of the N-terminus and His31 in the presence of Zn(II) may be
accounted for by the lower loading of β2m with Zn(II), 20% compared to 97% with
Cu(II). Future experiments using EXAFS and metal-catalyzed oxidation (MCO) are
necessary to completely delineate the Zn(II) and Ni(II) binding sites to more fully
understand the effect of each metal.
The existing covalent labeling data does, however, allow one to speculate about
the reasons why Cu(II) induces the formation of amyloid fibrils but Zn(II) does not.
Previous studies showed that the structural changes induced by Cu(II) binding enables
dimer formation of β2m, which initiates the pathway toward amyloid fibril formation.
These structural changes include: (1) drop in reactivity of Ser33 due to cis-trans
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isomerization of Pro32 [13,14], (2) increased reactivity of Arg3 making salt bridge
formation with Glu16 of an adjacent monomer possible [18], and (3) decreased reactivity
of Arg12, Ser28, Tyr63, and Tyr67 on the ABED β-sheet which help facilitate formation
of a dimer with an antiparallel ABED-ABED interface [19]. These rearrangements are
not reflected in the covalent labeling data in the presence of Zn(II). For instance, Ser33
has the same modification extent in the absence and presence of Zn(II). This indicates
that this residues does not undergo any rearrangement and that the cis to trans backbone
isomerization of Pro32 does not likely occur upon interaction with Zn(II). Likewise, the
reactivity of Arg3 did not change suggesting that it has the same conformation in the apo
and Zn(II)-bound β2m. Salt bridge formation with Glu16 of an adjacent β2m monomer is
probably not favored by this conformation. In addition, only Arg12 and Tyr63 on the
ABED β-sheet decreased in reactivity and several residues on the CFG β-sheet increased
in reactivity upon interaction with Zn(II). These rearrangements may likely facilitate
formation of a dimer with an interface distinct from that present in the dimer formed with
Cu(II). This alternative dimer does not form tetramers; it may have rearrangements that
give rise to the formation of hexameric interfaces instead. Future covalent labeling
experiments on this alternative dimer is required to determine its interface and any
alterations that facilitate hexamer formation. Moreover, Cu(II) and Ni(II), but not Zn(II),
are known to be able to bind to backbone amides [18,20-26]. We speculate that Cu(II)
binding to the backbone amide between Ile1 and Gln2 is important for causing the
structural changes necessary for β2m to form amyloid-competent oligomers. Hence, these
differences in metal-binding induced structural changes possibly account for the fact that
amyloid formation of β2m is only observed with Cu(II).
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Figure 6.7 Ribbon representation of monomeric β2m (PDB ID: 2D4F). Amino acids that
decrease (green) and increase (orange) in reactivity upon interaction with divalent metal
ions are shown as sticks. (A) Cu(II). (B). Ni(II). (C). Zn(II).
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6.4 Conclusions
Cu(II) but not Zn(II) or Ni(II) can induce the amyloid formation of β2m. The
unique effect of Cu(II) appears to be caused by the site at which the metal binds the
protein and the conformational changes it induces. Ni(II) does not cause oligomerization
or amyloid formation because it binds at a different site on the protein than Cu(II) does.
Zn(II) causes oligomerization and aggregation but does not induce amyloid fibril
formation. Zn(II) binds in the N-terminal region and is bound by the N-terminus and
His31. However, we speculate that Zn(II) is not bound to an amide backbone like Cu(II).
This difference possibly induces structural changes in β2m that are different from those
observed in the presence of Cu(II). The dimer formed with Zn(II) may therefore be
different from the antiparallel ABED-ABED arrangement observed with Cu(II). We
propose that the rearrangements in this alternative dimer make formation of hexamers
more favorable. Lastly, covalent labeling along with MS detection appears to be a useful
method for obtaining amino acid-level information about metal binding-induced
conformational changes in proteins. This ability could make this method useful for other
amyloid forming systems in which binding of metal ions have been implicated.
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CHAPTER 7
SUMMARY AND FUTURE DIRECTIONS

7.1 Summary
This dissertation has described the development of a protein surface mapping
method combined with mass spectrometry to elucidate the structural features of the
oligomers that precede Cu(II)-induced β-2-microglobulin (β2m) amyloid fibril formation.
The method involves covalent modification of amino acid side chains that are exposed to
solvent and the identification of the modified residues by MS. This method was found to
be very powerful for monitoring conformational changes in β2m as well as identifying
the protein-protein interfaces of its pre-amyloid dimer and tetramer.
The improved covalent modification and MS-based method addresses the need for
a reliable approach that both ensures protein structural integrity during labeling
experiments and provides readily detectable modifications. We demonstrated that
measuring the kinetics of the covalent labeling reactions ensures that the covalent probe
does not disrupt a protein’s structure during the labeling reaction. The dose-response
plots provide the added benefit of quantitative information about residue reactivity, which
could possibly provide more precise structural information. The modification rate
coefficients seem to reflect both the reactive atom’s solvent accessibility and amino acid
microenvironment, but stronger connections between these parameters requires further
work. In addition, we show that DEPC may have promise as a general covalent label
because of its ability to probe up to 25% of the residues in the average protein.
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Covalent labeling in conjunction with mass spectrometry was used to determine
the Cu(II) binding site in β2m and conformational changes induced by metal binding. The
labeling data confirms the involvement of the N-terminal amine and His31 in the binding
site and further rules out the interaction of His51 with Cu(II). The reactivity patterns in
the absence and presence of Cu(II) indicate that the Cu(II)-binding induced
conformational changes are predominantly localized at the N-terminal region and the
ABED β-sheet. Cu(II) binding to monomeric β2m repositions Arg3 and forces it to adopt
a new position that allows it to readily form a dimer-stabilizing intermolecular salt
bridge. The rearrangements of Arg12, Ser28, Tyr63, and Tyr67 on the ABED β-sheet
possibly creates a hydrophobic face that can promote dimerization via interaction with
another hydrophobic ABED β-sheet of an adjacent monomer.
Using three complementary covalent labels with MS detection, we were able to
determine models for the dimer and tetramer that precede fibril formation. The dimer was
found to have an interface that involves the antiparallel arrangement of ABED sheets
from two monomers. Our data, therefore, rules out two competing dimer models - the
dimer interface present in the P32A mutant and the interface formed by the C and D
chains of the H13F hexamer. Moreover, our covalent labeling data allows us to develop,
for the first time, a model for the tetramer in which the interface is mediated by
interactions between D strands of one dimer unit and the G strands of another dimer unit.
Our results rule out the possibility of a tetramer mediated by interactions between D
strands on separate dimer units as suggested previously.
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Finally, this surface mapping method was used to obtain insight into the unique
effect of Cu(II) on β2m. Cu(II) but not Zn(II) or Ni(II) can induce amyloid formation of
β2m. The unique effect of Cu(II) appears to be caused by the site at which the metal
binds the protein and the conformational changes it induces. Cu(II) and Zn(II) seem to
bind in similar regions of the protein (i.e. N-terminus and His31), whereas Ni(II) may
bind elsewhere. The similarity in binding by Cu(II) and Zn(II) might explain why β2m
oligomerization is observed for both of these metal ions but not Ni(II). The identity of the
other ligands that bind Zn(II) may be different from those with Cu(II) and certainly the
binding geometry of the two metals will be different given Zn(II) preference for a
tetrahedral binding geometry. Binding to these ligands probably induces structural
changes in β2m that are different from those observed in the presence of Cu(II), which is
why amyloid formation is not observed with Zn(II).
The covalent labeling of wild-type β2m under amyloid fibril-forming conditions
provides structural information relevant for understanding the Cu(II)-induced oligomeric
assembly. The knowledge gained in these studies about the subtle structural changes in
human β2m required for oligomerization and the interfaces in the dimer and tetramer will
serve as reference points in characterizing the larger oligomers (i.e. Cu(II)-free tetramer
and hexamer). Further structural changes are expected for the structures reported here to
adopt irreversible oligomeric conformations. One possibility is the release of Cu(II) in
tetramer I induces subtle structural changes in other regions of the protein but the
interfaces reported here are mostly retained. This structural information can also serve as
important foundational information in delineating the mechanism of conversion of the
oligomers to the insoluble, protease-resistant cross-β structure present in the fibrils.
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In addition, this work may contribute significantly not only in detecting relevant
targets for diagnosis but also in designing functional therapeutics to treat DRA. Based on
the structural information we obtained from the protein surface mapping methods, there
are two possible points in the oligomerization process that may be particularly attractive
targets for therapeutics. The first point is the conformational changes of the monomer
after interaction with Cu(II) that initiate dimer formation. Therapeutic agents can stabilize
the monomeric form of the protein, resulting in complete blockage of dimerization and
oligomerization. Interestingly, we find that the A and B β-strands of β2m which undergo
conformational changes after Cu(II) binding and form part of the dimer interface also
comprise the regions of β2m that form non-covalent interactions with the α1 domain of
the polymorphic α-chain in the MHC-I complex [1]. The sequence of the α1 domain that
makes contact with β2m can be used as reference in designing inhibitors that can bind to
monomeric β2m, and thus prevent dimerization. The second point would be the
prevention of tetramer formation by stabilization of the β2m dimer. The D β-strand which
is an integral part of the proposed tetramer interface also spans the region that interacts
with the α3 domain of the MHC-I complex [1]. The amino acid sequence of the α3
domain involved in the noncovalent interaction should permit the design of molecules
that prevent β2m oligomerization and fibril formation.
This study also highlights the use of selective covalent modification with mass
spectrometric detection in the characterization of metal binding and binding-induced
conformational changes as well as protein-protein interactions. This approach has been
useful in probing protein structure in situations where more than one protein species is
present in solution. This ability makes this method useful for other amyloid forming
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systems in which discrete oligomers precede fibril formation. This approach could take
on greater importance since in several amyloid diseases the pre-amyloid oligomers may
represent the species responsible for cellular toxicity rather than the amyloid fibrils
themselves [2,3]. Characterization of the structure of these intermediate oligomers may
be crucial to designing novel therapeutic strategies to prevent formation of the oligomer,
inhibiting their toxic activity, and in deciphering the mechanism of toxicity.
Furthermore, the common characteristics exhibited by the fibrils from different
precursor proteins suggest a general mechanism for amyloid formation [4]. This offers
the prospect that the Cu(II)-β2m can be used as a model system to systematically assess
the factors that predispose a native protein to form amyloid fibrils. Determining the
mechanism of Cu(II)-mediated oligomeric assembly is therefore important to develop a
more detailed understanding of the origin and progression of the increasing number of
human disorders associated with amyloid formation.

7.2 Future Directions
The following sections discuss future improvements to the covalent labeling
method, structural characterization of the β2m oligomers in the presence of Cu(II), and
structural characterization of the oligomers formed with Zn(II).
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7.2.1 Improving the Protein Surface Mapping Method
7.2.1.1 Multi-Amino Acid Labeling
Simultaneous labeling of numerous amino acids, rather than in parallel, will allow
investigation of several sites of the protein structure and thus provide more information
per experiment as well as possibly simplifying the modification protocol. Multi-amino
acid labeling will entail addition of at least 3 residue-specific labels followed by
proteolytic digestion and LC-MS analysis. To date, there has been no protein surface
mapping studies using multi-amino acid labeling by selective reagents. Hence, several
key issues have to be addressed. Will the reagents react with one another? Can we find
reaction conditions that will work for multiple reagents? Will the presence of multiple
reagents affect the labeling efficiency of each label? Will using multiple reagents affect
the maximum concentration that can be used for a given reagent before protein structure
is compromised? How will the amount of modification be accurately determined if a
given fragment has two or more different modifications?

7.2.1.2 Minimizing Reversibility of Covalent Modifications
Some covalent modifications are reversible. For instance, mono-modification of
histidine residues with DEPC is reversible under both acidic and alkaline conditions and
in

the

presence

of

nucleophiles

such

as

hydroxylamine

and

tris(hydroxymethyl)aminomethane (TRIS) [5]. The half-life of histidine residues
modified by N-carbethoxyimidazole is about 55 hours at pH 7, 2 hours at pH 2, and 18
min a pH 10 [6]. The adduct formed by arginine with butanedione is unstable at pH < 9
[7]. The reversibility and instability makes detection of modified residues difficult.
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One way to minimize these reversible reactions is to decrease the proteolysis
time. Natively-folded proteins are known to require many hours for adequate proteolysis
by enzymes under conventional conditions. Loss of modifications likely occurs during
these long digestion times. Studies have shown that microwave [8,9], ultrasonic [10,11],
and immobilized-trypsin [12,13] digestions can significantly accelerate the digestion
process to minutes versus hours by traditional methods. With these methods the MS
analysis can be performed within a few hours after the modification reactions, and
detection of the modified peptides will be easier if they are present in greater amount.
However, factors such as digestion completeness and effects of these digestion
procedures on modification stability have to be investigated.
Another way to minimize loss of modifications is by using top-down sequencing,
which entails performing MS/MS on the whole protein. The key advantage of the topdown approach is that the long enzymatic digestion step can be avoided, which allows the
analysis to be done more quickly and possibly avoids the loss of covalent labels that
might not be stable during the relatively long digestion step. Top-down sequencing has
been used effectively for mapping labeled sites so that 3D protein structural information
can be obtained [14-16].

7.2.2 Structural Characterization of Cu(II)-Induced Oligomer Assembly of β2m
In addition to the covalent labels used in this dissertation, other approaches can be
used to gain deeper insight into the Cu(II)-induced conformational changes and the
structural properties of the pre-amyloid oligomers of β2m. One example is amide H/D
exchange, which can be complementary to covalent labeling because it provides
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backbone information whereas covalent labels provide information about amino acid side
chains. It can potentially provide information that will support the proposed models for
the β2m dimer and tetramer. Something similar was done in the study of double-stranded
telomeric DNA interactions with the DNA-binding domain of human telomeric repeat
binding factor 2 (hTRF2) using selective acetylation of lysine residues in combination
with PLIMSTEX (protein-ligand interactions by mass spectrometry, titration, and H/D
exchange) [17].
Another covalent label that can potentially provide important structural
information is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC)
combined with nucleophiles like glycine ethyl ester (GEE) and glycineamide (GA).
These combined reagents modify acidic amino acid side chains. Reactions with
carbodiimides are typically carried out at room temperature in the pH range of 4.5 to 6
[18]. The relatively low pH conditions used for the reactions with EDC make it difficult
to use this reagent to probe protein structure under native conditions. However, a recent
study showed that a combination of EDC/GEE provides readily detectable modifications
at neutral pH [19]. Modification of Cu(II)-bound β2m and the oligomeric intermediates
can provide support to our conclusion that Cu(II) binds to the N-terminal region and to
our proposed structural models for the pre-amyloid dimer and tetramer. Specifically,
previous work demonstrated that Asp59 is one of the Cu(II) binding sites in β2m [20].
Thus, we expect its reactivity with EDC/GEE to decrease in the presence of Cu(II). In
addition, we recently postulated that Asp59 and Glu16 play crucial roles in forming
electrostatic interactions that stabilize the β2m dimer [21]. We predict that that
modification extent for these two acidic residues will decrease upon dimer formation.
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7.2.3 Structural Characterization of Zn(II)-Induced Oligomer Assembly of β2m
7.2.3.1 Zn(II) Binding Site
Aside from covalent labeling, the Cu(II) binding site was determined using
another MS-based method, metal-catalyzed oxidation (MCO). However, this MCO/MS
approach will not be directly applicable to the determination of the Zn(II) binding site
because Zn(II) does not undergo single-electron redox processes. One alternative that can
identify the ligands that bind Zn(II) is extended X-ray absorption fine structure (EXAFS).
EXAFS provides information about the number and type of atoms and their bond
distances from a metal atom in a metalloprotein. The X-ray spectra close to the
absorption edge of the core electrons show small oscillations, which are caused by
scattering of the photoelectron by the surrounding atoms. Therefore, these oscillations
contain information about the distance between the metal and the neighboring atoms, the
number of neighboring atoms at a certain distance, and the atomic number of these atoms
[22]. It is important to determine the Zn(II) binding site to understand more deeply why
Zn(II) does not induce amyloid formation even though it also binds in the N-terminal
region of β2m.

7.2.3.2 Oligomeric Intermediates
In addition to the Zn(II) binding site, the structural characterization of the
oligomers formed by β2m after incubation with Zn(II) is important to fully understand
why amyloid formation is only observed in the presence of Cu(II). Covalent labeling with
MS detection used to determine the interface of the dimer and tetramer formed with
Cu(II) could also be applied to Zn(II)-β2m oligomers. The modification patterns in
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different conditions (i.e. Zn(II)-bound monomer, Zn(II)-bound monomer plus dimer, etc.)
will help identify the amino acids involved in the oligomer formation. We speculate that
with Zn(II), β2m may form a hexamer with interfaces similar to that in the crystal
structure of the H13F mutant. This β2m mutant forms hexamer readily but no amyloid
fibrils are formed. Therefore, the H13F and Zn(II)-bound β2m both contain structural
features that prevent further aggregation. Lastly, the specific role of Zn(II) in the
formation and stability of the oligomeric intermediates is important and thus have to be
investigated. In the Cu(II)-β2m system, Cu(II) is only necessary for nucleation and its
release is required to form amyloid-competent oligomers [23]. One possible scenario is
that Zn(II) may be necessary for the stability of all oligomers formed, which may
preclude β2m from undergoing the structural changes required to adopt irreversible
oligomeric conformations.
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